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B non-Hodgkin lymphomas (NHLs) are a highly diverse group of lymphoid tumors character-
ized by the expansion of malignant B cells. Depending on the subtype, the disease ranges 
from indolent to aggressive. For aggressive B-NHLs, combination therapy of chemotherapy 
and rituximab is indicated. Despite advances in treatment options, survival is still poor for these 
patients, especially if they relapse or become refractory. The recent introduction of anti-CD19 
CAR T cell therapy succeeded in drastically improving survival. In CAR T cell therapy, patient-
derived T cells are genetically modified to express a chimeric receptor commonly directed to-
wards a surface antigen expressed by neoplastic cells. However, anti-CD19 CAR T cells can 
lack anti-tumor efficiency due to CD19 antigen loss or downregulation. In this thesis, anti-
CXCR5 CAR T cell therapy was investigated as an alternative to anti-CD19 CAR T cell therapy 
for the treatment of mature B-NHLs. CXCR5 is a B cell homing receptor expressed by mature 
B cells and a subset of T cells in the B cell follicle, which are termed follicular helper T (TFH) 
cells. These cells were described to support the tumor cells in chronic lymphocytic leukemia 
(CLL) and follicular lymphoma (FL). This expression pattern allows simultaneous targeting of 
the malignant cells as well as the tumor-supporting microenvironment by CAR T cell therapy 
against a chemokine receptor in an unprecedented manner. Main findings included that (1) 
anti-CXCR5 CAR T cells targeted specifically CXCR5 expressing mature B-NHL cell lines and 
patient samples in vitro and showed strong in vivo anti-tumor reactivity in an immunodeficient 
xenograft mouse model, (2) anti-CXCR5 CAR T cells targeted tumor-supportive TFH cells de-
rived from CLL and FL patient samples in vitro and (3) CXCR5 showed a safe expression 
profile. CXCR5 was strongly and frequently expressed by B-NHLs and its expression on 
healthy tissue was restricted to lymphoid cells. In summary, anti-CXCR5 CAR T cell therapy 
presents a novel treatment option for patients suffering from mature B-NHLs by eliminating the 
tumor and part of the tumor-supportive microenvironment. 
The second part of the project was focused on understanding the influence of tumor progres-
sion on the CXCR5 expressing T cell compartment and in particular TFH cells. For CLL patients, 
lymphomagenesis is described to alter TFH cells. The Eμ-Tcl1 murine lymphoma model, which 
mimics human CLL, was used to study the impact of lymphomagenesis on CXCR5+ T cells. 
Single cell RNA sequencing was the method of choice to obtain RNA expression profiles at 
single cell resolution. A profound influence of lymphoma growth on the T cell compartment in 
Eμ-Tcl1 tumor-challenged mice could be shown. In these mice, the fraction of TFH cells was 






B-Zell Non-Hodgkin-Lymphome sind eine hochdiverse Gruppe von lymphoiden Tumoren, die 
sich durch die Vermehrung von malignen B Zellen auszeichnen. Abhängig vom Subtyp kann 
die Erkrankung einen indolenten oder aggressiven Verlauf nehmen. Bei aggressiven B-NHL 
ist eine Kombinationstherapie mit Chemotherapeutika und Rituximab notwendig. Trotz Fort-
schritten in den Behandlungsmöglichkeiten ist die Prognose für diese Patienten schlecht, vor 
allem wenn sie nicht auf die Therapie ansprechen oder es zu einem Rezidiv kommt. Mit der 
Einführung der CAR-T-Zell-Therapie, gerichtet gegen CD19, konnte die Überlebensrate dras-
tisch verbessert werden. In der CAR-T-Zell-Therapie werden T Zellen des Patienten derart 
genetisch verändert, dass sie einen chimären Rezeptor exprimieren, der üblicherweise gegen 
ein Oberflächenantigen, das von neoplastischen Zellen exprimiert wird, gerichtet ist. Dennoch 
kann die anti-Tumor Wirksamkeit der anti-CD19 CAR-T-Zellen aufgrund von CD19 Antigen-
verlust oder Downregulation eingeschränkt sein. In dieser Arbeit wurde die anti-CXCR5 CAR-
T-Zell-Therapie als Alternative zur anti-CD19 CAR-T-Zell-Therapie für die Behandlung von rei-
fen B-NHLs untersucht. CXCR5 ist ein B-Zell-homing Rezeptor, der von reifen B Zellen und 
einer Subpopulation von T Zellen im B-Zell-Follikel, den follikulären T-Helferzellen (TFH Zellen), 
exprimiert wird. Diese Zellen wurden als tumor-unterstützend in chronisch lymphatischer Leu-
kämie (CLL) und im follikulären Lymphom (FL) beschrieben. Dieses Expressionsmuster er-
laubt es, auf einzigartige Weise zeitgleich die malignen Zellen und die tumorunterstützende 
Mikroumgebung mithilfe von CAR-T-Zell-Therapie gerichtet gegen einen Chemokinrezeptor 
anzugreifen. Die wichtigsten Ergebnisse dieser Arbeit waren, dass (1) die anti-CXCR5 CAR 
T-Zellen zielgerichtet CXCR5 positive reife B-NHL Zelllinien und Patientenproben in vitro eli-
minierten und eine starke anti-Tumor Reaktivität in einem immundefizienten Xenotransplanta-
tionsmausmodell zeigten, (2) die anti-CXCR5 CAR T-Zellen zielgerichtet die tumorunterstüt-
zenden TFH Zellen in CLL und FL Patientenproben in vitro erkannten und dass (3) CXCR5 ein 
sicheres Expressionsprofil zeigte. CXCR5 war stark und häufig auf B-NHL exprimiert und die 
Expression auf gesundem Gewebe war auf lymphoide Zellen beschränkt. Zusammenfassend 
lässt sich sagen, dass die anti-CXCR5 CAR-T-Zell-Therapie eine neue Behandlungsmöglich-
keit für Patienten mit reifen B-NHL darstellt, indem durch die anti-CXCR5 CAR-T Zellen sowohl 
der Tumor als auch ein Anteil der tumorunterstützende Mikroumgebung eliminiert werden. 
Im zweiten Teil der Arbeit wurde der Fokus darauf gelegt, den Einfluss des Tumorwachstums 
auf das CXCR5 exprimierende T Zell-Kompartiment, insbesondere auf die TFH Zellen, besser 
zu verstehen. Für CLL Patienten sind Veränderungen der TFH Zellen beschrieben worden. Das 
Eμ-Tcl1 murine Lymphommodell, das humane CLL nachahmt, wurde genutzt um die Auswir-
kung der Lymphomentwicklung auf die CXCR5+ T Zellen zu untersuchen. RNA-Einzelzell-




zu erhalten. Ein profunder Einfluss des Lymphomwachstums auf das T Zell-Kompartiment in 
Mäusen, denen Eμ-Tcl1 Zellen gespritzt wurden, konnte gezeigt werden. In den Mäusen war 










We are exposed to countless pathogens daily, but rarely get sick. Our immune system is ca-
pable of tirelessly repelling attacks of disease-causing bacteria, viruses and other microorgan-
isms. Threats also come from within. Genetic alterations, caused by environmental factors or 
spontaneous occurrence, modify the cellular protein machinery and can result in neoplastic 
growth. Foreign structures of various origins must therefore be distinguished from the body’s 
own tissues in a timely manner. In more detail, the immune system depends on two types of 
immune responses, the innate and the adaptive response (Alberts et al., 2002).  
The innate response has developed earlier during evolution and is not only present in verte-
brates, but also in invertebrates. The first line of defense are the epithelium, the skin and the 
linings of lung and gut, which serve as a physical barrier and prevent the entry of pathogens. 
Inner surfaces are equipped with mucus, which contains anti-microbial peptides, most im-
portantly defensins, and facilitates clearance by cilia movements. If microorganisms succeed 
in invading the body, the innate response starts fighting them within the first hours after infec-
tion. This fast response is credited to the ability to recognize certain structures, pathogen-
associated molecular patterns (PAMPs), which are prevalent on pathogens, but absent in hu-
mans. Bacterial and fungal cell wall components, bacterial DNA pieces and viral double-
stranded RNA are examples for PAMPs. This mechanism allows a quick reaction, even if the 
host has never been infected with the pathogen before.  
PAMPs trigger the inflammatory response, which includes the reactivity of the complement 
system, as well as phagocytosis. The complement system comprises more than 20 soluble 
proteins, mostly secreted by the liver, which are present in an inactive state in the blood and 
the extracellular fluid. Upon activation, they initiate a proteolytic cascade, leading to an en-
hanced antibody and phagocyte function. The phagocytic cells of the innate response are mac-
rophages and neutrophils. Upon pathogen encounter, they engulf the invader and degrade it. 
Macrophages are long-lived, tissue-resident and enriched in the lung and gut, areas with a 
higher likelihood of infection. As they are present in the tissues, they are usually the first cells 
to encounter a pathogen. Neutrophils are short-lived phagocytes prevalent in the blood, which 
are subsequently recruited to infection sites by macrophages and molecules produces by the 
intruders themselves. Apart from neutrophils, lymphocytes as part of the adaptive response, 
monocytes, tissue-resident macrophages and dendritic cells are attracted to the site of infec-
tion. Chemoattractive cytokines secreted by macrophages, which are called chemokines, play 
a role in this recruitment. The innate response is also engaged in viral infection. Cells infected 
with viruses secrete interferons, which act in an autocrine and paracrine manner. In stimulated 
cells, viral replication is hampered and natural killer (NK) cells, which are innate cells that can 




In vertebrates, the innate immune response acts in close collaboration with the adaptive im-
mune response. The adaptive immune system can elicit strong and, upon repeated encounter, 
fast responses to pathogens. As opposed to the innate response, it is able to establish long-
term protection after infection. However, in order to eliminate invaders and toxic substances 
produced by them, the adaptive response first has to learn to discriminate self from foreign. 
For that, mechanisms are in place to ensure the selection of non-self reactive cells. If this fails, 
the immune cells attack the body’s own tissues, resulting in autoimmune diseases. The adap-
tive immune system provides two main modes of action, a humoral response and a cell-medi-
ated response.  
The humoral response is mediated by antibody-producing B cells. B cells, as opposed to the 
other antigen-presenting cells (APCs), only present antigen specific to its B cell receptor. The 
antigen is bound, internalized, degraded and presented on the B cell’s surface. To support B 
cells, naive helper T cells are first activated by APCs, the most efficient being dendritic cells. 
They become effector helper T cells (TH2), which secrete cytokines and express costimulatory 
molecules, and can subsequently activate a B cell that presents an antigen matching their T 
cell receptor. Memory B cells or antibody-producing plasma cells can develop from activated 
B cells. Antibodies are immunoglobulins prevalent in the blood and other fluids, which specifi-
cally bind to the antigen that triggered their production. Antigen binding can neutralize viruses 
and toxins or tag a pathogen for phagocytosis by innate cells. Help from T cells is also crucial 
for the induction of B cell proliferation or antibody class switch. 
Cytotoxic CD8+ T cells are the main actors in the cell-mediated response. Their mode of action 
is direct killing of cells infected with viruses, intracellular bacteria or parasites. In order to be-
come effector cells, they first have to be activated by an infected antigen-presenting cell, which 
presents the T cell receptor specific antigen. This activation is only possible if it is supported 
by a helper T cell. In order to support cytotoxic T cells, CD4+ helper T cells have to be activated 
by APCs and become TH1 effector cells. Effector T cells promote expression of certain APC 
proteins, which induces a positive feedback loop and enhances the T cell response. Cytotoxic 
T cells kill their target cells by inducing apoptosis. This can be achieved by secretion of perforin, 
a pore-forming protein, or Fas ligand binding, which induces a caspase cascade. CD8+ and 
some CD4+ T cells show an additional anti-viral function by secreting interferon γ, which inhibits 
viral replication and makes infected cells more visible to cytotoxic T cells. 
In summary, both the innate and the adaptive immune response are crucial in the fight against 
pathogens. The innate system is able to initiate a very fast, unspecific response against intrud-
ers and plays an important role in the first hours and days after infection. The adaptive system 




unique ability to generate long-term memory and can elicit a very fast and strong response 
upon re-exposure with a pathogen (Alberts et al., 2002).  
 
1.1 T cell immunity 
T cells are crucial in the adaptive immune response. Various subtypes fulfill distinct functions 
and ensure immune maintenance in health and disease. Opposed to B cells, they only recog-
nize processed antigens presented in an MHC complex. T cells express a large variety of T 
cell receptors, which are generated by gene rearrangements and allow targeting of cells dis-
eased from infection or malignant transformation. Due to this capability, they attracted attention 
in the search of novel strategies for the fight against cancer. 
1.1.1 T cell development in the thymus 
The thymus, the site of T cell development, is supplied with hematopoietic progenitor cells from 
the bone marrow. The progenitor cells are mobilized from their niche and travel via the blood 
to the thymus, which they enter near the cortico-medullary junction. Upon entry, the cells are 
double-negative (DN1) and do not express CD4 or CD8. As the T cells mature, they migrate 
towards the subcapsular epithelium. T cell receptor (TCR) rearrangement takes place and α/β 
and γ/δ lineages develop (Starr et al., 2003). The majority of T cells carry TCRs composed of 
α/β subunit chains, which recognize peptide antigens. Less frequently, T cells express the γ/δ 
TCR and react to phosphoantigens. They are associated with the γ, δ, ε, and ζ subunits, which 
form the CD3 complex. This complex is responsible for signal transduction into the cells (Mor-
ath and Schamel, 2020). The large variety of TCRs, which ultimately allows an effective adap-
tive immune response, is based on the somatic assembly of TCR gene regions. During T cell 
development in the thymus, variable (V), diversity (D) and joining (J) gene segments are rear-
ranged by recombination-activating gene (RAG1/2) recombinases, which act by inducing dou-
ble-strand breaks at recombination signal sequences adjacent to the gene segments and non-
homologous end joining. After recombination of the TCRβ chain gene, the β chain first forms 
a pre-TCR together with a surrogate pre-α chain. Signaling through the pre-TCR induces re-
combinase downregulation, proliferation, differentiation and entry into the double positive state, 
in which T cells express both CD4 and CD8 (Krangel, 2009). CD4 and CD8 are coreceptors of 
the TCR required for T cell activation (Li et al., 2013). Double positive thymocytes subsequently 
reexpress the recombinases and the TCRα chain gene is recombined (Krangel, 2009).  
1.1.2 T cell maturation and differentiation 
Subsequent positive and negative selection steps ensure that the T cells released into the 
periphery are equipped with a functional, non-self reactive TCR. Positive selection is closely 




is terminated once an MHC-restricted receptor together with the TCRβ chain is formed. MHC 
molecules present peptides to the immune system. MHC class I molecules are expressed by 
virtually all cells and present endogenously synthesized peptide antigens to CD8+ cytotoxic T 
cells. MHC class II molecules are found on antigen-presenting cells (macrophages, dendritic 
cells and B cells) and present antigens after endocytic ingestion to CD4+ helper T cells (Rock 
et al., 2016). As successful TCR generation is an infrequent event, the majority of cells at this 
stage stays undifferentiated and expresses high levels of RAG enzymes (Starr et al., 2003). 
Over 90% of double positive thymocytes experience death by neglect and do not succeed in 
generating a useful TCR. Positive selection is granted to thymocytes that are capable of en-
gaging in interaction with cortical thymic epithelial cells (cTECs), a self-antigen presenting stro-
mal cell type. cTECs present MHC class I and II molecules on their surface. Interaction of 
double-positive cells with MHC class I molecules results in CD8 lineage commitment, interac-
tion with MHC class II molecules results in CD4 lineage commitment. After committing to the 
lineages, thymocytes migrate to the medulla. The single-positive cells undergo negative selec-
tion there by interacting with medullary thymic epithelial cells (mTECs) (Klein et al., 2014). In 
mTECs, the autoimmune regulator (AIRE) gene mediates the expression of peripheral tissue 
self-antigens on MHC class I molecules (Nagamine et al., 1997; Passos et al., 2018). The 
expression on MHC class II molecules is achieved by mTEC autophagy. Dendritic cells are 
additionally involved in self-antigen presentation on MHC class II molecules. Thymocytes in-
teract with several hundred antigen-presenting cells during their stay in the medulla. Single-
positive cells that show strong binding to these self-antigens are eliminated and undergo apop-
tosis (Klein et al., 2014). Negative selection ensures central tolerance and defects result in 
severe autoimmune disorders (Cheng and Anderson, 2018). Ultimately, non-self reactive, sin-
gle-positive naïve T cells, which express either CD8 or CD4, leave the thymus. 
CD8+ T cells directly kill their target cells and are termed cytotoxic T cells. CD4+ T cells, which 
are also termed helper T cells, assist other immune cells. Cytokines further influence the dif-
ferentiation of naïve T cells into various effector types. The effector types serve distinct function 
in the immune response. IL12 and IFNγ induce TH1 differentiation, which is required for antivi-
ral, antimicrobial and cell-mediated immunity. IL4 stimulation results in TH2 differentiation, 
which mediates the immune reaction against extracellular parasites. Certain cytokine combi-
nations initiate TH17 differentiation. TH17 cells provide immunity at mucocutaneous sites. Fol-
licular helper T (TFH) cells are differentiated by IL6, IL21 and/or IL27, and IL12 stimulation and 
support B cell activation, differentiation and generate long-term antibody responses (Tangye 
et al., 2013). The immunological tolerance towards self-tissues can only be maintained by an 
opponent CD4+ T cell type, the regulatory T (TREG) cells. Their main function lays in the op-




(Corthay, 2009). T cells can also differentiate into memory T cells, which provide long-term 
protection against pathogens and stay present decades after antigen exposure (Farber et al., 
2014). 
1.1.3 T cell activation 
Activation of a helper T cell or a cytotoxic T cell requires two signals in order to induce prolif-
eration and differentiation into an effector cell. These signals are provided by antigen-present-
ing cells. Signal 1 is induced by a peptide-MHC complex interacting with the T cell receptor 
and signaling through connected proteins. Signal 2 is provided by costimulatory proteins. Most 
importantly, CD28 on T cells engages with the B7 proteins (CD80 and CD86) on antigen-pre-
senting cells, which are upregulated by the innate response upon infection. T cells lacking 
signal 2 undergo apoptosis or cannot get activated anymore. T cell engagement with an anti-
gen-presenting cells results in induction of lymphocyte-function-associated protein 1 (LFA-1) 
on the T cells, which in turn binds to intracellular adhesion molecule 1 (ICAM-1) on the antigen-
presenting cells. This enhanced binding elongates the duration of the cell interaction and ena-
bles T cell activation. A negative feedback signal is provided by the inhibitory molecule CTLA-
4 expressed by T cells. It is similar to CD28, but allows B7 binding with higher affinity and 
represses T cell activation (Alberts et al., 2002).  
 
1.2 B cell immunity and malignancies 
1.2.1 B cell development and activation 
Conventional B cells (B2 B cells) originate from common lymphoid progenitor cells in the bone 
marrow. The early development stages depend on the status of the B cell receptor (BCR). The 
BCR consists of heavy and light chains, which require prior rearrangement of their immuno-
globulin gene segments. In pro-B cells, the heavy chain rearrangement takes place. The rear-
ranged heavy chain is expressed on the cell surface with a surrogate light chain (pre-BCR) 
and the cell enters the pre-B cell state (Mårtensson and Ceredig, 2000). Signaling through the 
pre-BCR terminates heavy chain rearrangement and initiates rearrangement of the light chain. 
After rearrangement of the κ or λ light chain, the immature B cells exit from the bone marrow 
to the periphery. Only non-self reactive B cells can exit the bone marrow. Self-reactive B cells 
are retained and can edit their receptor again by light-chain rearrangement (Hoffman et al., 
2016).  
Immature B cells leaving the bone marrow are called transitional T1 B cells. Primarily within 
the spleen, they acquire the T2 phenotype and further differentiate into marginal zone (MZ) or 




through the BCR. Low signaling strength favors MZ differentiation and high signal strength 
favors FO B cell differentiation. 
Marginal zone B cells reside in the marginal zone of the spleen and within structures of the 
lymph nodes and mucosa-associated lymphoid tissue. They directly interact with blood-borne 
antigen and transport it to the follicular dendritic cells (FDCs) in the follicles, which present 
antigens to B cells. FO B cells are enriched in primary follicles, but also represent the majority 
of mature B cells in the blood, bone marrow and other lymphoid organs. They interact with T 
cells and initiate germinal center (GC) responses (Cyster et al., 2000; Yam-Puc et al., 2018).  
Another subclass of B cells are B1 cells, which are not part of the adaptive immune system, 
but nevertheless take part in the humoral response. They produce natural immunoglobulins 
against conserved pathogen patterns (Prieto and Felippe, 2017). 
The BCR is crucial for B cell activation. Upon antigen binding to the BCR, internalization is 
initiated. The antigen is degraded and subsequently presented on the B cell surface in an MHC 
class II molecule. Activation can occur in a thymus-dependent or in a thymus-independent 
way. Protein antigens are thymus-dependent and require T cell help in order to elicit B cell 
activation. Helper T cells can recognize their specific antigen in an MHC class II complex. The 
T cell provides the B cell with the costimulatory molecule CD40L and cytokines, inducing B cell 
proliferation and differentiation in memory B cells and plasma cells, which secrete antibodies. 
Bacterial antigens are thymus-independent and do not require T cell help in order to enable a 
B cell response. Thymus-independent type 1 antigens, like lipopolysaccharides, can directly 
induce B cell proliferation. Thymus-independent type 2 antigens, such as polysaccharides of 
encapsulated bacteria, likely stimulate B cells by inducing crosslinking of B cell receptors and 
require costimulation by macrophages and dendritic cells (Murphy et al., 2008). FO B cells are 
preferably stimulated by thymus-dependent antigens, whereas marginal B cells and B1 B cells 
respond to thymus-independent antigens (Nutt et al., 2015).  
1.2.2 Lymphoid organs 
Lymphoid organs are classified as primary or secondary. Primary lymphoid organs are the 
bone marrow and the thymus, sites of lymphopoiesis and lymphocyte selection. The bone 
marrow in adults is located in the bone cavities of the central skeleton, the pelvis and parts of 
the long bones. Its main components are hematopoietic tissue islands, stem cells, adipocytes, 
stromal cells and vasculature (Nombela-Arrieta and Manz, 2017).  B and T progenitor cells are 
produced in the bone marrow. B cells also mature in the bone marrow, but T cells travel to the 
thymus, where they undergo differentiation and maturation (Pearse, 2006). Secondary lym-
phoid organs, which include the spleen, lymph nodes and mucosa-associated lymphoid tissue 
(MALT), are responsible for initiating an adaptive immune response by antigenic activation of 




erythrocytes; the white pulp hosts cells of the immune system. The marginal zone separates 
the white pulp from the red pulp. In the marginal zone, blood-borne antigen is collected by 
antigen-presenting cells, for instance marginal zone B cells. Rodents and primates show their 
greatest difference in lymphoid structure in the architecture of the marginal zone. In humans, 
the marginal zone is divided in an inner and outer zone, surrounded by the perifollicular zone, 
which hosts blood vessels endings wrapped by macrophages. Periarteriolar lymphoid sheaths 
(PALS) are regions of T cell accumulations around small vessels and B cells are located in 
adjacent follicles (Mebius and Kraal, 2005). Lymphocytes enter the lymph node and other 
SLOs, but not the spleen, via high endothelial venules (HEVs) from the blood (Indrasingh et 
al., 2002). Coming from tissues, antigens (mostly carried by dendritic cells) and leukocytes 
enter the lymph node via the afferent lymphatics (Braun et al., 2011). T cells are mostly located 
in the paracortex supported by a fibroblastic reticular cell (FRC) network, whereas B cells re-
side in follicles in the cortex supported by follicular dendritic cells (FDCs) (Bajénoff and Ger-
main, 2009). The structure of mucosa-associated lymphoid tissues (MALT), which are diffuse 
SLOs associated with the digestive tract (tonsils, Peyer‘s patches, appendix), is comparable 
concerning the T cell zones and B cell follicles (Cesta, 2006). Upon antigen contact, B cells 
initiate a germinal center (GC) reaction (Nieuwenhuis and Opstelten, 1984). In the GCs, B cells 
undergo B cell receptor (BCR) affinity maturation and class switch. Affinity maturation by so-
matic hypermutation of variable region genes is needed to achieve high antibody affinity (Vic-
tora and Nussenzweig, 2012).  
1.2.3 Lymphocyte migration and homing 
A functional immune response requires lymphocytes in certain places at certain times. B and 
T cells mature in primary lymphoid organs, travel in the blood to peripheral lymphoid tissues 
and migrate within lymphoid tissues. Lymphocytes continually circulate between peripheral 
lymphoid tissues, the blood and the lymph until they encounter antigen or eventually die. Key 
factors regulating entry into lymphoid organs from the blood and the lymph, and movements 
within these organs are chemokines. 
Chemokines are chemoattractive signaling proteins. Four subgroups were determined based 
on the location of the structurally critical cysteine residues closest to the N terminus: CC, CXC, 
CX3C and XC. They are the ligands for G protein-coupled heptahelical chemokine receptors. 
In most cases, the interaction between a chemokine and a receptor is promiscuous. Many 
chemokines bind to various receptors and many receptors can bind more than one chemokine 
(Hughes and Nibbs, 2018). Chemokine receptors are classified as homeostatic or inflamma-
tory. Homeostatic receptors are required for the shaping of lymphoid organs during develop-
ment and basal trafficking. Inflammatory receptors orchestrate leukocytes to sites of infection 




and inflammation (Bachelerie et al., 2014). The chemokine receptors CXCR4, CXCR5 and 
CCR7 are essential in homeostatic trafficking and maintaining the architecture of lymphoid 
structures (Förster et al., 1996, 1999; Ma et al., 1998). CXCR4 and its only ligand CXCL12 are 
highly conserved between species and crucial in embryonic development (D’Apuzzo et al., 
1997; DeVries et al., 2006). Most prominently, CXCL12 is expressed by stromal cells in the 
bone marrow and mediates the retention of stem cells and progenitor cells.  CXCL12 is also 
expressed in high endothelial venules, the lymph node medulla, the red pulp of the spleen and 
in germinal center reactions, especially in the dark zone. Thus, the CXCR4/CXCL12 axis reg-
ulates the entry to the bone marrow and secondary lymphoid organs and is required for ger-
minal center organization (Allen et al., 2004; Nie et al., 2004). CXCR5 is another chemokine 
receptor that plays a crucial role in maintaining lymphoid function and architecture. CXCL13, 
the only ligand for CXCR5, is produced by follicular dendritic cells (FDCs) and attracts CXCR5+ 
cells, leading to the formation of a B cell zone in secondary lymphoid organs (Cyster et al., 
2000). It is also indispensable for germinal center organization (Allen et al., 2004). CCR7 is 
another important chemokine receptor. In homeostasis, fibroblastic reticular cells (FRCs) se-
crete CCL19 and CCL21, the ligands for CCR7, and strongly attract CCR7+ cells, thus B cells, 
dendritic cells and naïve, regulatory and central memory T cells. In the lymph node for instance, 
the CCL19/21 gradient guides CCR7+ T cells to the T cell zone and CXCL13 leads CXCR5+ B 
cells to the B cell follicle. Upon activation, B cells downregulate CXCR5 and upregulate CCR7, 
resulting in a transient movement of follicular B cells to the T cell border, where they receive 
stimuli from helper T cells. A small subpopulation of T cells expresses only low levels of CCR7, 
but is CXCR5+. This chemokine expression profile enables these follicular helper T cells to 
provide B cell help for class switch and antibody production within the B cell follicle (Förster et 
al., 2008). Apart from the conventional chemokine receptors, atypical chemokine receptors 
have been identified, which fulfill other functions than the conventional receptors and usually 
do not activate signal transduction pathways. Instead, they regulate chemokine location and 
abundance by acting as chemokine shuttles or scavengers (Hughes and Nibbs, 2018). 
Adhesion molecules, especially integrins and selectins, also play a major role in the migration 
and homing of lymphocytes. Immune cells frequently travel via the blood and have to reach 
tissues to fulfill their functions. At their destination, they extravasate in order to migrate into the 
tissue. This process is called leukocyte extravasation cascade. First, the immune cells tether 
and slowly roll on the endothelium. The adhesion slows down the leukocyte movement and 
allows contact initiation between the vascular surface and the immune cell (Butcher and Picker, 
1996; Schnoor et al., 2015). Selectins are the initiators of leukocyte adhesion and mediate 
rolling on endothelial surfaces. They are transmembrane molecules with an N-terminal cal-




Lymphocytes express L-selectin (CD62L), whereas P-selectin and E-selectin are expressed 
by the endothelium. L-selectin guides naïve lymphocytes into secondary lymphoid organs via 
high endothelial venules (HEVs) by binding to CD34 and GlyCAM-1 on the vasculature. P-
selectin and E-selectin mediate adhesion of mature lymphocytes at sites of infection (Murphy 
et al., 2008). The cells subsequently firmly adhere to the vascular wall, crawl and form the 
transmigratory cup. Ultimately, the lymphocytes perform paracellular or transcellular diapede-
sis and cross the basement membrane (Butcher and Picker, 1996; Schnoor et al., 2015). 
These steps, as well as the previous rolling, are dependent on various integrins, most promi-
nently, LFA-1 and VLA-4 (Murphy et al., 2008). These integrins bind to ICAM-1 and VCAM-1 
on endothelial cells. Integrins are transmembrane αβ heterodimers, which link the cytoskeleton 
of the cells to the surrounding extracellular matrix. While rolling slowly, lymphocytes approach 
the endothelium and are activated by chemokines on the surface of endothelial cells. Chemo-
kine receptors on the lymphocytes engage with the chemokines and subsequently, lymphocyte 
integrins change their inactive confirmation and become activated (Muller, 2013). For instance, 
CCL21 is expressed by vascular HEVs, lymphoid tissue stromal cells and DCs in the T cell 
zones. The chemokine receptor CCR7, most prominently expressed on naïve T cells, recog-
nizes CCL21 on the endothelial cells and LFA-1 is subsequently activated, enhancing affinity 
for ICAM-1/2. ICAM-1 is found on HEVs on lymphoid organs, whereas ICAM-2 is ubiquitously 
expressed on endothelium. Upon entry into the T cell zone, naïve T cells are retained there by 
CCL19 and CCL21 and scan DC-MHC complexes for their TCR specific antigen (Murphy et 
al., 2008). Altogether, chemokines and adhesion molecules orchestrate the movement of leu-
kocytes in homeostasis and inflammation. 
1.2.4 The homeostatic chemokine receptor CXCR5 
The chemokine receptor CXCR5, also called CD185, was first identified in 1992. Originally 
detected in Burkitt’s lymphoma, it was named Burkitt’s lymphoma receptor 1 (BLR1). It was 
shown to be a novel member of the G protein-coupled receptor family with a limited expression 
pattern, which was indicative of a potential role in homeostatic trafficking and B cell activation 
in lymphoid tissues (Dobner et al., 1992). Flow cytometry analysis further revealed that CXCR5 
expression is restricted to B cells and subsets of CD4+ (14%) and CD8+ (2%) T cells in periph-
eral blood, and B and CD4+ T cells in secondary lymphoid organs, but is absent on B cells in 
the bone marrow, indicating that it marks mature B cells (Förster et al., 1994) (Figure 1). The 
expression profile for CXCR5 on B cells is therefore more stringent than for CD19, which is 





Figure 1: CXCR5 expression in B cell development. CXCR5 is expressed on mature B cells, GC B 
cells and memory B cells, whereas CD19 is also detected on Pro-/Pre-B cells and immature B cells. 
Stem cells and plasma cells do not express CXCR5 or CD19. The figure was adapted from Vale and 
Schroeder, 2010. 
 
Years of research showed that CXCR5 is indispensable in sustaining immune functions and 
lymphoid architecture. The quest for the ligand of CXCR5 ultimately revealed CXCL13 (origi-
nally termed B-cell attracting chemokine 1, BCA-1) as the only CXCR5-binding chemokine. 
CXCL13 is expressed at high levels in the follicles of the spleen, lymph nodes and Peyer’s 
patches. Analysis of the chemoattraction showed that it uniquely acts on mature B cells (Gunn 
et al., 1998; Legler et al., 1998). Follicular dendritic cells (FDCs) are a main source of CXCL13. 
FDCs are stromal cells in the follicle of SLOs, with the ability to trap immune complexes and 
presenting antigen to B cells. CXCL13 production allows them to gather CXCR5 expressing B 
cells in close proximity (Cyster et al., 2000). Later on, another mesenchymal cell type, marginal 
reticular cells (MRCs), which are located at the margin of SLOs, was identified as a producer 
of CXCL13. MRCs express MAdCAM-1 and CXCL13 at high levels in resting follicles, in which 
CXCL13 production by FDCs is limited (Katakai, 2012; Katakai et al., 2008). 
In order to study the function of CXCR5 in great detail, CXCR5 knock-out mice were generated. 
The mice were viable, fertile and showed structural abnormalities restricted to lymphoid tis-
sues. Structural abnormalities were only observed in CXCR5-/-, but not in CXCR5+/- mice. In 
CXCR5-/- mice, CXCR5 was virtually absent on B cells. Due to impaired lymphocyte migration, 
the structure of splenic follicles was disrupted. The formation of germinal centers was ham-
pered and activated B cells in the T cell areas could not enter the splenic B cell follicles. How-
ever, the humoral response to T cell-dependent antigens was not impaired and an antibody 
response was detected upon antigenic challenge. Moreover, the mutant mice lacked inguinal 
lymph nodes and Peyer’s patches were absent or structurally altered. Transfer experiments of 
B cells derived from CXCR5-/- mice into wild-type mice further showed that the mutant cells do 




the lymph nodes was not impaired. These knock-out experiments provided the first evidence 
that CXCR5 is involved in microenvironmental homing of lymphocytes and guides B cells to 
defined lymphoid structures (Förster et al., 1996).  
CXCR5 is, like the knock-out mouse model showed, involved in the organogenesis of second-
ary lymphoid organs. Together with other homeostatic chemokine receptors, especially CCR7, 
CXCR5 orchestrates the development of lymph nodes, mesenteric lymph nodes excluded, and 
Peyer’s patches. CXCR5 guides CD3-CD4+ hematopoietic precursor cells, which are attracted 
by mesenchymal cells, to these prospective lymphoid development sites. The precursor cells 
further express lymphotoxin (LT)α1β2, IL-7Rα and α4β7 integrin (Ohl et al., 2003). They even-
tually develop into antigen-presenting dendritic cells, macrophages or NK cells. Lymph node 
organogenesis is initiated by the formation of lymph sacs by budding of endothelial cells. Con-
nective tissue follows and gives rise to lymph node anlagen. The lymphatic vasculature sub-
sequently develops from the lymph sacs. Early in formation, the lymph node anlagen are pop-
ulated by the CXCR5 expressing precursor cells. They signal through their IL-7Rα, inducing 
lymphotoxin expression, which is indispensable in lymphoid organogenesis. Mutant mice with 
LTβR, LTα or LTβ deficiency do not develop lymph nodes (Mebius, 2003). The LTβR+ mesen-
chymal cells are stimulated to produce chemokines and adhesion molecules (Ohl et al., 2003). 
As lymphotoxin signaling pathways are also crucial in the development of Peyer’s patches, the 
mutant mice lacked those lymphoid structures as well. The development of Peyer’s patches 
starts at the adhesion molecules VCAM-1 and ICAM-1 expressing spots. Subsequently, the 
CD3-CD4+ hematopoietic precursor cells are recruited. In the last development phase, mature 
B and T cells populate the Peyer’s patch anlagen (Mebius, 2003). The organogenesis of the 
mesenteric lymph nodes and the spleen is not hampered in CXCR5-deficient mice and other 
mechanisms are in place to attract hematopoietic precursors; however, the structure of primary 
B cell follicles is severely disrupted (Ohl et al., 2003). The development of splenic B cell follicles 
requires a positive feedback loop involving the CXCR5/CXCL13 axis and lymphotoxin signal-
ing. Follicular dendritic cells express CXCL13 and attract CXCR5+ B cells. CXCR5 signaling 
initiates LTα1β2 expression on the B cells, resulting in LTβR signaling on FDCs, which in turn 
induces CXCL13 expression (Ansel et al., 2000; Ngo et al., 1999). 
In 2000, a CXCR5+ T cell subset was identified with the unique feature to home to the B cell 
follicles of secondary lymphoid organs. These cells were shown to promote the production of 
isotype switched antibodies in tonsillar B cells and termed follicular helper T (TFH) cells. Their 
expression profile showed that they are a subtype of memory T cells. In the blood, they coex-
press CD45RO, the T cell homing receptor CCR7 and the adhesion molecule CD62L. Inter-
estingly, around 10% of CXCR5+ cells in the blood are CD8+, whereas almost all CXCR5+ cells 




access to B cell follicles and germinal centers. In germinal centers, they highly express CD40 
ligand (CD40L) and the inducible costimulator (ICOS), which promote B cell activation and 
differentiation. In comparison with their CXCR5- counterparts, CD4+CD45RO+ TFH cells 
strongly support immunoglobulin A and G production. CXCR5+ T cells in the peripheral blood 
are however in a resting state and do not express costimulatory molecules (ICOS, CD40L, 
OX40) (Breitfeld et al., 2000; Schaerli et al., 2000a).  
Expression studies of lymphoma and leukemia cells revealed that CXCR5 is abundant on nu-
merous B cell malignancies, such as follicular lymphoma, mantle cell lymphoma, chronic lym-
phocytic leukemia; thus, on neoplasms derived from mature B cells. It is absent on precursor 
B-ALL and multiple myeloma, derived from immature B cells and plasma cells respectively 
(Dürig et al., 2001).  
1.2.5 Cellular origin and pathogenesis of B-NHLs 
Originating from malignant B cells, B non-Hodgkin lymphomas (NHL) are a highly diverse 
group of tumors. The lymphoma classification was provided by the World Health Organization. 
The classification of subtypes is based on morphologic, immunologic, genetic and histologic 
features of the malignant cells and clinical characteristics of the disease (Harris et al., 1994). 
It is frequently updated in order to include new entities and diagnosis criteria to facilitate treat-
ment decisions for clinicians (Swerdlow et al., 2016). Around 17.000 non-Hodgkin lymphoma 
patients are newly diagnosed every year in Germany (Robert Koch institute, 2018). It is largely 
a disease of the elderly with a median age of 69 years at diagnosis, with males having an 
earlier diagnosis and higher incident rates (Smith et al., 2015). The overall 5-year relative sur-
vival for these patients is 63%, decreasing in old age and highly dependent on the lymphoma 
entity. The most common entities, follicular lymphoma and diffuse B cell lymphoma, have sur-
vival rates of 78% and 57% respectively (Pulte et al., 2013). Acquired or congenital immuno-
deficiency, treatment for certain types of cancer, the exposure to solvents and infection with 
Epstein-Barr virus or Helicobacter pylori are considered to be risk factors for developing certain 
non-Hodgkin lymphomas (Cocco et al., 2010; Ekström Smedby et al., 2008; Goedert et al., 
1998; Henle et al., 1968; Kaldor et al., 1987; Wotherspoon et al., 1991). Figure 2 gives an 






Figure 2: The cellular origin of B cell lymphomas. ALL (Acute lymphoblastic leukemia) is a B cell 
progenitor neoplasm. CLL (Chronic lymphocytic leukemia) is either derived from pre-germinal center 
(GC) CD5+ B cells or GC B cells. MCL (Mantle cell lymphoma) is derived from pre-GC mantle zone B 
cells. cHL (Classical Hodgkin’s lymphoma), FL (Follicular lymphoma), BL (Burkitt’s lymphoma), DLBCL 
(Diffuse large B cell lymphoma) and MZL (Marginal zone lymphoma) have their origin in GC/post-GC B 
cells. MM (Multiple myeloma) originates from plasma cells. Pre-GC-derived neoplasms do not harbor 
mutations in variable-region genes; GC/post-GC-derived malignancies show somatic mutations in vari-
able-region genes. Figure was adapted from Küppers et al., 1999. 
 
Diffuse large B cell lymphoma (DLBCL) is the most frequent type with 31% of NHL cases (The 
Non-Hodgkin’s Lymphoma Classification Project, 1997). Mutated variable region genes indi-
cate that DLBCL is derived from (post) germinal center B cells. They accumulate a particularly 
high number of mutations due to prolonged residence in the germinal center (Küppers et al., 
1997). Therapeutic outcome shows great heterogeneity due to previously unrecognized sub-
classifications. (Alizadeh et al., 2000; Choi et al., 2009).  
With 22% of NHL patients, follicular lymphoma (FL) is the second most frequent type (The 
Non-Hodgkin’s Lymphoma Classification Project, 1997). Considered incurable, FL is however 
an indolent disease with a medium survival of over 10 years (Vidal et al., 2017).  Most patients 
carry a t(14;18) translocation that juxtaposes the antiapoptotic gene BCL2 with the immuno-
globulin heavy chain locus (McDonnell et al., 1989; Tsujimoto et al., 1985; Vaux et al., 1988). 
Follicular lymphoma cells show somatic mutations in variable chain genes, which indicate their 
origin in germinal center B cells (Bahler et al., 1991; Oprea and Perelson, 1997).  
Marginal zone lymphoma is the third most common subtype of NHL with 9% of patients (The 
Non-Hodgkin’s Lymphoma Classification Project, 1997). The cells of origin are marginal zone 
B cells that show somatic mutations in variable region genes (Tierens et al., 1998). Most pa-
tients show extranodal involvement of mucosa-associated lymphoid tissue (MALT); nodal and 
splenic MZL are less common (Olszewski and Castillo, 2013; Swerdlow et al., 2016). In gastric 




infection (Wotherspoon et al., 1991). The overall 5-year survival for MZL patients is around 
80%, with differences depending on the site of origin (Olszewski and Castillo, 2013). 
7% of non-Hodgkin lymphoma patients suffer from mantle cell lymphoma (MCL) (The Non-
Hodgkin’s Lymphoma Classification Project, 1997). MCL is derived from pre-germinal center 
B cells and somatic mutations are absent or very rare (Hummel et al., 1994). It is an aggressive 
disease with a five-year overall survival rate between 34% and 83%, depending on the risk 
classification (Hoster et al., 2014). At the time of diagnosis, patients present with advanced 
disease with involvement of lymph nodes, bone marrow and in some cases with lymphocytosis 
and gastrointestinal disease. Most cases show t(11;14) translocation with Bcl1 rearrangement 
and cyclin D1 deregulation, which disrupts cell cycle regulation (Baldin et al., 1993; Samaha 
et al., 1998; Shui et al., 2003). 
Chronic lymphocytic leukemia (CLL) cases account for 7% of all NHL diagnoses (The Non-
Hodgkin’s Lymphoma Classification Project, 1997). It is characterized by expansion of mature 
lymphocytes in the blood and possibly in the lymph nodes, bone marrow and spleen (Cheson 
et al., 1996). Small lymphocytic leukemia is identical to CLL, with CLL patients showing a 
higher count of lymphocytes in the peripheral blood (Tsimberidou et al., 2007). Somatic muta-
tions are found in more than half the cases, indicating their origin in (post) GC B cells. A large 
fraction of CLL patients does not show any mutations, indicating that the origin of their disease 
is germinal center independent (Fais et al., 1998). The unmutated form is associated with a 
more aggressive disease progression (Hamblin et al., 1999). The neoplastic B cells show dis-
tinctive CD5 expression and a particularly low amount of surface immunoglobulin (Marti et al., 
1992; Ternynck et al., 1974). Many patients do not require immediate treatment and the pro-
gression of their disease is only monitored (CLL Trialists’ Collaborative Group, 1999). 
Burkitt lymphoma (BL) is a rare subtype with less than 1% of NHL patients suffering from this 
disease (The Non-Hodgkin’s Lymphoma Classification Project, 1997). Unlike in the other sub-
types of B non-Hodgkin lymphoma described, around half the patients are under 40 years old, 
with a 5-year relative survival of 56% among all age groups and a worse survival in the older 
age groups (Costa et al., 2013). It was the first cancer that could be associated with viral in-
fection (Epstein et al., 1964). The hallmark translocation t(8;14) leads to myc deregulation 
(Taub et al., 1982; Zech et al., 1976). It can be further classified as sporadic, endemic (Epstein-
Barr virus and malaria associated) or immunodeficiency-related (HIV associated) (Jaffe et al., 
1999; Mutalima et al., 2008). 
1.2.6 Dissemination and localization of B-NHLs 
The migration and homing of lymphocytes to lymphoid organs is strongly regulated by chem-
okines. Expression of chemokine receptors on lymphoma and leukemic cells allows them to 




lymphocytes. CXCR4 is broadly expressed in B cell malignancies. It is found on precursor B-
ALL, but also on neoplasms originating from mature B cells, such as chronic lymphocytic leu-
kemia, follicular lymphoma, mantle cell lymphoma, and plasma cell-derived multiple myeloma 
(Dürig et al., 2001). CXCR5 shows a smaller expression profile and is absent on precursor B-
ALL and multiple myeloma, but expressed by diffuse large B cell lymphoma (DLBCL), marginal 
zone lymphoma (MZL), CLL, FL and MCL. CCR7 expression was described for DLBCL, CLL 
and MCL. Especially CLL cells express high levels of the three chemokine receptors CXCR4, 
CXCR5 and CCR7. Generally, the chemokine receptor profile of lymphoma and leukemia cells 
parallels that of their cells of origin. The neoplastic receptor combination determines to which 
anatomical sites within the body the malignant cells migrate (Du et al., 2019; López-Giral et 
al., 2004; Middle et al., 2015a). In secondary lymphoid organs, follicular lymphoma and diffuse 
large B cell lymphoma are frequently found, whereas this location is less common for marginal 
zone lymphoma and mantle cell lymphoma. The majority of lymphomas in the extranodal site 
of the ocular adnexa are extranodal marginal zone lymphomas. Blood involvement is most 
often described for follicular lymphoma and mantle cell lymphoma. Certain molecules orches-
trate lymphoma dissemination into the distinct anatomical locations. CCR7, CCL21 and LFA-
1 regulate the entry into secondary lymphoid organs for healthy lymphocytes. However, in 
malignancy, only CCL21 is highly upregulated in lymphomas with SLO involvement and facili-
tates lymph node dissemination. Healthy lymphocytes require CXCR4, CXCL12 and VLA-4 to 
access extranodal tissues. Analysis of lymphoma cells showed that CXCR4 and VLA-4 are 
expressed at higher levels and play a role in the migration of malignant cells to extranodal sites 
like the ocular adnexa (Middle et al., 2015a). The CXCR4/CXCL12 axis is especially crucial in 
bone marrow homing. Bone marrow stromal cells produce CXCL12 and attract CXCR4 ex-
pressing lymphoma cells, allowing them access to survival niches (Burger, 2011; Panayiotidis 
et al., 1996). CXCR4 expression was shown to promote tumor cell proliferation and reduce 
apoptosis (Huang et al., 2019). The axis can be inhibited by CXCR4 antagonists, resulting in 
the release of lymphoma cells into the blood, which makes them more accessible to treatments 
like chemotherapy or B cell antibodies (Burger, 2011; Hu et al., 2012). Factors that regulate 
tissue retention are CXCR5, CXCL13 and the lipid signaling receptor S1PR2. In lymphoma, 
CXCR5 is upregulated in malignancies involving SLO and extranodal sites, whereas S1PR2 is 
only expressed at higher levels in SLOs (Middle et al., 2015b). Lymphoma cells expressing 
CXCR5 are activated and attracted by CXCL13 (Burger, 2011). The egress receptor S1PR1 is 
highly upregulated in leukemic lymphomas, which is surprising as S1PR1 on healthy lympho-
cytes is rapidly internalized upon ligand binding and they only express S1PR1 at very low 





1.3 The tumor microenvironment  
Tumorigenesis is a multistep process. Cells gradually gain capabilities, termed the six hall-
marks of cancer, which turn them malignant (Hanahan and Weinberg, 2000, 2011). Most im-
portantly, cancer cells maintain proliferative signaling. Genetic alterations cause continuous 
activation of signaling pathways or dysfunctions in negative-feedback loops. Also, tumor cells 
learn to escape growth suppressors, mainly dependent on the function of tumor-suppressor 
genes, which act as gatekeepers. Malfunction results in constitutive proliferation (Feitelson et 
al., 2015). Another hallmark is cell death inhibition. Benign cells undergo apoptosis under cer-
tain circumstances, but this mechanism is disrupted in malignant cells. Also, as cancer cells 
evade apoptosis and senescence, they achieve replicative immortality (Lowe and Lin, 2000; 
Voutsadakis, 2000). As tumor cells grow, they increasingly require access to nutrients and 
oxygen. Thus, inducing angiogenesis is another hallmark of cancer (Hanahan and Folkman, 
1996; Ruan et al., 2009). It is also characteristic of malignant cells to metastasize and invade 
tissues. Cancerous cells metastasize by altering their shape and the expression of molecules 
that attach them to neighboring cells and the extracellular matrix (Cavallaro and Christofori, 
2004). A recently added hallmark considers the altered energy metabolism in tumor cells. Tu-
morigenic growth and proliferation require reprogramming of metabolic processes. Most prom-
inently, a metabolic switch that allows aerobic glycolysis is frequently found in neoplastic cells 
(DeBerardinis et al., 2008). In short, the hallmarks of cancer are acquired functional capabilities 
that allow survival, proliferation and dissemination of tumor cells. Their acquisition is driven by 
two enabling characteristics. First, a lack of genomic stability in cancer cells causes random 
mutations, which can equip them with the hallmark capabilities (Negrini et al., 2010). A fraction 
of mutant cells gains selective advantages, achieving outgrowth and dominance. Secondly, in 
recent years, immune cells were recognized as active contributors to tumorigenesis in the in-
flammatory environment of premalignant and malignant lesions. Tumors have long been 
known to be abundantly infiltrated with cells of the innate and adaptive immune system, creat-
ing an environment similar to inflammation in non-neoplastic tissues (Grivennikov et al., 2010; 
Pagès et al., 2010). In the past, the involvement of the immune system was considered exclu-
sively an anti-tumor response. Mouse models showed that tumor incidence or progression is 
increased in animals with T cell, NK cell or macrophage deficiencies; similarly, in humans, 
immunodeficient and immunosuppressed individuals also show significantly higher suscepti-
bility to cancer (Ostroumov et al., 2018). Cancer is indeed pressured to avoid destruction by 
the immune system, but recent research surprisingly indicates that tumor-associated inflam-
mation promotes tumorigenesis. Inflammatory processes were shown to provide factors for all 
hallmark capabilities, such as survival factors, growth factors, and enzymes that modify the 




Zhou, 2009). Interestingly, the immune system is already involved at the very early stages of 
tumorigenesis and even contributes to mutagenesis by releasing mutagenic reactive oxygen 
species (Hussain et al., 2003). The tumor microenvironment contributes in a previously unex-
pected manner to the accumulation of hallmark traits and promotes tumorigenesis (Hanahan 
and Weinberg, 2011). 
1.3.1 The tumor microenvironment in B cell lymphoma and leukemia 
B cell neoplasms are a highly diverse group of cancers; the composition and inflammatory 
status of their tumor microenvironment differs greatly depending on the subtype. Three major 
patterns of tumor microenvironments in lymphoma can be distinguished. The first is the “re-
education” pattern, which occurs for instance in follicular lymphoma. In this pattern, the lym-
phoma cells are strongly dependent on survival and proliferation stimuli from their environment. 
The microenvironment is largely similar to healthy lymphoid tissue. The second pattern, “re-
cruitment”, is found in classical Hodgkin’s lymphoma and provides a microenvironment that 
differs from normal tissue, but strongly supports the lymphoma cells.  “Effacement” is the third 
pattern, which occurs in Burkitt’s lymphoma. In this pattern, genetic alterations provide the 
tumor cells with strong autonomy from their surroundings. The microenvironment in these lym-
phomas is minor and effaced by tumor cells (Scott and Gascoyne, 2014). The malignant cells 
in lymphoma and leukemia benefit to a smaller or larger extend from the environment intended 
for the maturation and proliferation of normal B cells. In the development of healthy lympho-
cytes, proliferation stimuli in the bone marrow give rise to B cells with a functional B cell recep-
tor. The B cells migrate to secondary lymphoid organs and mature in germinal centers with 
help from CD4+ T cells and stromal cells. Cells of the microenvironment provide support at all 
development stages for non-transformed B cells. Lymphoma cells do not only take advantage 
of these mechanisms, but also manipulate their surrounding in order to support tumorigenesis. 
1.3.2 Tumor-stroma interaction and microenvironment remodeling in B cell  
neoplasms 
In the microenvironment of B cell lymphoma and leukemia, stromal cells, conventional and 
regulatory T cells, and tumor-infiltrating myeloid cells (TIMs) derived from bone marrow hem-
atopoietic stem cells were shown to be closely involved in pathogenesis. Interestingly, the tu-
mor cells are engaged in reciprocal interactions with the cells of the microenvironment and 
remodel their surroundings to meet their needs (Höpken and Rehm, 2019). 
Stromal cells in lymphoma include mesenchymal cells and vascular endothelial cells. Mesen-
chymal cells in the bone marrow support normal hematopoiesis by providing growth factors 
and attachment sites and can be accessed by the CXCR4/CXCL12 axis. Fibroblastic reticular 
cells, which provide the cytokines CCL19 and CCL21, and follicular dendritic cells, which se-




proliferation of B cells in SLOs. Lymphoma cells benefit from stimulation by chemokines and 
other factors secreted by mesenchymal cells in lymphoid organs (Burger, 2011; Höpken and 
Rehm, 2019). The importance of bone marrow stromal cells (BMSCs), which are obtained from 
human bone marrow donations, was shown in numerous coculture experiments with lym-
phoma cells. First demonstrated for CLL cells, BMSCs activate the tumor cells in vitro and 
provide them with drug resistance (Panayiotidis et al., 1996). Cocultures of primary mantle cell 
lymphoma with bone marrow-derived stromal cells showed correspondingly that the tumor 
cells are able to expand long-term and are also provided with increased drug resistance. The 
mesenchymal cells produce BAFF (B cell activating factor), which binds to BAFF-R on MCL 
cells and constitutively activates the nuclear factor-κB (NF-κB) pathway. NF-κB signaling in-
duces MCL chemotaxis towards CXCL12/CXCL13 and upregulates anti-apoptotic proteins like 
BCL2 (Medina et al., 2012). BMSCs additionally induce oncogenic signaling pathways, for in-
stance by β-catenin stabilization in the Wnt pathway in CLL or acute lymphoblastic leukemia 
(ALL), which induces constitutive activation (Mangolini et al., 2018; Yang et al., 2013). En-
hanced proliferation activity of lymphoma cells requires them to fulfill their need for increased 
uptake of nutrients. The required changes in the neoplastic metabolism can be induced by 
mesenchymal cells. BMSCs were described to promote mitochondrial oxidative phosphoryla-
tion and glycolysis in multiple myeloma (Marlein et al., 2019).  
FRCs and FDCs, which are mesenchymal cells in secondary lymphoid organs, cannot be eas-
ily obtained from humans and their function was mainly studied in mouse models. Access to 
follicular FDCs was shown to be crucial in the pathogenesis of murine chronic lymphocytic 
leukemia. As mentioned earlier, access to FDCs is CXCR5-dependent and induces prolifera-
tion in leukemic cells. Correspondingly, access to the FRC network within T cell zones is 
CCR7-regulated and can provide murine lymphoma cells with survival stimuli. The interaction 
between leukemic cells and FRCs/FDCs was shown to be reciprocal and establishes a positive 
feedback loop. Chemokine receptor-mediated signaling induces LTα1β2 expression on the 
malignant B cells, leading to LTβR signaling on FRCs and FDCs, which in turn triggers chem-
okine expression (Heinig et al., 2014; Rehm et al., 2011). Numerous mechanisms for reciprocal 
interactions were not only described for mesenchymal cells in the SLOs, but also in the bone 
marrow. In B acute lymphoblastic leukemia, leukemic cell adhesion via VCAM-1/VLA-4 was 
shown to induce NF-κB signaling in BMSCs, which provided a pro-inflammatory environment 
and chemoresistance for the malignant cells (Jacamo et al., 2014). Reciprocal interactions 
were also described to induce metabolic alterations in BMSCs. CLL cells require cysteine, 
which is however limited due to poor uptake ability of the oxidized form. BMSCs are able to 
take up the oxidized cysteine and convert it to the usable form of cysteine for the lymphoma 




Summing up, mesenchymal cells were shown to establish three of the hallmarks of cancer in 
lymphoma cells. They promote apoptosis evasion by inducing anti-apoptotic proteins in the 
malignant cells; they induce constitutive proliferation upon induction of oncogenic signaling 
pathways and make changes to the lymphoma metabolism. The interaction between leukemic 
cells and mesenchymal cells is reciprocal and the tumor cells have the capability to remodel 
their mesenchymal neighbor cells. Most importantly, lymphoma cells alter the gene expression 
following the induction of signaling pathways and change the metabolism of mesenchymal 
cells. These alterations result in the production of pro-inflammatory chemokines and activation 
markers in mesenchymal cells, which creates a pro-inflammatory tumor microenvironment  
(Mangolini and Ringshausen, 2020).  
Endothelial cells of the vasculature are another stromal cell subtype in lymphoma and leuke-
mia. Lymphoma cells can induce angiogenesis by expressing vascular endothelial growth fac-
tors (Gloger et al., 2020). Vascularization is especially prominent in aggressive lymphoma and 
an angiogenesis-related expression profile was shown to be associated with poor prognosis 
for DLBCL (Ribatti et al., 2013). 
Tumor-infiltrating myeloid cells, which include macrophages, dendritic cells, neutrophils and 
myeloid-derived suppressor cells, strongly hamper the adaptive and innate anti-tumor re-
sponse. They differentiate from hematopoietic stem cells upon long-term stimulation with sub-
stances released from the tumor, but tumor-associated macrophages also develop from tissue-
resident macrophages. As they are tumor-induced, they provide an example for tumor micro-
environment remodeling. Lymphoma infiltration with TIMs is associated with therapy failure 
(Awad et al., 2018). 
T cells and NK cells are lymphoid cells that play a role in lymphoma/leukemia progression, for 
instance by lymphoma stimulation or reduced killing capacities. CD4+ helper T cells were de-
scribed to stimulate lymphoma cell proliferation in various B-NHL entities. For example, they 
were shown to engage with CLL cells in proliferation centers or pseudofollicles located in the 
white pulp of the spleen, the bone marrow and the lymph nodes. There, they activate CLL 
tumor cells by CD40L signaling (Ghia et al., 2002; Patten et al., 2008). CD40-mediated stimu-
lation was equally important for follicular lymphoma and IL4 provided by follicular helper T cells 
was shown to induce proliferation (Scott and Gascoyne, 2014). T cell activities are closely 
related to the interactions that contribute to the lymphoma’s ability to escape the antitumor 
response of the immune system. Three main mechanisms contribute to this immune evasion. 
First, the tumor cells alter expression of surface molecules, which allows them to minimize 
their immunogenicity. Secondly, lymphoma cells directly weaken the function of immune cells 
and thirdly, they engage immunosuppressive cells at the site of lymphoma progression. As the 




loss is prevalent in malignant cells. Lymphoma cells lose MHC II expression by homozygous 
gene deletions, translocation of the CIITA MHC II master regulator or partial plasma cell differ-
entiation. MHC II downregulation contributes to invisibility from the immune system, most likely 
by preventing tumor antigen presentation to helper T cells, which in turn hampers cytotoxic T 
cell activation. Additionally, mutations in a subunit of the MHC I molecule, the β2-microglobulin, 
were shown to be very common in DLBCL, which allows immune escape from cytotoxic T cells 
as it prevents successful tumor antigen presentation. MHC I loss makes the tumor cells vul-
nerable to NK cells, which recognize MHC I downregulation; however, the malignant cells also 
lack CD58, a ligand required for cell elimination by NK cells and cytotoxic T cells. Some lym-
phomas express PD-L1 and PD-L2, which are the ligands for programmed cell death 1 (PD-
1), and induce exhaustion in cytotoxic T cells and T helper cells. In the tumor microenvironment 
of FL and classical Hodgkin’s lymphoma, recruitment of immunosuppressive immune cells was 
described. These lymphomas are especially enriched in regulatory T cells, which were shown 
to hamper the proliferation and cytotoxic activity of CD8+ T cells (Scott and Gascoyne, 2014).  
The mechanisms of lymphoma immune escape also present a challenge in adoptive T cell 
therapy in lymphoma treatment, which has to be addressed and overcome.  
1.3.3 B non-Hodgkin lymphoma mouse models 
Various mouse models make it possible to study the onset and progression of B cell neo-
plasms. They further allow investigation of migration pattern of malignant cells and testing of 
novel treatment options. Murine models are either spontaneous and occur in genetically mod-
ified animals or induced by implantation of malignant cells (Donnou et al., 2012). A very com-
monly used mouse model is the Eμ-myc model. In these transgenic mice, c-myc is expressed 
under the IgH enhancer (Adams et al., 1985). MYC is highly expressed in proliferating cells 
and deregulated in many types of cancer. Most prominently, it is translocated in Burkitt’s lym-
phoma, but it is also rearranged in diffuse large B cell lymphoma (Nesbit et al., 1999). The Eμ-
myc model recapitulates the pathogenesis of these two lymphomas. At an early time of tumor 
onset, the malignant cells show features similar to tumor cells in Burkitt’s lymphoma. After day 
400, neoplastic mature B cells are detected, which resemble DLBCL (Donnou et al., 2012; 
Mori et al., 2008). Bichi et al. generated and described the Eμ-Tcl1 model, in which mice de-
velop expansion of CD5+ B cells. Tcl1 is involved in chromosomal translocation and inversion 
in mature T cell leukemias, but it is also highly expressed in some B cell lines derived from 
human tumors and B cell malignancies. Double-negative T cells and B cells at several devel-
opment stages, ranging from pre-B cells to GC B cells, are healthy cells expressing Tcl1. In 
Eμ-Tcl1 mice, the human Tcl1 transgene was introduced under the control of the immuno-
globulin heavy chain Eμ-enhancer, targeting expression of Tcl1 in immature and mature B 




with pathogenesis corresponding to chronic lymphocytic leukemia (CLL) in humans. Their 
spleens and livers are enlarged, the cellularity in the peritoneal cave and the number of circu-
lating lymphocytes is increased and they suffer from advanced lymphadenopathy. Human CLL 
cells show low proliferative activity, which was resembled by the Eμ-Tcl1 tumor cells as they 
do not actively divide (Bichi et al., 2002). The Eμ-Tcl1 tumor cells strongly express CXCR5, 
CXCR4 and CCR7. In our group, it was shown that the leukemic cells require CXCR5 to access 
the follicular dendritic cells in the B cell follicle, which provide them with proliferation stimuli. 
CLL cells that lack CXCR5 are denied access to their survival niche and disease progression 
was delayed in these mice (Heinig et al., 2014). 
Oftentimes, immunodeficient mouse models are used in leukemia/lymphoma research, as they 
allow engraftment of human tumor cells. They bridge the gap between humans and rodent 
models (Shultz et al., 2012). NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice harbor genetic mu-
tations causing immunodeficiency. A severe combined immunodeficiency (scid) mutation in 
the DNA repair protein Prkdc induces B and T cell deficiency. The null allele of the IL2 receptor 
common gamma chain (IL2rgnull) inhibits cytokine signaling and results in NK cell deficiency. 
The mutations were crossed onto the NOD strain background, which is intrinsically defective 
in innate immune functions. Due to the lack of lymphocytes, lymphoid structures are severely 
affected. The splenic follicular structure is lost and lymph nodes are hypocellular and strongly 
diminished in size (Shultz et al., 2005). The development of immunodeficient mice allowed 
studying human cells and tissues in vivo. NSG mice engrafted with human patient-derived 
xenografts (PDX) or cell lines are used to study carcinogenesis, metastasis and the efficacy of 
drugs or immunotherapeutic treatments (Shultz et al., 2007). 
 
1.4 Pharmacological and immunological targeting of B-NHLs 
1.4.1 Pharmacological treatment of B-NHLs 
Indolent types of for B non-Hodgkin lymphomas are frequently monitored and might not need 
treatment. In early stages, radiation treatment of affected and adjacent lymph nodes is an op-
tion (Ahmed et al., 2013; Ott et al., 2003). Often, treatment of slowly progressing low-grade 
lymphoma is not advantageous and is usually only initiated upon disease aggravation (CLL 
Trialists’ Collaborative Group, 1999). 
For aggressive B-NHL entities, intensive chemotherapy is indicated. Combinatorial therapy 
has been long shown to be beneficial for patient survival (Habermann et al., 2006). Chemo-
therapy is therefore administered in combination with immunotherapy. In more detail, the 
standard first-line treatment for B non-Hodgkin lymphomas has been R-CHOP (Rituximab, Cy-
clophosphamide, Doxorubicin, Vincristine and Prednisone) (Watanabe et al., 2011). The cyto-




the anti-inflammatory glucocorticoid Prednisone (CHOP) (Below and M Das, 2020; Johnson-
Arbor and Dubey, 2020; Ogino and Tadi, 2020; Puckett et al., 2020). CHOP is often supple-
mented with Rituximab, a B cell specific monoclonal CD20 antibody, which was shown to be 
superior to CHOP-only treatment (Habermann et al., 2006; Reff et al., 1994; Tariq et al., 2018). 
Monoclonal antibodies can hamper tumor growth and destroy lymphoma cells in various ways. 
For instance, Fc receptor expressing effector cells mediate antibody-dependent cytotoxicity 
and the complement system induces lysis by complement-dependent cytotoxicity upon anti-
body opsonization of tumor cells (Harjunpää et al., 2000; Manches et al., 2003). Pathway in-
hibitors are another addition to targeted therapy. These small molecules inhibit for instance 
BCR signaling and hamper neoplastic growth (Advani et al., 2013; Herman et al., 2014). Ibru-
tinib is an oral BCR inhibitor that works by inhibiting Brutin tyrosine kinase, which acts down-
stream of the BCR (Crisci et al., 2019). Moreover, checkpoint inhibitors are used to unleash 
the anti-tumor potency of the immune system. PD-1 and CTLA-4 are co-inhibitory receptors 
that downregulate T cell activity (Blank et al., 2004; Freeman et al., 2000; Krummel and Allison, 
1995). Monoclonal antibodies can inhibit the activation of these receptors and potentiate the T 
cell anti-tumor response. Nivolumab, directed towards PD-1, and Ipilimumab, directed towards 
CTLA-4, are antibodies used in clinical application (Ansell et al., 2009; Lesokhin et al., 2016).  
1.4.2 Adoptive T cell transfer 
Despite improvements in the therapy options for B non-Hodgkin lymphoma patients, such as 
monoclonal antibodies, pathway inhibitors and checkpoint inhibitors, many patients still relapse 
(Coiffier et al., 2010; Kluin-Nelemans et al., 2012). These relapsed patients can be further 
treated with adoptive T cell transfer (ATT). ATT is the treatment of patients with autologous or 
allogenic T cells, thus patient-derived or donor-derived cells.  
For many decades, stem cell transplantation has been the treatment of choice. Autologous 
transplantation, using patient-derived blood or bone marrow, is more common and shows less 
toxicity (Ali et al., 2015; Buadi et al., 2006; Philip et al., 1995; Smith et al., 2018). In allogenic 
transplantation, the donor cells can remove residual tumor cells in the patient in a graft-versus-
leukemia effect, however, in these patients, the graft-versus-host effect is extremely pro-
nounced and has to be clinically managed (Barnes et al., 1956; Weiden et al., 1979). Patients 
that relapse after allogenic transplantation can be further treated with donor lymphocyte infu-
sion. They receive blood from the original marrow donor and take advantage of the graft-ver-
sus-leukemia effect by the donor immune cells. The challenge in this treatment is again the 
induction of a severe graft-versus-host effect (Kolb et al., 1990, 1995). 
In recent years, adoptive T cell transfer has advanced and T cell receptor (TCR) therapy, tu-
mor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) therapy are applied in 




the patient’s body and modified in order to improve anti-tumor efficacy before reinjection. The 
use of patient-derived cells is safer for the patient as adverse effects, for instance graft-versus-
host disease by donor T cells or transplant rejection by the host immune system can be 
avoided (Jeon et al., 2019; Murphy et al., 1987; Storb et al., 1983). Antigens for targeted T cell 
mediated therapies can be divided in two groups. Antigens that are exclusively expressed in 
malignant cells are called tumor-specific antigens (TSAs) or neoantigens. They are absent in 
healthy cells and provide an ideal target in therapy, as non-neoplastic tissue is not recognized 
by the targeted T cells. TSAs occur upon nonsynonymous mutations. Tumor-associated anti-
gens (TAAs) are highly expressed by tumor cells, but also, although often at low levels, ex-
pressed by healthy cells. Naturally occurring high-affinity TCRs against TAAs are usually re-
moved during thymic selection and targeting TAAs can result in severe tissue damages by off 
tumor/on target effects (Jiang et al., 2019).  
Tumor-infiltrating lymphocytes can be extracted from a patient’s tumor, expanded and acti-
vated ex vivo, and reinjected into the patient (Rosenberg et al., 1988; Topalian et al., 1988). 
TILs within the tumor microenvironment are strongly suppressed and their anti-tumor efficacy 
is disturbed (Holmes, 1985). Reactivation outside of the hostile milieu reconstitutes their ca-
pacities and enables tumor reduction in patients (Dudley et al., 2003). TILs have been admin-
istered, among others, for the treatment of melanoma and ovarian cancer (Aoki et al., 1991; 
Rosenberg et al., 2011).  
In T cell receptor therapy, autologous T cells are equipped with a TCR specific for an antigen. 
The α and β chains genes of the TCR are transferred into T cells and redirect them towards 
the antigen (Clay et al., 1999). Ex vivo culture allows the generation of sufficient numbers of T 
cells for the treatment of patients (Petersen et al., 2018; Tumeh et al., 2010). Antigen-specific 
TCRs can be derived by various ways. For instance, they can be isolated from tumor-infiltrating 
T cells of patients that showed a strong anti-tumor response or using a screening system with 
a HLA transgenic mouse (Hughes et al., 2005; Obenaus et al., 2015). A clinical study was 
pioneered with a TCR against the melanoma-associated antigen MART-1 (Morgan et al., 
2006). TCRs are mostly used in the treatment of solid tumors, but can also target hematopoi-
etic malignancies (Rapoport et al., 2015; Robbins et al., 2011). TCR therapy still faces numer-
ous challenges. TCR antigen recognition is MHC restricted and thus only possible for antigens 
that are successfully presented by MHC (Garboczi et al., 1996; Katz et al., 1973; Zinkernagel 
and Doherty, 1974). Also, on-target toxicity by T cells attacking healthy tissue and autoreac-
tivity after mispairing of transferred TCR chains with the endogenous TCR, resulting in unpre-
dicted epitope recognition, are safety concerns (Bendle et al., 2010; Johnson et al., 2009; van 




A milestone in adoptive T cell transfer was the approval of Kymriah and Yescarta by the US 
food and drug administration in 2017. Those were the first chimeric antigen receptor (CAR) 
products directed against certain CD19+ B-NHL malignancies administered to patients (Jain et 
al., 2018; Liu et al., 2017). Patient-derived T cells are genetically modified in order to express 
a chimeric antigen receptor that targets an epitope expressed by tumor cells (Vormittag et al., 
2018). Opposed to TCRs, they allow MHC-independent antigen recognition (Mezzanzanica et 
al., 1998). A CAR binds its antigen with single-chain variable fragments (scFv) derived from 
an antibody sequence. The scFvs are composed of a variable heavy (VH) and a variable light 
(VL) chain connected via a linker sequence (Bird et al., 1988). A commonly IgG-derived spacer 
(hinge region) joins the variable fragments to the transmembrane domain and allows flexibility 
to improve target recognition. The ideal spacer length is antigen dependent (Guest et al., 2005; 
Hudecek et al., 2015). The transmembrane domain anchors the CAR in the T cell membrane 
and can be derived from CD3ζ, CD4, CD8α or CD28 (Alabanza et al., 2017; Bridgeman et al., 
2010; Fitzer-Attas et al., 1998). The CAR endodomains are the costimulatory domain and the 
activation domain. The costimulatory domain originates from the tumor necrosis factor receptor 
family (4-1BB, CD27, OX40) or the CD28 family (CD28, ICOS) (Finney et al., 2004; Guedan 
et al., 2014; Song et al., 2012). The activation domain is based on CD3ζ of the TCR complex 
(Finney et al., 2004). T cell activation is transmitted by phosphorylation of the CD3ζ immuno-
receptor tyrosine-based activation motifs (ITAMs) (Irving and Weiss, 1991; Ramello et al., 
2019). 
CARs were first developed by Kuwana et al. and Gross et al. (Gross et al., 1989; Kuwana et 
al., 1987). Ever since the advent of CAR T cell therapy, efforts have been made to improve the 
constructs. It appeared that these first generation CARs without costimulatory domain bene-
fited from additional costimulation to establish a stable cytokine response (Gong et al., 1999). 
Thus, second generation CARs equipped with a costimulatory domain were developed. T cells 
endowed with a second generation CAR showed superior expansion and persistence com-
pared with first generation CARs (Maher et al., 2002; Savoldo et al., 2011). CD28 and 4-1BB 
are the most commonly used costimulatory domains (Chavez et al., 2019; Weinkove et al., 
2019). The CD28 costimulatory domain is derived from a costimulatory T cell protein which, 
upon ligand binding by B7.1 and B7.2 on antigen-presenting cells, provides a proliferative sig-
nal in combination with TCR/CD3 activation (Linsley et al., 1990; Stein et al., 1994; Turka et 
al., 1990). The T cell activation receptor 4-1BB (CD137) from the tumor necrosis factor super-
family, which is also involved in T cell proliferation, was the basis for the second widely used 
costimulatory domain (DeBenedette et al., 1995; Pollok et al., 1993). In more detail, the CD28 
costimulatory domain allows a rapid anti-tumor effect and the 4-1BB costimulatory domain al-




differences could lay in the distinct metabolic regulation. T cells with CD28 costimulatory do-
mains formed an effector memory compartment with enhanced glycolysis, whereas 4-1BB 
yielded an increase in CD8+ central memory cells and upregulation of mitochondrial biogenesis 
and fatty acid metabolism (Kawalekar et al., 2016). 
In an effort to combine the benefits of the CD28 and the 4-1BB costimulatory domain of second 
generations CARs, third generation CARs, which combine two costimulatory domains, were 
developed (Zhong et al., 2010). However, it is not clear if these have any advantage over 
second generation CAR constructs (Guedan et al., 2018; Haso et al., 2013; Yi et al., 2018).  
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2 Aim of this thesis 
Anti-CD19 CAR T cell therapy improved the prognosis for patients suffering from relapsed and 
refractory aggressive B non-Hodgkin lymphomas; however, many patients do not respond to 
treatment or relapse (Crump et al., 2017; Locke et al., 2019; Maziarz et al., 2020). Therefore, 
there is a high demand for treatment alternatives. The chemokine receptor CXCR5, which 
guides B cells to the B cell zones of secondary lymphoid organs, was identified as a novel 
target for immunotherapy (Heinig et al., 2014; Panjideh et al., 2014). CXCR5 is not only ex-
pressed on mature B cells and their neoplastic counterparts, but also on follicular helper T cells 
(Breitfeld et al., 2000; Schaerli et al., 2000a). This T cell subset is described to have a tumor-
supportive function in follicular lymphoma and chronic lymphocytic leukemia (Ahearne et al., 
2013; Pangault et al., 2010). Previously in the group, an anti-CXCR5 CAR construct based on 
a monoclonal antibody was designed. In this thesis, the anti-CXCR5 CAR product was func-
tionally characterized and the safety of anti-CXCR5 treatment was assessed. 
In detail, the following questions were addressed in this thesis: 
(1) Do anti-CXCR5 CAR T cells exhibit a specific and efficient anti-tumor effect against CXCR5 
expressing B non-Hodgkin lymphoma in vitro and in vivo? 
(2) Do anti-CXCR5 CAR T cells target tumor-supportive TFH cells in follicular lymphoma and 
chronic lymphocytic leukemia? 
(3) Does CXCR5 show a safe expression profile and can on-target/off-tumor toxicity be 
avoided? 
As anti-CXCR5 CAR T cells target subsets of CXCR5 expressing T cells, it is of interest to 
study the CXCR5+ T cell compartment in closer detail, especially upon lymphoma challenge. 
Therefore, the influence of lymphomagenesis on the splenic CXCR5+ T cells was studied in 
the syngeneic Eμ-Tcl1 mouse model by means of single cell RNA sequencing. 
Additional questions addressed in the second part of the thesis were: 
(4) Is the composition of CXCR5+ T cell subsets changed upon lymphomagenesis? 
(5) Which transcriptional changes are induced in TFH cells upon tumor challenge? In particular, 
are tumor-supportive genes upregulated? 
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3 Material and Methods 
3.1 Material  
3.1.1  Chemicals and consumables 
Abbott Laboratories: Isoflurane 
BD Biosciences: 7-AAD, TMB Substrate Reagent Set  
Biolegend: Human TruStain FcX, TruStain Monocyte Blocker  
Carl Roth: Phosphate-buffered formaldehyde (PFA) 
Gibco: DMEM high glucose, fetal calf serum (FCS), Non-Essential Amino Acid Solution 100x, 
Penicillin/Streptomycin, RPMI 1640, Sodium Pyruvate 100mM, Trypsin/EDTA  
Merck: Biocoll, Polybrene  
Miltenyi Biotec: rhIL2, rhIL7, rhIL15  
PeproTech: hIFNγ  
PromoCell: Accutase-Solution  
Sigma-Aldrich: Dimethyl sulfoxide (DMSO), Poly-L-lysine solution  
TaKaRa: RetroNectin 
ThermoFisher Scientific: LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit,  
O’RangeRuler 100bp, Phusion High-Fidelity DNA Polymerase  
3.1.2 Primary cells and media 
Table 1: Primary cells and media 
Cell type Medium 
HUAEC (PromoCell) Endothelial cell growth medium and supplements  
(PromoCell) 
Human astrocytes (ScienCell) HA medium and supplements (ScienCell) 
Human colonic epithelial cells 
(ScienCell) 
HCoEpiC medium and supplements (ScienCell) 
Human cervical epithelium cells 
(ScienCell) 
HCerEpic medium and supplements (ScienCell) 
Human neurons (ScienCell) HN medium and supplements (ScienCell) 
Human perineurial cells 
(ScienCell) 
Fibroblast medium and supplements (ScienCell) 
Human urothelial cells  
(ScienCell) 
HUC medium and supplements (ScienCell) 
HUVEC single donor  
(PromoCell) 
Endothelial cell growth medium and supplements  
(PromoCell) 
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3.1.3 Cell lines and media 
Table 2: Cell lines and media 
Cell type Supplier Medium 
293Vec-Galv (Packaging cell 
line) 
Biovec Pharma (Québec) DMEM high glucose complete 
DOHH-2 (Follicular lym-
phoma) 
DSMZ (Braunschweig) RPMI 1640 complete 




DMEM high glucose complete 
HEK-293T (Human embry-
onic kidney) 
ATCC (USA) DMEM high glucose complete 
HepG2 (Hepatocellular carci-
noma) 
DSMZ (Braunschweig) DMEM high glucose complete 
JEKO-1 (Mantle cell lym-
phoma) 
DSMZ (Braunschweig) RPMI 1640 complete 
Jurkat (Acute T lymphoblastic 
leukemia) 
DSMZ (Braunschweig) RPMI 1640 complete 
NALM-6 (Acute T lympho-
blastic leukemia 
Dr. Stephan Mathas 
(MDC, Berlin) 
RPMI 1640 complete 
NCI-H929 (Multiple myeloma) DSMZ (Braunschweig) RPMI 1640 complete 
OCI-Ly7 (Diffuse large B-cell 
lymphoma) 
DSMZ (Braunschweig) RPMI 1640 complete 
Raji (Burkitt’s lymphoma) DSMZ (Braunschweig) RPMI 1640 complete 
REH (Acute B lymphoblastic 
lymphoma) 
Dr. Stephan Mathas 
(MDC, Berlin) 
RPMI 1640 complete 
SC-1 (Follicular lymphoma) DSMZ (Braunschweig) RPMI 1640 complete 
SU-DHL4 (Diffuse large B-cell 
lymphoma) 
DSMZ (Braunschweig) RPMI 1640 complete 
SW620 (Colorectal carci-
noma) 
CLS Inc. (Eppelheim) DMEM high glucose complete 
Complete: Medium supplemented with 10% FCS, 1x Penicillin/Streptomycin, 1x Non-Essential 
Amino Acids Solution and 1 mM Sodium Pyruvate  
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3.1.4 Patient-derived xenografts 
Table 3: Patient-derived xenografts 
PDX Supplier 
#44685 (Mantle cell lym-
phoma) 
Public Repository of Xenografts (PRoXe) platform of the 
Dana-Farber Cancer Institute (USA) 
#96069 (Mantle cell lym-
phoma) 
Public Repository of Xenografts (PRoXe) platform of the 
Dana-Farber Cancer Institute (USA) 
3.1.5 Antibodies   
Table 4: Anti-human antibodies for flow cytometry 
Antigen Fluorescence Clone Isotype Supplier Dilution 
CD1c FITC L161 Mouse IgG1 Biolegend 1:100 
CD3 BV510 SK7 Mouse IgG1 Biolegend 1:100 
CD3 FITC HIT3a Mouse IgG2a Biolegend 1:100 
CD3 PB HIT3a Mouse IgG2a Biolegend 1:100 
CD4 APC/Cy7 OKT4 Mouse IgG2b Biolegend 1:100 
CD4 BV421 RPA-T4 Mouse IgG1 Biolegend 1:200 
CD4  FITC OKT4 Mouse IgG2b Biolegend 1:100 
CD5 PB UCHT2 Mouse IgG1 Biolegend 1:165 
CD8 APC/Fire750 SK1 Mouse IgG1 Biolegend 1:100 
CD8a APC HIT8a Mouse IgG1 Biolegend 1:100 
CD8a APC/Cy7 HIT8a Mouse IgG1 Biolegend 1:200 
CD8a PE/Cy7 HIT8a Mouse IgG1 Biolegend 1:100 
CD11c PE/Cy7 Bu15 Mouse IgG1 Biolegend 1:100 
CD14 APC HCD14 Mouse IgG1 Biolegend 1:100 
CD19 PB HIB19 Mouse IgG1 Biolegend 1:200 
CD19 BV510 SJ25C1 Mouse IgG1 Biolegend 1:100 
CD20 APC 2H7 Mouse IgG2b Biolegend 1:100 
CD25 APC MOPC-21 Mouse IgG1 Biolegend 1:100 
CD45RA PerCP/Cy5.5 HI100 Mouse IgG2b Biolegend 1:200 
CD45RO FITC HCHL1 Mouse IgG2a Biolegend 1:200 
CD56 Pe/Cy7 5.1H11 Mouse IgG1 Biolegend 1:100 
CD62L AF647 DREG-56 Mouse IgG1 Biolegend 1:200 
CD197 PE/Cy7 G043H7 Mouse IgG2a Biolegend 1:200 
CD303 APC/Fire750 201A Mouse IgG2a Biolegend 1:100 
CXCR5 PE 51505 Mouse IgG2b R&D 1:10 
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HLA-DR BV421 L243 Mouse IgG2a Biolegend 1:100 
IgG Biotin IS11-
12E4.23.20 
Mouse IgG1 Miltenyi  
Biotec 
1:10 
IgG FITC polyclonal Goat IgG Southern 
Biotech 
1:400 
IgG PE polyclonal Goat IgG Southern 
Biotech 
1:600 
LAG-3 AF647 11C3C65 Mouse IgG1 Biolegend 1:50 
PD-1 BV421 EH12.2H7 Mouse IgG1 Biolegend 1:50 
PD-1 PE Eh12.2H7 Mouse IgG1 Biolegend 1:50 
TIM-3 BV421 F38-2E2 Mouse IgG1 Biolegend 1:50 
 
Table 5: Anti-mouse antibodies for flow cytometry 
Antigen Fluorescence Clone Isotype Supplier Dilution 
CD3e APC 145-2C11 Hamster IgG Biolegend 1:400 
CD5 APC 53-7.3 Rat IgG2a Biolegend 1:400 
CD19 FITC 6D5 Rat IgG2a Biolegend 1:400 
CD45.2 PB 104 Mouse IgG2a Biolegend 1:100 
CXCR5 BV421 L138D7 Rat IgG2b Biolegend 1:50 
 
Table 6: Isotype control antibodies 
Antigen Fluorescence Clone Supplier Dilution 
Mouse IgG1 AF647 MOPC-21 Biolegend 1:50 
Mouse IgG1 APC MOPC-21 Biolegend 1:200 
Mouse IgG1 Biotin IS5-21F5 Miltenyi Biotec 1:50 
Mouse IgG1 BV421 MOPC-21 Biolegend 1:50 
Mouse IgG1 BV510 MOPC-21 Biolegend 1:100 
Mouse IgG1 FITC MOPC-21 Biolegend 1:125 
Mouse IgG1 PE MOPC-21 Biolegend 1:200 
Mouse IgG1 PE/Cy7 RMG1-1 Biolegend 1:200 
Mouse IgG2a APC/Fire750 MOPC-173 Biolegend 1:100 
Mouse IgG2a BV421 MOPC-173 Biolegend 1:200 
Mouse IgG2b PE 133303 R&D 1:10 
Rat IgG2b BV421 RTK4530 Biolegend 1:25 




Table 7: Oligonucleotides 








BD Biosciences: OptEIA™ Human IFN-γ ELISA Set, PE Quantibrite beads (Phycoerythrin Flu-
orescence Quantitation Kit) 
Miltenyi Biotech: Pan B Cell Isolation Kit II (mouse), Pan T cell isolation Kit II (mouse) 
Stemcell Technologies: EasySep Human CD4+ T Cell Isolation Kit, EasySep Human PE 
Positive Selection Kit 
3.1.8 Devices 
BD Biosciences: FACSCanto II Cell Analyzer, FACSAria Fusion Cell Sorter 
BioTek Instruments: PowerWave X Select microplate UV/VIS reader  
Innovatis: CASY Cell Counter TTC 
Miltenyi Biotech: MACSQuant Analyzer 10 
PerkinElmer: IVIS Spectrum In Vivo Imaging System 
ThermoFisher Scientific: Microm HM355S Rotary Microtome 
Vilber Lourmat: Quantum Gel Documentation Imaging 
Zeiss: AxioCam MRm camera, Axio Imager 2 microscope  
3.1.9 Software 
Adobe: Illustrator CS6 
BD: FACS Diva, Flowjo 10.5.3 
GraphPad: Prism 7 
ImageJ: ImageJ 2.0.0 
Microsoft: Excel 14.7.3, Word 14.7.3 
PerkinElmer: Living Image 3.2/4.5  
Zeiss: Axio Vision 4.5  
3.1.10 Mice 
E-Tcl1 mice on a C57BL/6 background were generated by Heinig et al. (Heinig et al., 2014). 
C57BL/6 and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred and housed at the MDC 
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Berlin animal facility. Animal studies were performed in accordance with institutional and Berlin 
State guidelines (G0373/13; G0050/16; G0104/16). 
 
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Cryoconservation 
Cells were resuspended in freshly prepared, cooled FCS (Gibco) with 10% DMSO (Sigma-
Aldrich). The cryotubes (Corning) were immediately frozen at -80°C in a cryotube holder (Cell-
Camper) and later transferred into liquid nitrogen. Thawing was performed at 37°C in a water 
bath, the cells were transferred into cold medium, immediately centrifuged (350 g, 5 min) and 
resuspended in fresh medium. 
3.2.1.2 Maintenance of cell lines 
Adherent cell lines were cultured in DMEM complete (DMEM high glucose with 10% FCS and 
1x Penicillin/Streptomycin, non-essential amino acid solution and sodium pyruvate) and split 
upon confluency using trypsin/EDTA. 
Suspension cell lines were cultured in RPMI complete (RPMI 1640 with 10% FCS and 1x Pen-
icillin/Streptomycin, non-essential amino acid solution and sodium pyruvate) and split every 
second or third day. Cells were cultured in a Binder CB210 incubator (Thermo Fisher Scientific) 
at 37°C and 5% CO2. 
3.2.1.3 Cell count determination 
In order to determine the quantity of mouse spleen or bone marrow cells, the cell suspension 
was diluted with CASYton (1:1000) and measured by the CASY Cell Counter TTC. Cell lines 
and human lymphocytes were counted in a Neubauer hemocytometer with 10% trypan blue in 
PBS or with the MACSQuant. 
3.2.1.4 Culture of primary cells 
Primary cells were cultured according to the manufacturer’s instructions and detached using 
Accutase. 
3.2.1.5 Isolation of PBMCs from donor blood 
Recruiting of voluntary blood donors was approved by the Charité Universitätsmedizin ethics 
committee. Donor blood was diluted with an equal volume RPMI 1640 and 25 ml were carefully 
layered over 12.5 ml Biocoll separating solution (Biochrom) in a 50 ml falcon tube. Density 
gradient centrifugation was performed (650 g, 20 min, RT, without brake), followed by a recov-
ery of the leukocyte containing intermediate phase. The cells were resuspended in 50 ml RPMI 
1640 and centrifuged (350 g, 15 min, RT). The cells were again resuspended and centrifuged 
(300 g, 10 min, RT).  
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3.2.1.6 Isolation of CXCR5+ CD4+ T cells from PBMCs 
CD4+ cells were isolated from PBMCs using the EasySep Human CD4+ T Cell Isolation Kit 
(Stemcell Technologies) according to the manufacturer’s instruction. CXCR5+ cells were iso-
lated from the resulting CD4+ cells with the EasySep Human PE Positive Selection Kit (Stem-
cell Technologies) according to the manufacturer’s instruction after labeling with the CXCR5 
PE antibody at 1.3 µg/ml for 15 min at room temperature (R&D). 
3.2.1.7 Virus production 
Virus for human T cell transduction was produced using virus producing 293Vec-Galv cells 
lines stably transduced with the MP71 vector. Cells were cultured in DMEM complete (DMEM 
high glucose with 10% FCS and 1x Penicillin/Streptomycin, non-essential amino acid solution 
and sodium pyruvate) until 70% confluency was reached. DMEM was removed and 293Vec-
Galv cells were cultured in RPMI complete (RPMI 1640 with 10% FCS and 1x Penicillin/Strep-
tomycin, non-essential amino acid solution and sodium pyruvate) at 0.1 ml/cm2 for 24 h. Viral 
supernatant was filtered with a 0.45 μm filter and stored at -80°C.  
3.2.1.8 Transduction of human T cells 
A 24 well non-tissue culture treated plate was prepared by incubation with anti-CD3 (5 μg/ml) 
and anti-CD28 (1 μg/ml) antibodies in PBS over night at 4°C. The plate was blocked with 2% 
BSA in PBS at 37°C and washed twice. Human peripheral blood mononuclear cells were 
seeded at 1-1,3x106 cells/well in 1 ml/well RPMI complete (RPMI 1640 with 10% FCS and 1x 
Penicillin/Streptomycin, non-essential amino acid solution and sodium pyruvate), for in vivo 
experiments and the stress test with 10 ng/ml rhIL7 and rhIL15, for in vitro experiments with 
10 ng/ml rhIL2 (Miltenyi Biotec). The cells were incubated for 48 h, always at 37°C and 5% 
CO2. Another 24 well non-tissue culture treated plate was prepared by incubation with ret-
roNectin (12,5 μg/ml) over night at 4°C. The plate was blocked with 2% BSA in PBS at 37°C 
and washed twice. Virus solution was added and the plate was centrifuged for 90 min (3000 
g, 4°C). The virus solution was removed and the cells were transferred into the virus-precoated 
wells. Virus solution was added and a final volume of 2 ml/well was obtained by addition of 
RPMI complete with a final concentration of 10 ng/ml IL7/IL15 or IL2. The plate was centrifuged 
for 20 min (800 g, 32°C). After 24 h incubation, 1 ml/well was removed and the transduction 
was repeated. 4 h after centrifugation, the cells were removed from the wells and pooled in 
cell culture flasks with addition of twice their volume fresh RPMI complete containing 10 ng/ml 
IL7/IL15 or IL2, cultured in an upright position.  
3.2.1.9 T cell culture 
T cells were expanded in RPMI complete (RPMI 1640 with 10% FCS and 1x Penicillin/Strep-
tomycin, non-essential amino acid solution and sodium pyruvate) in cell culture flasks in an 
upright position at 37°C and 5% CO2. T cells prepared for in vivo experiments (10 day culture) 
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and the stress test (10-14 day culture) were cultured with 10 ng/ml IL7/IL15; for in vitro exper-
iments (13 day culture) with 10 ng/ml IL2. IL2 stimulated T cells were cultured in fresh medium 
with low IL2 (1 ng/ml) for the last three days of culture. 
3.2.1.10 Transduction of patient-derived xenograft cells 
PDX #96069 cells were thawed and immediately transduced with a lentiviral luciferase-eGFP 
construct. 3x106 cells/well were seeded in a 24-well plate with 1.5 ml RPMI complete (RPMI 
1640 with 10% FCS and 1x Penicillin/Streptomycin, non-essential amino acid solution and 
sodium pyruvate), 0.5 ml viral supernatant and 16 μl polybrene. After a 2 h centrifugation step 
(800 g, 37°C), cells were incubated at 37°C and 5% CO2 for another 2 h. Cells were washed 
with PBS and immediately injected intravenously in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice (3x106 cells/animal). After six weeks, spleens were harvested, eGFP+ cells were sorted 
by FACS and reinjected in NSG mice. Expansion and sorting was performed twice. 
3.2.2 Immunological techniques 
3.2.2.1 Flow cytometry 
For flow cytometric analysis, 1x106 cells/well were transferred into a 96 well plate. For blocking 
of unspecific binding sites, cells were centrifuged (350 g, 3 min), the supernatant was dis-
carded and the cells were blocked in 50 μl 5% human serum in FACS buffer (PBS, 2% FCS, 
10 mM EDTA) for 10 min at RT. Subsequently, 50 μl FACS buffer containing the antibodies 
were added. If an IgG antibody (to determine the CAR transduction rate) was used, blocking 
was omitted and after centrifugation (350 g, 3 min), the supernatant was discarded and 100 μl 
FACS buffer containing the antibodies were added. The IgG antibody had to be incubated 
separately, prior to the other antibodies and followed by two wash steps. Ultimately, the cells 
were stained for 10-15 min at RT in 100 μl FACS buffer. The cells were washed twice with 
FACS buffer and resuspended in 50-150 μl FACS buffer for the FACS measurement. If 7AAD 
was used, it was added into the FACS buffer (1:100). The cells were analyzed using a 
FACSCanto II Cell Analyzer (BD Biosciences). For the quantification of molecules on the cell 
surface, PE Phycoerythrin Fluorescence Quantibrite beads were used according to the manu-
facturer’s instructions. 
3.2.2.2 CAR T cell cocultures 
CAR T cells were expanded over the course of 13 days with rhIL2. For the last 3 days, the T 
cells were resuspended in fresh medium with low IL2 (1 ng/ml) to induce a resting state and 
subsequently frozen. In order to quantify the effector function of CAR T cells, they were thawed 
and incubated with various target cells in a 96-well plate. The effector/target cell ratio was 1:1. 
5x104 target cells were incubated with 5x104 CAR+ T cells per well. As not all T cells were 
transduced with the CAR, the total T cell number per well was higher than 5x104. For adherent 
target cells, flat bottom plates were used and 1x104 cells were seeded after Accutase treatment 
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one day prior to allow adherence. For suspension target cells, V-bottom plates were used. The 
cells were incubated in 200 μl RPMI complete (RPMI 1640 with 10% FCS and 1x Penicil-
lin/Streptomycin, non-essential amino acid solution and sodium pyruvate) per well. If the target 
cells required another medium, 100 μl RPMI complete and 100 μl of the target cell medium 
were used. For the minimum value, the CAR T cells were incubated without target cells; for 
the maximum value, they were incubated with 1 μM ionomycin and 5 ng/ml PMA. The plates 
were incubated for 12-24 h at 37°C and 5% CO2. The supernatant was frozen at -80°C. 
3.2.2.3 CAR T cell blocking coculture 
JEKO-1 cells were cocultured with CAR-transduced cells as described under CAR T cell co-
cultures. Peptides synthesized by Biosyntan were added. The peptides were generated by 
simultaneous multiple peptide synthesis and quality control was performed by mass spectrom-
etry. The epitope peptide is derived from the CXCR5 N-terminus and harbors the epitope rec-
ognized by the anti-CXCR5 CAR; the control peptide is derived from a sequence located in the 
extracellular loop region of CXCR5. 
3.2.2.4 Stress test 
For the stress test, T cells were expanded for 14 days (for the 1:1 assay) or 10 days (for the 
1:10 assay) with rhIL7/15. In order to analyze T cell exhaustion, CAR T cells were cocultured 
at a 1:1 or 1:10 ratio with JEKO-1 tumor cells in a 24-well plate with 2 ml RPMI complete/well 
(RPMI 1640 with 10% FCS and 1x Penicillin/Streptomycin, non-essential amino acid solution 
and sodium pyruvate) supplemented with 1 ng/ml IL7/IL15. For the 1:1 assay, 5x105 T cells 
were cocultured with 5x105 JEKO-1 cells per well; for the 1:10 assay, 5x104 CAR T cells were 
cocultured with 5x105 JEKO-1 cells per well.  Every third day, the supernatant was collected 
and frozen at -80°C and the cells were analyzed by flow cytometry. 
3.2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The BD OptEIA™ ELISA kit was used to analyze cell culture supernatants according to the 
manufacturer’s instructions. The standard series was performed in duplicates, starting at 8 ng. 
Data acquisition was performed using a PowerWave X Select microplate UV/VIS reader (Bio-
Tek Instruments, USA). 
  
Material and Methods 
36 
 
3.2.3 Molecular Biology 
3.2.3.1 Polymerase chain reaction 
The HMRT103 TissueScanTM Human Normal cDNA Array was analyzed by PCR with the fol-
lowing settings and according to the manufacturer’s instruction: 
Reaction mix: 5 μl 5x HF buffer 
 0.5 μl 10 mM dNTPs 
 0.063 μl 100 μM primer mix 
 0.25 μl Phusion polymerase 
 ad 25 μl H2O 
 
Cycler program: 1. 98°C 0:30 min 
 2. 98°C 0:08 min 
Annealing  3. 63°C-68°C 0:12 min 
 4. 72°C 0:12 min 
 Repeat 2.-4. 35x  
 5. 72°C 5:00 min 
 6. 4°C hold 
The annealing temperature was 63°C for the CXCR5 PCR, 64°C for the GAPDH PCR and 
68°C for the CD19 PCR. 
Agarose gel electrophoresis was performed with a 1,5% agarose gel with ethidium bromide at 
120 V. O’RangeRuler 100 bp was used to confirm the correct length of the PCR products. 
3.2.4 Animal experiments 
3.2.4.1 Xenograft mouse model  
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (8 to 10 weeks old) were used for xenograft ex-
periments. The mice were injected intravenously in the tail vein with 100 μl cell suspension in 
RPMI 1640 (without additives) with lucifericed tumor cells (JEKO-1 6x105). Upon visible tumor 
growth by IVIS imaging, 3x106 CAR T cells were injected in 100 μl RPMI 1640 (without addi-
tives) intravenously in the tail vein. The number of total T cells was adjusted using the trans-
duction rate. The tumor challenged mice were analyzed by IVIS imaging twice a week. Their 
weight and wellbeing was monitored and the experiments were usually terminated before the 
mice showed visible symptoms of disease. 
3.2.4.2 Serum analysis 
Peripheral blood was collected by retroorbital puncture and serum was processed by the ani-
mal phenotyping facility at the MDC Berlin. 
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3.2.4.3 Isolation of spleen and bone marrow 
Mice were killed with an overdose of the inhalational anesthetic Isoflurane (Abbott Laborato-
ries). Spleen and bone marrow of the femur were isolated at the end point of animal experi-
ments for flow cytometry analysis. Spleens were disrupted in FACS buffer (PBS, 2% FCS, 2 
mM EDTA) using the plunger of a 5 ml syringe. Femur was isolated, muscle and skin tissue 
were removed and the bone was cut open at the epiphysis on both sides. The bone marrow 
was flushed with PBS using a syringe and a 26-gauge needle (B. Braun). Isolated spleen and 
bone marrow cells were filtered using a 100 μm cell strainer in FACS buffer. Subsequently, the 
cells were centrifuged at 350 g for 5 min, supernatant was removed and red blood cell lysis 
was performed for 5 min (10x lysis buffer: 8,29 g NH4Cl, 1 g KHCO3, 37,2 mg Na2-EDTA, ad 1 
l H2O with pH 7,3). The cells were stored in FACS buffer on ice during the experiments. 
3.2.4.4 Histology 
Lung, colon and liver tissue was fixed in 4 % phosphate-buffered formaldehyde (Carl Roth) for 
24 to 48 h and subsequently dehydrated in an ethanol dilution series. The organs were em-
bedded in paraffin for 24 h, with three paraffin changes. 5 μm cuts were made on the Microm 
HM355S Rotary Microtome (ThermoFisher Scientific), transferred to SuperFrost Plus Menzel 
slides (ThermoFisher Scientific) and stained with hematoxylin and eosin (H&E) using a Microm 
HMS 740 robot-stainer (ThermoFisher Scientific). Pictures were recorded with the AxioCam 
MRm camera an Axio Imager 2 microscope (Zeiss). Processing was performed using Axio 
Vision 4.5 (Zeiss) and ImageJ 2.0.0 (ImageJ). 
3.2.4.5 IVIS in vivo imaging 
Mice were anesthetized by isoflurane inhalation in the IVIS induction chamber (PerkinElmer) 
and injected intraperitoneally with 150 μg luciferin (Biosynth). The mice were incubated for 10 
min and transferred into the IVIS Spectrum (PerkinElmer). A photographic image and several 
bioluminescent images (1-300 sec exposure time) were acquired. The Living Image 3.2 and 
4.5 software (PerkinElmer) was used for further analysis.  
3.2.4.6 Splenic T cell preparation for RNA single cell sequencing 
10-week-old female C57BL/6N mice were injected intravenously with 3x106 Eμ-Tcl1 tumor 
cells harvested from the spleens of female transgenic Eμ-Tcl1 mice. Control animals were 
injected with 3x106 B cells harvested from the spleens of healthy C57BL/6N mice isolated using 
the Pan B Cell Isolation Kit II (Miltenyi Biotec). Two weeks after tumor/B cell injection, spleens 
were harvested and after red blood cell lysis, the tumor load was determined as CD5+CD19+ 
cells. 2 mice were pooled per sample. Three samples were processed: Control, high tumor 
load (45%, 46%) and low tumor load (22%, 31%). CD3+ T cells were isolated using the Pan T 
cell isolation Kit (Miltenyi). Prior to antibody staining in FACS buffer (PBS, 2% FCS, 2 mM 
EDTA), cells were blocked with CD16/32. Cells were sorted for 7-AAD and CD19 negativity, 
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and CD3 and CXCR5 positivity using the FACSAria Fusion sorter (BD Biosciences). Sorting 
tubes were coated with FCS to prevent sticking of the cells to the tube surface. Cells were 
sorted into PBS. 
3.2.5 RNA single cell sequencing 
3.2.5.1 RNA single cell sample processing 
Splenic CXCR5+ T cells were processed at the Genomics platform at the Berlin Institute for 
Medical Systems Biology using the Chromium Single Cell 3' Reagent Kit (v3.1 Chemistry, 10x 
Genomics) according to the manufacturer’s instructions. Successful library preparation was 
confirmed with the Bioanalyzer device (DNA HS kit, Agilent) and KAPA Library Quantification 
(KK4857, Roche). Library sequencing was performed using Illumina NovaSeq 6000. Barcode 
processing, mapping, counting of unique molecular identifiers and dimension reduction was 
conducted using Cell ranger (v3.1.0, 10x Genomics). 
3.2.5.2 RNA single cell analysis 
Analysis was performed in R (Version 3.6.1) using the package Seurat (Version 3.2.2) (Hafe-
meister and Satija, 2019; Stuart et al., 2019). Dead cells and doublets were removed by filtering 
out outliers (cell with less than 2000 or more than 4900 features, percent mitochondrial genes 
over 8). Contaminating plasma cells and macrophages were excluded. After principal compo-
nent analysis, cells were visualized upon uniform manifold approximation and projection 
(UMAP) dimensional reduction (McInnes et al., 2020). Clusters were identified by an algorithm 
based on shared nearest neighbor (SNN) modularity optimization. 
3.2.6 Statistics 
Statistical significance was determined using GraphPad Prism (Version 7). Arithmetic mean 
and standard error of the mean (SEM) are shown and p-values were calculated by applying 






The prognosis for patients diagnosed with refractory or relapsed aggressive B-cell lymphomas 
remains poor. As summarized in the retrospective SCHOLAR-1 study, the two-year survival 
rate for patients with refractory DLBCL treated with conventional therapy options is 20% 
(Crump et al., 2017). The advent of CAR T cell therapy finally expanded treatment options for 
patients with B cell neoplasms. In 2017, thirty years after the first papers about this technology 
were published, CAR T cell therapy first received approval by the US food and drug admin-
istration (FDA) and shortly after by the European Medicines Agency (EMA) (Yu et al., 2018). 
Up to now, three CAR products, all of them targeting CD19, were approved by the FDA. Axi-
cabtagene ciloleucel, marketed under the name Yescarta, has a CD28 costimulatory domain 
and is approved for the treatment of relapsed or refractory types of large B-cell lymphoma 
(diffuse large B cell lymphoma, transformed follicular lymphoma, primary mediastinal B-cell 
lymphoma) (Jain et al., 2018). Tisagenlecleucel, sold under the name Kymriah, is a 4-1BB 
CAR product for the treatment of relapsed or refractory DLBCL and B-ALL (Liu et al., 2017; 
Zavras et al., 2019). This year, a third anti-CD19 CAR entered the clinic with the approval of 
brexucabtagene autoleucel (Tecartus) for the treatment of refractory and relapsed mantle cell 
lymphoma (Wang et al., 2020). Of the large B-cell lymphoma patients qualifying for treatment 
with Yescarta in the ZUMA-1 study, complete responses were noticed in 58% of patients, with 
a two-year survival rate of around 50% (Locke et al., 2019). For the Kymriah JULIET study, 
complete response was reported for 40% of patients and 65% showed relapse-free survival 
12 months after the initial response (Maziarz et al., 2020; Schuster et al., 2019). Trials of re-
lapsed or refractory chronic lymphocytic leukemia patients treated with CD19 CAR T cells 
showed that around 20-30% of patients obtained a complete response (Porter et al., 2015; 
Turtle et al., 2017).  
These CD19 CAR products proved extraordinary successful in patients that were previously 
running out of treatment options. However, many patients are refractory to treatment or relapse 
after CAR T cell infusion. Numerous mechanisms are involved in treatment failure. They can 
be caused by loss of CD19 expression, immune evasion, CAR T cell exhaustion and lack of 
persistence (Abramson et al., 2019).  
Oftentimes, CD19 expression is heterogeneous and patients harbor tumor cell populations that 
lack CD19 or show only dim expression. Lymphoma cells lacking CD19 go unrecognized by 
CAR T cells and escape CAR-mediated killing, resulting in the outgrowth of loss variants. In 
B-ALL, CD19 loss variants are frequently observed in relapse. In DLBCL, 10% of relapse cases 
are CD19 negative (Abramson et al., 2019). Patients with refractory or relapsed B cell lympho-
mas are still in dire need for treatment options targeting novel antigens. Novel antigens are 




which are strongly expressed in malignant cells, but not restricted to them. A tumor-associated 
antigen, CXCR5, which functions as the B cell homing receptor to secondary lymphoid organs, 
was identified as a promising target for CAR T cell therapy. 
 
4.1 The anti-CXCR5 CAR construct was successfully transduced into  
human T cells 
The anti-CXCR5 CAR binds CXCR5 with the single chain variable fragment (scFv) derived 
from a monoclonal antibody directed towards human CXCR5. The affinity of the antibody was 
determined, which resulted in a dissociation constant of around 0.7 nM (Emrich, 1995; Förster 
et al., 1993). The rat hybridoma RF8B2 variable chains were sequenced by ProMab Biotech-
nologies. The scFv, excluding the complementary determining regions, was humanized ac-
cording to IgBlast. GeneArt Gene Synthesis synthesized the single chain variable fragments. 
In detail, the Lk leader was followed by the VH chain, the Whitlow linker and the VL chain. The 
scFv was cloned into an MP71 vector (Bluhm, 2018). The retroviral MP71 vector, which has 
an optimized 5’ untranslated leader region, shows excellent transgene expression in human 
primary T cells and provides an ideal tool for gene therapy (Engels et al., 2003; Hildinger et 
al., 1999). The final second generation CAR construct further includes an IgG1Δ spacer that 
connects the variable fragments to the CD28-derived transmembrane domain. The costimula-
tory domain, also derived from CD28, is intracellular and followed by the CD3ζ activation do-
main for signal transduction (Figure 3) (Bluhm, 2018). 
 
 
Figure 3: Overview of the anti-CXCR5 CAR construct. The anti-CXCR5 CAR construct is composed 
of a single chain variable fragment (scFv) of light chain (VL) and heavy chain (VH) connected with a 
linker (L), an IgG1Δ spacer, CD28 transmembrane and costimulatory domains and a CD3ζ activation 
domain. 
 
The anti-CXCR5, anti-CD19 and anti-SP6 CAR constructs as well as the corresponding virus-
producing GalV cells were provided by the group. The construct was successfully transduced 
into human T cells using γ-retroviral transduction, which stably integrates the transgene in the 
target genome. GalV cells were used as virus producers. They are a packaging cell line based 
on HEK-293 with stable production of viral vectors pseudotyped by Gibbon Ape Leukemia 




for the highest producers, which allowed virus production in large quantities at high titers. Hu-
man primary T cells transduced with a chimeric antigen receptor, further called CAR T cells, 
were identified by flow cytometry after an expansion period of 7 days after transduction or as 
indicated. Staining was performed with an IgG antibody that binds in the spacer region of the 
CAR construct (Figure 4A). The transduction rate was determined for every batch of trans-
duced T cells and transduction rates of 50-55% were achieved for the CXCR5, the CD19 and 
the SP6 construct (Figure 4B). The anti-CD19 CAR T cells were included in most experiments 
as a reference. The anti-CD19 CAR construct is derived from the murine anti-CD19 mAb 
FMC63 (Nicholson et al., 1997) and, like the anti-CXCR5 CAR construct, it is a second gener-
ation CAR with a CD28 costimulatory domain. The anti-CD19 CAR was ideal for a comparison 
with the anti-CXCR5 CAR, as the expression profiles of their targeted antigens overlap and 
many lymphoma entities express both CD19 and CXCR5. Therefore, it was feasible to include 
the anti-CD19 CAR T cells in both in vitro and in vivo assays. T cells transduced with the 
second generation SP6 construct against the not naturally occurring 2,4,6-Trinitrophenyl were 
included in the assays as a negative control. Additionally, non-transduced T cells (UT) were 
used as a negative control. CAR T cells were further analyzed for the proportion of CD4+/CD8+ 
T cell subpopulations. On average, for the CXCR5, the CD19 as well as the SP6 construct, 
CAR transduced T cells showed a slightly enlarged fraction of CD8+ T cells of around 60%, but 
the ratio was consistent across constructs and experiments (Figure 4C). As CXCR5 is upreg-
ulated on a T cell fraction upon activation (Förster et al., 1994), expansion rates of the CAR 
were compared in order to determine if the anti-CXCR5 CAR T cells are potentially engaged 
in fratricide. Viable T cells in the cultures, which were expanded using rhIL7/15 over the course 
of 10 days after seeding (7 days after transduction), were counted at the end of the expansion 
period. Each T cell, from the time point of seeding to the end of expansion, multiplied on aver-
age 15-27 times, with CXCR5 CAR T cell cultures showing slightly reduced expansion rates 
(Figure 4D). Nevertheless, it was easily feasible to produce sufficient numbers of CAR T cells 





Figure 4: The CXCR5 CAR construct was successfully transduced into human T cells. A Repre-
sentative flow cytometry plots of non-transduced T cells and CXCR5-, CD19-, and SP6-transduced T 
cells 7 days after transduction are shown. Cells were gated on singlets. B The transduction rates of the 
CXCR5, CD19 and SP6 CAR constructs transduced into human T cells 7 to 10 days after transduction 
are shown. Bars represent mean ± SEM of 13 independent experiments (CXCR5 CAR, SP6 CAR) or 8 
independent experiments (CD19 CAR). C The fractions of CD4+ T cells (defined as CD8-) and CD8+ T 
cells of positively transduced CAR T cells are shown for human T cells transduced with the CXCR5, 
CD19 and SP6 CAR constructs 7 to 10 days after transduction. Bars represent mean ± SEM of 13 
independent experiments (CXCR5 CAR, SP6 CAR) or 8 independent experiments (CD19 CAR). D Ex-
pansion rates of CAR T cells expanded using rhIL7/15 for 7 days after transduction are depicted. Bars 
represent mean ± SEM of 2 independent experiments. 
 
4.2 CXCR5 CAR T cells specifically recognize CXCR5 positive cell lines 
and PDX cells in vitro 
4.2.1 CXCR5 is selectively expressed on mature B-NHL cell lines and patient  
derived xenografts 
The expression pattern of CXCR5 on B cell malignancies has been previously described in the 
literature. CXCR5 was described to be expressed by mature B cell malignancies, such as dif-
fuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma and to be absent 
on B cell precursor ALL and multiple myeloma (Dürig et al., 2001; Middle et al., 2015b). In 
order to verify and expand the expression data, a variety of lymphoma and leukemia cell lines 
was carefully analyzed for CXCR5 expression on protein level by flow cytometry (Figure 5). 
This analysis was performed to validate the cell lines as targets for in vitro assays, in which 
the antigen-specific reactivity of the anti-CXCR5 CAR T cells was assessed.  
The cell lines were labeled with an anti-CXCR5 monoclonal antibody and, as a control, the 




non-Hodgkin lymphoma such as diffuse large B cell lymphoma (OCI-Ly7, SU-DHL4), follicular 
lymphoma (SC-1, DOHH-2), mantle cell lymphoma (JEKO-1) and Burkitt’s lymphoma (Raji) 
were shown to express CXCR5. Cell lines derived from B cell precursor leukemia, such as B 
acute lymphoblastic leukemia (NALM-6, REH), did not express CXCR5. A cell line that origi-
nates from multiple myeloma (NCI-H929), which develops from plasma cells, and Jurkat, a T 
acute lymphoblastic leukemia cell line were also negative for CXCR5. 
 
 
Figure 5: CXCR5 is selectively expressed on mature B lymphoma cell lines. The cell lines were 
analyzed by flow cytometry after staining with the CXCR5 antibody (black line) or the respective isotype 
control antibody (grey filled line). Histograms show relative fluorescence intensity of A B non-Hodgkin 
lymphoma (Diffuse large B cell lymphoma (OCI-Ly7, SU-DHL4), follicular lymphoma (SC-1, DOHH-2), 
mantle cell lymphoma (JEKO-1) and Burkitt’s lymphoma (Raji)), B B-ALL (REH, NALM-6), C MM (NCI-
H929) and T-ALL (Jurkat). Representative histograms of at least three independent experiments were 
selected. 
 
Additionally, Quantibrite beads were applied to analyze the CXCR5 molecule quantity on the 
cell surface (Figure 6A). In the Quantibrite assay, the cell lines were stained with a PE antibody 
and measured by flow cytometry, applying the same settings as for the measurement of the 
Quantibrite PE beads. Subsequently, the number of molecules labeled with the PE antibody 
could be calculated per cell. The stated values were averaged over at least three independent 
measurements. DOHH-2 (5146 molecules/cell) had the highest CXCR5 expression. SU-DHL4 
(2846 molecules/cell), SC-1 (2602 molecules/cell), JEKO-1 (1667 molecules/cell) and Raji 
(1287 molecules/cell) showed medium CXCR5 expression. OCI-Ly7 (418 molecules/cell) had 





Figure 6: CXCR5 and CD19 were quantified on lymphoma cell lines. Various B-NHL cell lines (SU-
HDL4, OCI-Ly7, DOHH-2, SC-1, JEKO-1, Raji), B-ALL (REH, NALM-6), MM (NCI-H929) and T-ALL 
(Jurkat) were analyzed for surface expression of A CXCR5 and B CD19 by Quantibrite assay. At least 
3 independent measurements were performed; data points represent individual measurements, mean 
and SEM are shown. 
 
CD19 expression was high on the analyzed lymphoma cell lines (Figure 6B). The highest ex-
pression was detected for Raji (64012 molecules/cell) and NALM-6 (49841 molecules/cell), 
followed by DOHH-2 (36092 molecules/cell), REH (29780 molecules/cell) and OCI-Ly7 (21641 
molecules/cell). SU-DHL4 (13392 molecules/cell), JEKO-1 cells (10940 molecules) and SC-1 
(4285 molecules/cell) showed the lowest CD19 expression. The multiple myeloma cell line 
NCI-H929 and the T-ALL cell line Jurkat did not express CD19. 
Apart from cell lines, patient derived xenografts (PDX) were analyzed for CXCR5 expression. 
PDX models are established through xenotransplantation of human primary cancer cells into 
immunodeficient mice. They provide a tool to study human tumorigenesis in vivo (Lai et al., 
2017). Two mantle cell lymphoma derived xenografts were analyzed and CXCR5 expression 
was detected. Quantification using the Quantibrite assay showed that MCL #44685  expressed 
726 CXCR5 molecules per cell on average and #96069 had 1109 molecules/cell. CXCR5 
quantities on PDX cells were therefore lower than on most analyzed CXCR5+ cell lines, includ-





Figure 7: CXCR5 expression was detected on patient-derived MCL xenografts. A MCL PDX 
#44685 and #96069 were analyzed by flow cytometry after staining with the CXCR5 antibody (black 
line) or the respective isotype control antibody (grey filled line). Histograms show relative fluorescence 
intensity. Representative histograms of at least three independent experiments were selected. B Sur-
face CXCR5 expression was quantified using the Quantibrite beads. At least 4 independent measure-
ments were performed; data points represent individual measurements, mean and SEM are shown.  
 
Altogether, CXCR5 was present on mature B-NHL cell lines and absent on precursor B/T cell 
leukemia cell lines and multiple myeloma. Thus, CXCR5 was exclusively detected on cell lines 
derived from lymphoma that originated from mature B cells. The anti-CXCR5 CAR T cells are 
expected to react in response to the CXCR5 expressing B-NHL cell lines and patient derived 
xenografts. 
4.2.2 Effector cytokines are released upon incubation of CXCR5 CAR T cells with 
CXCR5 positive cell lines and patient derived xenografts 
Human primary T cells were successfully equipped with the anti-CXCR5 chimeric antigen re-
ceptor and expanded over 13 days in the presence of rhIL2, with a three-day low IL2 phase at 
the end of culture. CAR T cell effector function was analyzed in vitro by 24 h coculture with 
numerous B-NHL cell lines (SU-HDL4, OCI-Ly7, DOHH-2, JEKO-1, Raji), which were con-
firmed to be CXCR5+ by flow cytometry, and B-ALL (REH, NALM-6), MM (NCI-H929) and T-
ALL (Jurkat) cell lines, which lacked CXCR5 expression (Figure 8A). The CAR T cells were 
incubated at a 1:1 ration with the target cells (5x104 each per well in a 96-well plate). The read-
out for effector function was IFNγ release by the CAR T cells, which was quantified in the 
supernatant by ELISA. The assay was validated with a minimum value (MIN) and a maximum 
value (MAX). For the minimum value, CAR T cells were incubated without target cells. For the 
maximum value, the CAR T cells were stimulated with PMA/ionomycin to induce IFNγ release. 
The effector function of CXCR5 CAR T cells was compared with CD19 CAR T cells; non-





Figure 8: CXCR5 CAR T cells show in vitro reactivity against B-NHL cell lines and xenografts. A 
IFNγ release of CAR T cells or non-transduced cells (UT) upon 24 h incubation with various cell lines of 
lymphoid origin was quantified by ELISA. Bars represent mean ± SEM of 7 independent donors (CXCR5 
CAR, SP6 CAR, UT) or 4 independent donors (CD19 CAR). B IFNγ release of CAR T cells or non-
transduced cells (UT) upon 24 h incubation with patient-derived mantle cell lymphoma xenografts was 
quantified by ELISA. Bars represent mean ± SEM of 4 independent donors (CXCR5 CAR, SP6 CAR, 
UT) or 3 independent donors (CD19 CAR). P-values (*P<0.01) were calculated using an unpaired T test 
comparing CXCR5-CAR transduced T cells (red) or CD19-CAR transduced T cells (blue) with SP6-CAR 
transduced T cells. Data was collected in collaboration with Dr. Mario Bunse. 
 
The CXCR5 CAR T cells were shown to be exclusively reactive towards the CXCR5 express-
ing B-NHL cell lines DOHH-2, OCI-Ly7, SU-DHL4 and JEKO-1 and released IFNγ quantities 
similar to the CD19 CAR T cells, which was especially remarkable considering the lower anti-
gen density of CXCR5 compared with CD19 on the cell lines. They did not release IFNγ when 
cocultured with CXCR5 negative cell lines. 
IFNγ release for the CD19 positive B cell precursor leukemia cell lines REH and NALM-6 was 
only detected for the CD19 CAR T cells. NCI-H929 and Jurkat, which are neither CXCR5 nor 
CD19 positive, were not recognized. For OCI-Ly7, the cell line with the lowest antigen expres-
sion, the IFNγ release correlated and showed the lowest amount. Effector function in response 
to patient-derived mantle cell lymphoma xenografts was evaluated correspondingly (Figure 
8B). For both #44685 and #96069, IFNγ release could be detected for the anti-CXCR5 and 
anti-CD19 CAR T cells. In short, the CXCR5 CAR T cells reacted selectively towards antigen 
expressing cell lines and patient-derived xenografts, releasing IFNγ levels comparable to the 







4.3 CXCR5 shows a selective expression profile in the human body 
Toxicities in CAR T cell therapy can occur if healthy tissues express the targeted antigen. On-
target/off-tumor effects can cause severe organ damage and result in the patient’s death. In 
preclinical CAR development, this issue can be addressed by extensive investigation of anti-
gen expression throughout human tissues (Brudno and Kochenderfer, 2016). Anti-CXCR5 
CAR T cells showed effector function in response to incubation with CXCR5+ lymphoma cell 
lines. If a patient was administered anti-CXCR5 CAR T cells, they would presumably target 
CXCR5 expressing cells all over the body. Therefore, CXCR5 expression on healthy human 
tissue had to be carefully investigated. 
4.3.1 CXCR5 is selectively expressed in the hematopoietic compartment 
CXCR5 expression on lymphoid cells was first described in 1994 by Förster et al. Mature B 
cells and small fractions of CD4+ and CD8+ T cells were shown to express CXCR5 (Förster et 
al., 1994). Blood cells are the first cells to be encountered by CAR T cells upon infusion; thus, 
knowledge about CXCR5 expression in hematopoietic cells allows risk assessment. 
In this thesis, in-depth analysis of CXCR5 expression in the hematopoietic compartment of the 
peripheral blood, both on cells of lymphoid and myeloid origin, was performed. 
Peripheral blood from healthy donors was freshly prepared to analyze the expression of 
CXCR5 on untouched cells of the hematopoietic compartment. In the lymphoid lineage, CD4+ 
T cells, in particular CD4highCXCR5+PD-1+CD25- TFH cells, CD8+ T cells and CD56+ NK cells 
were analyzed by means of flow cytometry (Figure 9). The cells were gated on single cells, 
lymphocytes and live cells. After gating on CD8+, CD4high (Figure 9A), CD56+ or CD19+ (Figure 
9B), the subset of CXCR5+ cells was quantified. On average among the three donors, 12% of 
CD4high T cells, 3.2% of CD8+ T cells and 97% of CD19+ B cells were CXCR5 positive. CD56+ 
NK cells were CXCR5 negative (Figure 9B). The mean CXCR5 expression on lymphoid cells 
was quantified by Quantibrite assay as previously described. B cells showed the highest 
CXCR5 expression with a mean of 8544 molecules/cell. The CD8+ T cells had the lowest 
CXCR5 expression with 992 molecules/cell. CD4high T cells had on average 1860 CXCR5 mol-
ecules on their surface and TFH cells, defined as CD4highCXCR5+PD-1+CD25-, expressed 1890 





Figure 9: CXCR5 is expressed on subsets of peripheral blood lymphoid cells. The cells were gated 
on singlets, lymphocytes and live cells by 7AAD+ exclusion. The cells were further gated on A CD8+ or 
CD4high. CD4high cells were additionally analyzed for their PD-1 and CD25 expression. B CD56+ or 
CD19+. CXCR5 expression was analyzed on these subsets. C The fraction of CXCR5+ cells is shown 
for CD4high, CD8+ and CD19+ B cells. D CXCR5 molecules per cell were quantified using the Quantibrite 
assay. Molecules/cell were quantified for CXCR5+CD4high cells, TFH cells (CD4highCXCR5+PD-1+CD25-), 
CD8+ cells and CD19+ B cells. Data points represent individual measurements, mean and SEM are 
shown (n=3). 
 
Apart from cells of the lymphoid lineage, myeloid cells were analyzed. Monocytes 
(CD14+CD11c+HLA-DR+) and dendritic cells (CD11c+HLA-DR+), in more detail CD303+ 
plasmacytoid dendritic cells (pDC) and CD1c+ myeloid dendritic cells (mDC1) were analyzed 
for their CXCR5 expression by flow cytometry (Figure 10A). After gating on single cells, lym-
phocytes and live cells, the subset of CXCR5+ cells of monocytes and dendritic cells was quan-
tified (Figure 10B). CXCR5 was virtually absent on these myeloid cells, with a mean frequency 





Figure 10: CXCR5 is virtually absent on peripheral blood myeloid cells. A The cells were previously 
gated on singlets, lymphocytes and live cells by 7AAD+ exclusion. The cells were further gated on 
CD14+CD11c+HLA-DR+ monocytes and CD11c+HLA-DR+ dendritic cells, additionally defined by CD303+ 
plasmacytoid DCs (pDC) and CD1c+ myeloid DCs (mDC1). B The fraction of CXCR5+ cells is shown for 
monocytes, plasmacytoid dendritic cells (pDC) and myeloid dendritic cells (mDC) gated applying the 
scheme from A. Data points represent individual measurements, mean and SEM are shown (n=3). 
 
4.3.2 CXCR5 CAR T cells react towards benign B cells in vitro 
Commonly, malignant lymphocytes express or overexpress the chemokine receptors ex-
pressed by their benign counterparts (López-Giral et al., 2004). As shown by flow cytometry, 
CXCR5 is highly expressed on mature B cells in the peripheral blood of healthy donors. Recog-
nition of mature B cells by anti-CXCR5 CAR T cells would induce removal of B cells in patients. 
This condition, which is called B cell aplasia, is a frequent side effect observed in the treatment 
with anti-CD19 CAR T cells, but can be clinically managed (Bhoj et al., 2016). Therefore, in 
order to assess whether anti-CXCR5 CAR T cells react towards benign B cells, coculture ex-
periments were performed. 
B cells from peripheral blood of a healthy donor were incubated with CAR T cells in a 24 h 
coculture assay at a 1:1 ratio (Figure 11A). The anti-CXCR5 CAR T cells released IFNγ in 
response to these benign B cells. Additionally, anti-CXCR5 CAR T cells were able to kill mature 
B cells of a healthy donor in a 72 h coculture (Figure 11B). The removal of B cells in this 
coincubation experiment was confirmed in flow cytometry and, for clearer visualization, nor-




These results illustrate that anti-CXCR5 CAR T cells show in vitro reactivity towards benign 
CXCR5+ mature B cells. 
 
 
Figure 11: CXCR5 CAR T cells show in vitro reactivity towards benign mature B cells. A IFNγ 
release of CAR T cells or non-transduced cells (UT) upon 24 h incubation with B cells isolated from the 
blood of a healthy donor was quantified by ELISA. Bars represent mean ± SEM of 3 independent donors. 
B Cocultures of PBMCs isolated from the blood of a healthy donor at 1:1 ratio with CXCR5, CD19 and 
SP6 CAR T cells and non-transduced cells were analyzed by flow cytometry. Cells were gated on single 
cells and 7-AAD-. Percentages shown are B cell fractions (CD3-CXCR5+) relative to non-transduced 
(UT) cells. Bars represent mean ± SEM of 4 independent donors (CXCR5 CAR, SP6 CAR, UT) or 3 
independent donors (CD19 CAR). P-values (*P<0.05, **P<0.01, ***P<0.001) were calculated using an 
unpaired T test comparing CXCR5-CAR transduced T cells (red) or CD19-CAR transduced T cells (blue) 







4.3.3 CXCR5 is selectively expressed in human tissue 
CXCR5 is expressed on cells of the hematopoietic compartment; however, its expression in 
unrelated human tissue had to be carefully examined in order to exclude on-target/off-tumor 
toxicity of CXCR5 CAR T cell treatment. The HMRT103 TissueScan Human Normal cDNA 
Array was applied to screen for Cxcr5 RNA expression in numerous human tissues (Figure 
12). Apart from the Gapdh PCR that served as a cDNA quantity control, the Cd19 PCR was 
performed to detect Cd19 expressing B cells in the tissue samples.  
 
 
Figure 12: Cxcr5 tissue expression was analyzed by a cDNA library PCR. Cxcr5 PCR was 
performed on the HMRT103 TissueScan Human Normal cDNA Array to screen for Cxcr5 tissue expres-
sion. Additionally, a Cd19 PCR and a Gapdh PCR were performed as controls. A marker was applied 
to confirm the correctness of the fragments at 318, 336 and 286 base pairs.  
 
The majority of tissues were Cxcr5 negative. Cxcr5 was coexpressed with Cd19 in lymphoid 
tissue (bone marrow, lymph node, blood lymphocytes, spleen, thymus, tonsil), indicating the 
presence of mature B cells. Some non-lymphoid tissue (colon, fat, lung, mammary gland, pan-
creas, prostate, skin, stomach, small intestine) showed Cxcr5, but also Cd19 expression. Most 
likely, these tissues harbored lymphocytic infiltrates, which contained CD19+CXCR5+ mature 
B cells. Cd19 expression independent from Cxcr5 expression was detected in some tissues 
(e.g. duodenum, stomach and trachea), indicating the presence of Cd19+Cxcr5- plasmablasts 
(Llinàs et al., 2011). Cxcr5 expression was selectively detected in tissues with Cd19 expres-
sion in lymphoid and non-lymphoid organs, but not on other, unrelated tissues. Minor bands 
for CXCR5 expression were detected for liver, cervix and urinary bladder; primary cells of these 
tissues were therefore subsequently analyzed for protein expression. Summing up the tissue 
distribution of Cxcr5, Cxcr5 mRNA expression was highly selective in non-lymphoid tissue and 




CXCR5 CAR T cells spare these Cxcr5 negative tissues, the Cxcr5 mRNA expression data 
largely excluded potential safety risks for a large number of tissues. 
4.3.4 CXCR5 is absent on non-hematopoietic primary cells and cell lines 
The CXCR5 expression on numerous primary cells (Figure 13A) and cell lines (Figure 13B) of 
non-hematopoietic origin was analyzed by flow cytometry. HUVEC (Human Umbilical Vein En-
dothelial Cell) and HUAEC (Human Umbilical Artery Endothelial Cell) are vascular primary 
cells in immediate proximity of CAR T cells upon infusion. Thus, CXCR5 negativity had to be 
ensured in order to being able to safely administer anti-CXCR5 CAR T cells to patients. Human 
Cervical Epithelial Cells (HCerEpiC), Human Urothelial Cells (HUC) and the hepatocellular 
carcinoma cell line HepG2 were further investigated as low Cxcr5 mRNA levels were detected 
for liver, cervix and urinary bladder in the HMRT103 TissueScan Human Normal cDNA Array. 
Human Perineurial Cells (HPNC), Human Astrocytes (HA) and Human Neurons (HN) were 
analyzed in order to exclude potential neurotoxic events due to CXCR5 expression on tissues 
of the nervous system. Additionally, the CXCR5 expression on the gastro-intestinal primary 
cells HCoEpiC (Human Colonic Epithelial Cells) and cell line SW620 (colorectal carcinoma), 
and HEK-293 (Human Embryonic Kidney) was measured.  The adherent cells were gently 
dissociated using Accutase and subsequently labeled with the CXCR5 antibody or the isotype 
control antibody, dead cells were excluded by 7AAD positivity. All primary cells and cancer cell 





Figure 13: CXCR5 is absent on unrelated primary cells and cell lines. Primary cells and cell lines 
were analyzed by flow cytometry after labeling with the CXCR5 antibody (black line) or the isotype con-
trol antibody (grey filled line). Representative histograms of at least three independent experiments were 
selected. A CXCR5 expression was plotted for the human primary cells HUVEC (Human Umbilical Vein 
Endothelial Cell), HUAEC (Human Umbilical Artery Endothelial Cell), Human Urothelial Cells (HUC), 
Human Colonic Epithelial Cells (HCoEpiC), Human Cervical Epithelial Cells (HCerEpiC), HN (Human 
Neurons), HA (Human Astrocytes) and HPNC (Human Perineurial Cells). B CXCR5 expression was 
plotted for the human gastro-intestinal cancer cell lines HepG2 (hepatocellular carcinoma), SW620 (col-
orectal carcinoma) and HEK-293 (Human Embryonic Kidney). JEKO-1 lymphoma cells are shown as 
positive control. Data was collected in collaboration with Dr. Mario Bunse. 
 
4.3.5 CXCR5 is absent on non-hematopoietic primary cells under inflammatory 
conditions 
Jiang et al. published that murine astrocytes expressed CXCR5 in a neuropathic pain model. 
The authors utilized a spinal nerve ligation model, in which they found upregulation of CXCL13 
in inflamed neurons and induction of CXCR5 on activated murine astrocytes (Jiang et al., 2016) 
Therefore, it was necessary to further exclude possible anti-CXCR5 CAR-mediated on-tar-
get/off-tumor effects under inflammatory conditions. Primary vascular cells (HUVEC and 
HUAEC), primary perineurial cells (HPNC) and astrocytes (HA) were incubated with 25 ng/ml 
IFNγ for 24 h to induce an inflammatory status. Subsequently, they were gently dissociated 
using Accutase and labeled. 7AAD was used to exclude dead cells. The inflammatory status 
was confirmed by MHC I upregulation (Figure 14A). FACS analysis confirmed that CXCR5 
was not upregulated upon IFNγ stimulation in the primary cells (Figure 14B). 
 
Figure 14: Primary cells do not express CXCR5 under inflammatory conditions. HUVEC (Human 
Umbilical Vein Endothelial Cell), HUAEC (Human Umbilical Artery Endothelial Cell), HPNC (Human 
Perineurial Cells) and HA (Human Astrocytes) were incubated with 25 ng/ml IFNγ for 24 h and further 
analyzed by flow cytometry (n=2). A The staining of the MHC I antibody is shown. The continuous line 
represents cells incubated with 25 ng/ml IFNγ for 24 h, the dotted line represents untreated cells. B The 
black line represents staining with the CXCR5 antibody, the grey filled line shows the staining with the 




4.4 CXCR5 CAR T cells do not recognize CXCR5 negative cells in vitro 
and in vivo 
The expression profile of CXCR5 on mRNA level was investigated for a plethora of tissues. 
Additionally, extensive expression analysis by flow cytometry was performed for human pri-
mary cells and cell lines in order to exclude CXCR5 expression on non-hematopoietic tissues 
on protein level. However, most importantly, it had to be confirmed that anti-CXCR5 CAR T 
cells do not react towards these unrelated cells upon direct contact. Experiments were per-
formed to cover on-target/off-tumor as well as off-tumor/off-target effects. On-target/off-tumor 
effects occur upon CXCR5 expression by unrelated tissues, off-tumor/off-target effects de-
scribe unspecific reactions of CAR T cells against CXCR5 negative benign tissues. 
4.4.1 Effector cytokines are not released upon incubation of CXCR5 CAR T cells 
with CXCR5 negative primary cells and cell lines 
Cocultures were performed with anti-CXCR5 CAR T cells as effector cells and various human 
primary cells (HUVEC, HUAEC, HPNC, HA, HUC, HCerEpiC and HCoEpiC) and gastro-intes-
tinal cancer cell lines (HepG2, SW620 and HEK-293) as targets (Figure 15). Effector and target 
cells were cocultured at a 1:1 ratio (5x104 cells per well each, in a 96-well plate). The target 
cells were seeded one day prior, upon gentle Accutase dissociation, to allow adherence. After 
a 24 h incubation period, IFNγ in the supernatant was quantified by ELISA. The CXCR5 CAR 
T cells did not release IFNγ in response to incubation with CXCR5 negative primary cells and 
cell lines, showing that they did not recognize their epitope. Thus, the absence of CXCR5 on 
these cells, as shown by flow cytometry, could be confirmed. Also, this indicates that the 
CXCR5 CAR T cells do not react to other, undefined structures on the target cells. To validate 







Figure 15: CXCR5 CAR T cells do not show in vitro reactivity against CXCR5 negative primary 
cells and cell lines. IFNγ release of CAR T cells or non-transduced cells (UT) upon 24 h incubation 
with the human primary cells HUVEC (Human Umbilical Vein Endothelial Cell), HUAEC (Human Umbil-
ical Artery Endothelial Cell), Human Urothelial Cells (HUC), Human Colonic Epithelial Cells (HCoEpiC), 
Human Cervical Epithelial Cells (HCerEpiC), HN (Human Neurons), HA (Human Astrocytes), HPNC 
(Human Perineurial Cells) and the human gastro-intestinal cancer cell lines HepG2 (hepatocellular car-
cinoma), SW620 (colorectal carcinoma) and HEK-293 (Human Embryonic Kidney) was quantified by 
ELISA. JEKO-1 CXCR5+ lymphoma cells served as a positive control. Bars represent mean ± SEM of 7 
independent donors. Data was collected in collaboration with Dr. Mario Bunse. 
 
4.4.2 Effector cytokines are not released upon incubation of CXCR5 CAR T cells 
with CXCR5 negative primary cells under inflammatory conditions 
As demonstrated by flow cytometry, primary vascular (HUVEC) and perineurial (HPNC) cells, 
as well as primary astrocytes (HA) did not upregulate CXCR5 expression upon induction of an 
inflammatory status by IFNγ incubation. Additionally, it was investigated whether CXCR5 CAR 
T cells showed in vitro reactivity against these inflamed cells. HUVEC, HPNC and HA were 
first stimulated for 24 h with 25 ng/ml IFNγ to induce inflammation. After washing, they were 
coincubated with CAR T cells for 24 h at a 1:1 ratio. CXCR5+ JEKO-1 cells were included in 
the coculture as a positive control for CXCR5 CAR T cell activity; CXCR5- Jurkat cells served 
as a negative control. IFNγ in the supernatant was quantified by ELISA (Figure 16). The 
CXCR5 CAR T cells did not release IFNγ in response to untreated or IFNγ-treated (+) target 




Figure 16: CXCR5 CAR T cells do not show in vitro reactivity against CXCR5 negative primary 
cells under inflammatory conditions. HUVEC (Human Umbilical Vein Endothelial Cell), HPNC (Hu-
man Perineurial Cells) and HA (Human Astrocytes) were incubated with 25 ng/ml IFNγ for 24 h to induce 
an inflammatory status. Subsequently CAR T cells or non-transduced cells (UT) were coincubated with 
the non-stimulated or stimulated (+) primary cells and IFNγ in the supernatant was quantified by ELISA. 
Jurkat CXCR5- cells served as a negative control. JEKO-1 CXCR5+ lymphoma cells served as a positive 
control. Bars represent mean ± SEM of 7 independent experiments. Data was collected in collaboration 




4.4.3 CXCR5 CAR T cells do not show off-target reactivity in vivo 
In cocultures with CXCR5- non-hematopoietic primary cells and cell lines, it was demonstrated 
that anti-CXCR5 CAR T cells do not react towards unrelated structures on the target cells in a 
nonspecific manner in vitro. Subsequently, it was investigated whether anti-CXCR5 CAR T 
cells recognize unrelated epitopes in vivo. For this purpose, immunodeficient NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were injected with CXCR5 CAR T cells (1x106 or 1x107 T 
cells per mouse). Immunodeficient mice were used to avoid reactions of the murine immune 
system against the human T cells. After one and three days, serum parameters were analyzed 
in peripheral blood collected by retroorbital puncture. It was shown that the liver markers ala-
nine transaminase (ALT) and aspartate transaminase (AST) were not elevated compared with 
naive mice, indicating that liver tissue was not harmed by the CXCR5 CAR T cells. AST up-
regulation is additionally associated with damage of cardiac and skeletal muscle, which could 
also be excluded. Creatinine, a marker of renal function, was comparable between the groups. 
General tissue damage could be excluded as lactate dehydrogenase (LDH) values were not 
increased in the treated mice. Altogether, the CAR T cells did not cause an increase in serum 
markers associated with tissue damage (Figure 17A). Paraffin embedded tissue sections of 
lung, liver and colon, which were stained with hematoxylin and eosin, were screened for lym-
phoid infiltrates caused by CAR T cells attacking the tissues, but such infiltrates were absent 
and there were no differences visible between the treated and naive mice (Figure 17B). Thus, 
CXCR5 CAR T cells did not show off-target reactivity in vivo by reacting towards unrelated 





Figure 17: CXCR5 CAR T cells do not show off-target reactivity in vivo. A Representative hema-
toxylin and eosin stainings show lung, colon and liver sections of CXCR5 CAR T cell injected mice and 
naive mice three days after injection. B Markers for liver damage (ALT, AST), kidney damage (CRE) 
and general organ damage (LDH) were analyzed in the serum of naive mice and mice injected with 
CXCR5 CAR T cells (1x106 or 1x107 T cells) one or three days after injection (n=3-8). 
 
4.5 CXCR5 CAR T cells recognize CXCR5 positive primary B-NHL patient 
samples in vitro 
4.5.1 CXCR5 is highly expressed on B-NHL patient samples 
Clinical trial eligibility criteria include, among others, prior treatments and physical condition of 
the patient, but most importantly disease characteristics (Gerber et al., 2015). For a prospec-
tive CXCR5 CAR trial and potential therapeutic use in patients, it had to be confirmed that 
CXCR5 is an epitope frequently expressed on primary malignant cells of B-NHL patients. In 
the literature, CXCR5 expression on mature B cell malignancies, such as chronic lymphocytic 
leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and marginal zone 
lymphoma (MZL) has been described (Dürig et al., 2001; Middle et al., 2015b). 
First, antigen expression on patient biopsies was evaluated by flow cytometry. Bone marrow 
(FL #85, #1054, #1100, #1129; MCL #545, #777; CLL #890, #821) or peripheral blood mono-




#441, #728, #769; CLL #12, #31, #33, #47, #75, #819) were kindly provided by Prof. Jörg 
Westermann (Department of Hematology, Oncology and Tumorimmunology; Charité-Univer-
sity Medicine). 
The samples were labeled with the CXCR5 antibody or the corresponding isotype control an-
tibody. Gating included doublet, dead cell, and CD3+ exclusion. Histograms showing profound 
CXCR5 expression on the B tumor population demonstrated that CXCR5 was expressed on 
the majority of samples, supporting the findings in the literature (Figure 18). Additionally, apart 
from confirming CXCR5 expression on the primary patient samples, the antigen quantity per 
cell was determined using Quantibrite beads, which added novel information to the expression 
data. The highest mean expression was measured for the CLL samples (4452 molecules/cell), 
followed by MCL (2035 molecules/cell). 1813 molecules/cell were detected on average on the 
FL samples. MZL showed mean CXCR5 expression of 672 molecules/cell, with one sample 
showing high expression and three samples having low expression (Figure 18E). Altogether, 
CXCR5 was strongly expressed in almost all analyzed patient samples, with quantities com-





Figure 18: B-NHL biopsies frequently express high levels of CXCR5. CXCR5 expression on B-NHL 
patient samples was assessed by flow cytometry. Doublets, dead cells, and CD3+ cells were excluded. 
Each sample was measured once due to limited material. CXCR5 expression on A follicular lymphoma, 
B mantle cell lymphoma, C marginal zone lymphoma and D chronic lymphocytic leukemia patient sam-
ples was depicted in histograms. Black lines show staining with the CXCR5 antibody; grey filled lines 
depict staining with the isotype control antibody. Histograms show relative fluorescence intensity. E 
CXCR5 molecules on the cell surface of B-NHL patient samples were quantified with the Quantibrite 
assay. Data points represent individual measurements, mean and SEM are shown. Data was collected 





For each patient biopsy, CXCR5 and CD19 expression was depicted in plots (Figure 19). A 
healthy donor peripheral blood sample illustrated the difference to the tumor samples. In 
healthy blood, only 17% of CD3- cells were mature B cells and expressed CD19 and CXCR5 
(Figure 19A). In the lymphoma/leukemia primary samples, the fraction of cells expressing 
CD19/CXCR5 was strongly increased, indicating that the majority of cells in these samples 
were tumor cells. FL biopsies expressed CXCR5 and CD19 to various degrees. CD19 expres-
sion was the least homogeneous in FL. In some FL samples, a fraction of tumor cells was 
CD19-CXCR5+ (#252, #457, #563, #1054). All FL patient samples, except #85, showed robust 
CXCR5 expression. FL #85, which is a bone marrow biopsy, also harbored a CXCR5- subset, 
possibly due to immature CD19+CXCR5- B cells (Figure 19B). In MCL, half the samples highly 
expressed CXCR5 (#114, #578, #624) and half of them showed lower expression levels (#545, 
#777, #988). The MCL samples were positive for CD19 (Figure 19C). Of the four MZL samples, 
only one strongly expressed CXCR5 (#728); the other three samples showed only minor ex-
pression levels on a small subset of tumor cells. CD19 was abundant on MZL biopsies (Figure 
19D). CLL samples strongly and homogeneously expressed CD19 and CXCR5. CLL #819 
harbored a fraction of CD19-CXCR5+ cells (Figure 19E). The fraction of CXCR5+CD19+ cells 
is drastically enriched in the primary patient samples compared with the healthy donor sample. 
It can be assumed that benign mature B cells were virtually absent and replaced by malignant 
cells in these samples. As the fraction of tumor cells in these samples was very high, complete 
patient samples, which were not specifically enriched for tumor cells, were used in subsequent 
in vitro assays.  
For patient samples that lack CD19 expression on a subset of tumor cells, anti-CD19 CAR T 
cells would not be able to target the tumor cells homogeneously. However, if CXCR5 is ex-
pressed on all tumor cells, anti-CXCR5 CAR T cells would be able to completely eradicate all 
tumor cells. The activity of anti-CXCR5 and anti-CD19 CAR T cells was further studied in co-
cultures, which shed light on the cytokine secretion and killing capacity upon incubation with 





Figure 19: CD19 and CXCR5 expression was assessed on B-NHL patient material. Expression of 
CXCR5 and CD19 was assessed on CD3- cells in primary material from A a healthy donor, B follicular 
lymphoma, C mantle cell lymphoma, D marginal zone lymphoma and E chronic lymphocytic leukemia. 
Cells were pregated on singlets and live cells. Quadrant gate was adjusted according to isotype controls. 






4.5.2 CXCR5 CAR T cells release IFNγ upon incubation with CXCR5 positive  
B-NHL patient samples 
Strong CXCR5 expression was demonstrated for the majority of patient material. For the treat-
ment of patients, it is crucial that the CXCR5 CAR T cells recognize and react towards CXCR5 
positive primary patient material. CAR T cells were incubated with the lymphoma patient sam-
ples for 12-24 h at a 1:1 ratio of target and effector cells (5x104 cells each). IFNγ release in the 
supernatant was quantified by ELISA (Figure 20). As a positive control for CAR T cell activity, 
the CXCR5+CD19+ cell line JEKO-1 was used. Generally, the anti-CXCR5 CAR T cells re-
leased more IFNγ than the anti-CD19 CAR T cells in response to FL, MCL and CLL samples. 
In FL, anti-CXCR5 CAR T cells reacted stronger towards #252, #457, #563, #1054 (which 
harbored CD19 negative tumor cell fractions) and #1100. For #457 and #1054, anti-CD19 CAR 
T cells even lacked IFNγ release. #85, which only weakly expressed CXCR5, elicited a 
stronger response in the anti-CD19 CAR T cells. For unknown reasons, #1129, which ex-
pressed both CXCR5 and CD19, did not trigger a response by any of the CAR T cells (Figure 
20A). Anti-CXCR5 CAR T cells released more IFNγ than the anti-CD19 CAR T cells in re-
sponse to the MCL samples #114, #545, #578, #624 and #777. MCL #988 barely triggered 
any release by any of the CAR T cells, but the reason for this is unclear, as the tumor cells 
expressed CD19 and CXCR5 (Figure 20B). Despite very weak CXCR5 expression on three 
MZL samples (#421, #441, #769), the anti-CXCR5 CAR T cells released some IFNγ. The re-
action of the anti-CD19 CAR T cells was stronger towards these samples, as they expressed 
higher levels of CD19. MZL #728, which expressed both CXCR5 and CD19, triggered robust 
IFNγ release of both CAR T cell types, with stronger release by the anti-CD19 CAR T cells 
(Figure 20C). CLL patient samples, which showed very homogeneous CXCR5 and CD19 ex-
pression in flow cytometry, generally triggered a stronger reaction of the anti-CXCR5 CAR T 
cells (Figure 20D). It can be concluded that the anti-CXCR5 CAR T cells react towards the 
CXCR5 positive patient samples. Frequently, they show greater activity than the anti-CD19 





Figure 20: CXCR5 CAR T cells show in vitro reactivity against B-NHL biopsies. Patient B-NHL cells 
were incubated with CAR transduced cells or non-transduced T cells for 12-24 h. IFNγ in the supernatant 
was quantified by ELISA. CXCR5+ JEKO-1 cells served as a positive control. Bars represent mean ± 
SEM of 4 independent donors (CXCR5 CAR, SP6 CAR, UT) or 3 independent donors (CD19 CAR). P-
values (*P<0.05, **P<0.01, ***P<0.001) were calculated using an unpaired T test comparing CXCR5-
CAR transduced T cells (red) or CD19-CAR transduced T cells (blue) with SP6-CAR transduced T cells. 
A Follicular lymphoma (FL), B mantle cell lymphoma (MCL), C marginal zone lymphoma (MZL) and D 
chronic lymphocytic leukemia (CLL) patient samples were analyzed. Data was collected in collaboration 
with Dr. Mario Bunse. 
 
4.5.3 CXCR5 CAR T cells kill tumor cells in B-NHL patient samples 
It was demonstrated that CXCR5 CAR T cells released IFNγ in response to lymphoma patient 
samples. Another crucial functional feature of CAR T cells for clinical application is efficient 
killing of malignant cells. Lymphoma cell killing in patient samples in vitro was further analyzed 
in a coculture. Previously, numerous experiments were performed to establish a solid protocol 
for in vitro primary lymphoma killing. Ultimately, a time frame of 48 h yielded the best results, 
considering patient cell viability and CAR T cell activity. Patient cells and CAR-transduced cells 
were incubated at a 1:1 ratio (5x104 cells each). To facilitate further analysis, the amount of T 




were analyzed by flow cytometry and gated for the CXCR5+, CD20+ or CD5+ tumor fraction. 
Patient material of follicular lymphoma (Figure 21A), mantle cell lymphoma (Figure 21B), mar-
ginal zone lymphoma (Figure 21C) and chronic lymphocytic leukemia (Figure 21D) was included 
in the assay. The amount of viable tumor cells at the end of the culture was highly variable 
between patient samples; therefore, the tumor cell fraction was depicted in relation to the viable 
tumor cells in the control sample incubated with non-transduced T cells. Interestingly, anti-
CD19 CAR T cell-mediated killing was weak and not statistically significant, despite proving its 
activity against the MCL cell line JEKO-1, which was included as a positive control. The anti-
CXCR5 CAR T cells showed strong tumor eradication towards most FL and MCL samples. 
Against MZL samples with minor CXCR5 expression, the anti-CXCR5 CAR T cell killing was 
weak. CLL samples were eliminated by the anti-CXCR5 CAR T cells to strongly varying de-
grees. In this in vitro killing assay, the anti-CXCR5 CAR T cells showed stronger functionality 
in comparison with the anti-CD19 CAR T cells. 
 
 
Figure 21: CXCR5 CAR T cells kill primary B-NHL lymphoma cells in vitro. Cocultures of lymphoma 
patient cells at a 1:1 ratio with CXCR5, CD19 and SP6 CAR T cells and non-transduced cells were 
analyzed by flow cytometry. Cells were gated on single cells and 7-AAD-. Percentages shown are tumor 
cell fractions (CXCR5+, CD20+ or CD5+) relative to tumor cell fractions in the samples with non-
transduced T cells. Bars represent mean ± SEM of 4 independent donors (CXCR5 CAR, SP6 CAR, UT) 
or 3 independent donors (CD19 CAR). P-values (*P<0.05, **P<0.01, ***P<0.001) were calculated using 




(blue) with SP6-CAR transduced T cells. A Follicular lymphoma (FL), B mantle cell lymphoma (MCL), 
C marginal zone lymphoma (MZL) and D chronic lymphocytic leukemia (CLL) patient samples were 
analyzed. Data was collected in collaboration with Dr. Mario Bunse. 
 
4.6 CXCR5 CAR T cells recognize CXCR5 expressing T cells in vitro 
CXCR5 is not only expressed on mature B cells, but also on subsets of CD4+ T cells. Follicular 
helper T (TFH) cells are classified as CD4+ helper T cells in the B cell follicle and germinal 
centers. They are able to enter these B cell areas upon CXCR5 expression and provide B cell 
help (Breitfeld et al., 2000; Schaerli et al., 2000b). They are commonly described to coexpress 
PD-1 and/or ICOS. Further, they were described to actively contribute to pathogenesis in fol-
licular lymphoma and chronic lymphocytic leukemia. Their counterparts in the peripheral blood 
were termed circulating follicular helper T (cTFH) cells and preferentially studied in disease due 
to their easy accessibility in patients (Crotty, 2014).  
4.6.1 CXCR5 CAR T cells release IFNγ upon incubation with CXCR5 expressing  
T cells 
Human CXCR5+ T cells were isolated from peripheral blood. Immunomagnetic sorting was 
chosen over fluorescence-activated cell sorting (FACS), as it was not feasible to obtain suffi-
cient numbers of viable cells by FACS. Therefore, it was not possible to isolate PD-1+CD25- 
cTFH cells, but in a rather general approach, CXCR5+CD4+ cells were harvested, which in-
cluded cTFH cells. First, an immunomagnetic negative sort for CD4+ cells was performed, fol-
lowed by a positive sort for CXCR5+ cells. Flow cytometry analysis confirmed that 
CD4+CXCR5+ cells were strongly enriched in the positive sort fraction and absent from the 
negative sort fraction (Figure 22A). The CXCR5 negative and positive sort fractions were co-
cultured in an overnight assay with the anti-CXCR5, anti-CD19 and SP6-transduced T cells 
and non-transduced T cells at a 1:1 ratio (5x104 cells each per well) (Figure 22B). JEKO-1 
tumor cells were included as a positive control. The anti-CD19 CAR T cells did not release 
IFNγ in response to the CD4+ T cell fractions. The anti-CXCR5 CAR T cells however secreted 
IFNγ exclusively in response to the CD4+CXCR5+ fraction. The CD4+CXCR5- fraction was not 
recognized by the CAR T cells. This demonstrated that the anti-CXCR5 CAR T cells react 
specifically towards CXCR5 expressing helper T cells in the peripheral blood, which include 
the cTFH cells. 





Figure 22: CXCR5 CAR T cells show in vitro reactivity against CXCR5+ T cells. A Cells from pe-
ripheral blood were analyzed for CD4+CXCR5+ cells before magnetic sorting and afterwards. Doublets 
and dead cells were excluded. Plots are shown before the sort and of the negative and positive CXCR5 
sort fractions. B CD4+ T cells from peripheral blood magnetically sorted into the CXCR5- and CXCR5+ 
fractions were incubated with CAR transduced cells or non-transduced T cells for 16 h. IFNγ in the 
supernatant was quantified by ELISA. CXCR5+ JEKO-1 cells served as a positive control. Bars represent 
mean ± SEM of 4 independent donors (CXCR5 CAR, SP6 CAR, UT) or 3 independent donors (CD19 
CAR). P-values (*P<0.05, **P<0.01, ***P<0.001) were calculated using an unpaired T test comparing 
CXCR5-CAR transduced T cells (red) or CD19-CAR transduced T cells (blue) with SP6-CAR transduced 
T cells. Data was collected in collaboration with Dr. Mario Bunse. 
 
4.6.2 CXCR5 CAR T cells kill follicular helper T cells in follicular lymphoma and 
chronic lymphocytic leukemia patient samples 
Follicular helper T cells were described to support malignant cells in follicular lymphoma and 
chronic lymphocytic leukemia. They stimulate the tumor cells with mechanisms intended for 
the support of B cell proliferation, such as IL4/21 production and CD40/CD40L signaling. For 
CLL, expansion of cTFH cells in the blood was described (Ahearne et al., 2013; Amé-Thomas 
et al., 2012). First, peripheral blood samples from FL patients, CLL patients and healthy donors 
were analyzed by flow cytometry for cTFH cells. After exclusion of dead cells and doublets, 
CD4+CD25- cells were selected and expression of CXCR5 and PD-1 was analyzed. Double 
positive cells represented the cTFH cell fraction (Figure 23A). Healthy donors harbored cTFH cell 
fractions of around 5%. For the two analyzed FL samples, cTFH cell fractions were in a similar 
range, indicating that cTFH cells were not enriched in these patients. Five CLL samples were 
measured, of which three showed strongly enlarged cTFH cell fractions from 9% to 26%. Due 
to the low sample number, these percentages are not intended to describe the cTFH cell frac-
tions in FL or CLL patients, but rather to demonstrate that cTFH cells were present at the onset 
of the killing assay. In addition to showing in vitro killing of the tumor cells, flow cytometry of 
cTFH cells after coculture was performed to assess whether the CAR T cells are capable of 
killing them. The FL and CLL samples were incubated with the CAR T cells for 48 h. After 
gating on CD4+CD25-, the cTFH fractions are shown as PD-1+CXCR5+ (Figure 23B). The TFH 




and SP6 CAR T cells (Figure 23C). PBMCs from healthy donors were included as controls. 
Incubation with the anti-CXCR5 CAR T cells, and not with anti-CD19 CAR T cells, could ex-
clusively deplete the cTFH population in the FL and CLL samples. 
 
 
Figure 23: CXCR5 CAR T cells kill primary follicular helper T cells derived from FL and CLL 
biopsies. TFH cell fractions are defined as PD-1+CXCR5+ of CD4+CD25- cells. A Distribution of TFH cell 
fractions of peripheral blood patient biopsis of FL, CLL and healthy donors are depicted. B Cocultures 
of follicular lymphoma patient cells with CXCR5, CD19 and SP6 CAR T cells were analyzed by flow 
cytometry. Cells were gated on single cells, 7-AAD- and CD4+CD25-. Percentages shown are follicular 
helper T cell fractions. Representative contour plots of 3-4 independent experiments are shown. C The 
TFH cell fraction determined as described in B is depicted. Bars represent mean ± SEM of 4 independent 
donors (CXCR5 CAR, SP6 CAR, UT) or 3 independent donors (CD19 CAR). P-values (*P<0.05, 
**P<0.01, ***P<0.001) were calculated using an unpaired T test comparing CXCR5-CAR transduced T 
cells (red) or CD19-CAR transduced T cells (blue) with SP6-CAR transduced T cells. Data was collected 






4.7 CXCR5 CAR T cells show a strong anti-tumor effect in vivo against B-
NHL 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, which lack B and T cells and are defective in 
functions of the innate immune system, were used in a xenograft mouse model (Shultz et al., 
2005). Due to these deficiencies, human cells, including lymphoma cell lines or patient-derived 
xenografts, engraft in the mice. The mice can also be subsequently administered with human 
CAR T cells to investigate an antigen-specific anti-tumor effect. 
It is of particular interest to not only analyze mice at the end point of an experiment, but also 
at earlier time points to gain a better understanding of tumor kinetics and the anti-tumor func-
tion of CAR T cells. In vivo bioluminescence imaging using the IVIS spectrum device allowed 
visualization of luciferized tumor cells within the mice, without the need to sacrifice animals at 
different time points during the experiment. IVIS is equipped with a sensitive camera to detect 
the emission of bioluminescence in cells within the living animal. These cells must express 
luciferase, an enzyme derived from firefly or sea pansy. At the time of measurement, the mice 
are injected with the corresponding substrate called luciferin. The substrate is transformed by 
the luciferase and light is emitted.  
4.7.1 PDX cells could not be sufficiently luciferized to be used in a xenograft NSG 
mouse model 
A couple of CXCR5 expressing cell lines were tested in order to find a candidate that engrafts 
upon intravenous injection in a lymphoma-typical pattern. Ultimately, two mantle cell lymphoma 
entities, the cell line JEKO-1 and the patient-derived xenograft (PDX) #96069, were shown to 
be suitable for the xenograft experiments. Luciferized JEKO-1 cells were provided at the start 
of the project; the PDX cells were transduced as part of this thesis.  
A PDX is established by injecting human tumor cells, originating from a patient, into immuno-
deficient mice, as they lack the immune system to reject the graft. They are gradually adapted 
to the murine environment by passaging. PDX cells have to be expanded in vivo, because they 
do not proliferate in cell culture, which required the application of a special transduction proto-
col to equip them with a luciferase-eGFP construct. After transduction, the cells were immedi-
ately injected in mice and after several weeks, the spleen was harvested, sorted for positively 
transduced cells and reinjected into a mouse to expand these cells. Sorting was performed 





Figure 24: Mantle cell lymphoma PDX #96069 cells were luciferized by viral transduction. PDX 
#96069 cells were transduced, expanded in NSG mice and sorted twice. IVIS images of the injected 
mice and analysis of cells harvested from the spleen by flow cytometry after single cell gating are shown.  
A IVIS image with 240 s exposure time six weeks after the first injection, flow cytometry showed that 
only a minor cell fraction is positively transduced and expresses eGFP. These cells were sorted and 
reinjected into an NSG mouse. B IVIS image with 240 s exposure time six weeks after injection of once 
sorted PDX cells, flow cytometry revealed that the eGFP+ fraction is strongly enriched. The eGFP+ cells 
were sorted and expanded in NSG mice. C The IVIS image with 60 s exposure time and flow cytometry 
analysis show that the majority of PDX cells are GFP+ after sorting them twice. D JEKO-1 eGFP trans-
duced tumor cells, eGFP transduced PDX cells and non-transduced JEKO-1 cells were analyzed for 
eGFP expression by flow cytometry, gated on singlets and live cells by 7-AAD negativity. eGFP histo-
grams are shown. 
The MCL PDX cells were subsequently used in an NSG mouse experiment to analyze the anti-
tumor effect of CXCR5-CAR T cells. However, the PDX cells did not show sufficient expression 
of bioluminescence during the course of the experiment. Compared to luciferase-eGFP trans-
duced JEKO-1 cells, fluorescence intensity of eGFP was around 10-fold lower in the PDX cells 
(Figure 24D). It was not possible to generate PDX cells with high expression levels and they 
were not suitable to monitor the course of the experiment by bioluminescence imaging. JEKO-
1 cells with a higher luciferase-eGFP expression were preferred for the following experiments 
to assess the anti-tumor activity of the anti-CXCR5 CAR T cells against mantle cell lymphoma 
in vivo. 
4.7.2 CXCR5 CAR T cells show a strong anti-tumor effect in vivo against a mantle 
cell lymphoma cell line 
JEKO-1 was used as a target cell line in the xenotransplantation model due to its high lucifer-
ase expression and ideal engraftment upon intravenous injection. For in vivo experiments, 
JEKO-1 cells were expanded before injection and culture medium was added a day prior to 
ensure high viability. 6x105 JEKO-1 cells per mouse were injected intravenously. CAR T cells 
were expanded supplemented with rhIL7/15 over the course of 10 days. The T cells were 




administration, transduction rates were considered and a fixed number of CAR T cells was 
injected (3x106), the total T cell number was higher.  
The JEKO-1 xenotransplantation experiment was performed twice with a comparison between 
the anti-CXCR5 and anti-CD19 CAR T cells. In the first experiment, onset of tumor growth was 
confirmed by bioluminescence imaging on day 7 at 300s (Figure 25A). In the second experi-
ment, onset of growth was already visible on day 5 at 120 s exposure time (Figure 26A). The 
tumor cells predominantly locate to the bone marrow. Upon visible tumor growth, anti-CXCR5, 
CD19 and SP6 CAR T cells were injected the following day and progression was monitored by 
IVIS. An exposure time of 15 s was selected, which allowed showing the images of all groups 
without oversaturating the images of the SP6 CAR group that had stronger bioluminescence 
signals (Figure 25+Figure 26B). The antigen-specific CXCR5 and CD19 CAR T cells were able 
to reduce tumor growth over the course of the experiment. No reduction of tumor growth was 
observed in the SP6 group, except of a single animal in the first experiment. As tumor load 
increased, bioluminescence signals were detected mostly in the bone marrow of the femur and 
chest area; in one animal they were localized in the spleen (Figure 25B) In the second exper-
iment, tumor removal by the anti-CXCR5 and anti-CD19 CAR T cells was less efficient and 
residual tumor mass, especially in the head region was increasingly detected during the course 
of the experiment (Figure 26B). Quantification of bioluminescence signals of the luciferized 
tumor cells illustrated that tumor load was decreased in the CXCR5 CAR and CD19 CAR 
groups compared with the SP6 group (Figure 25+Figure 26C). At the end point of the experi-
ments, mice were sacrificed, spleen and bone marrow of the femur were harvested. Flow cy-
tometry analysis confirmed that the tumor cells strongly located to the bone marrow of SP6 
mice. In the CXCR5 CAR and CD19 CAR groups of the first experiment, JEKO-1 cells were 
virtually absent from bone marrow; only one mouse in the CXCR5 CAR group harbored tumor 
cells in the spleen (Figure 25D). The tumor load was generally higher in the second experiment 
than in the first experiment. Tumor load in the SP6 group was on average 7% in the bone 
marrow and 0.1% in the spleen in the first experiment; for the second experiment, the tumor 
load was 69% and 31%, respectively (Figure 25+Figure 26D). IVIS imaging and flow cytometry 
analysis illustrated the strong anti-tumor effect of the anti-CXCR5 and anti-CD19 CAR T cells, 
especially at the primary site of lymphomagenesis, the bone marrow. The anti-CD19 CAR T 
cells showed slightly stronger anti-tumor efficacy in the first experiment, while the anti-CXCR5 
CAR T cells performed better in the second experiment. The JEKO-1 tumor cells were ana-
lyzed concerning their CXCR5 expression. In both experiments, expression was consistent 
among the groups, which excluded the outgrowth of antigen-loss variants (Figure 25+Figure 
26E). Further, expression of the exhaustion marker PD-1 was assessed to get an impression 




increased compared with the anti-SP6 CAR T cells, indicating that the CAR T cells did not 
suffer from exhaustion (Figure 25+Figure 26F).  
 
 
Figure 25: CXCR5 CAR T cells show a strong anti-tumor activity in vivo.  NSG mice were injected 
with 6x105 JEKO-1 tumor cells and subsequently with CXCR5, CD19 or SP6 CAR T cells (3x106 CAR 
T cells per mouse). A Tumor growth was verified on day 7 after tumor cell injection by IVIS (exposure 




of 18 days after T cell injection. C Average Radiance is depicted for the different groups (n=3-6 mice 
per group). P-values (*P<0.05, **P<0.01, ***P<0.001) were calculated using an unpaired T test compar-
ing animals of the CXCR5 group (red) or animals of the CD19 group (blue) with SP6 animals. Cells were 
analyzed by flow cytometry on day 19 and 20. D Tumor load as fraction of viable JEKO-1 cells is shown 
for the spleen and the bone marrow. E CXCR5 gMFI on JEKO-1 tumor cells is depicted. An unpaired T 
test comparing animals of the CXCR5 and the CD19 group was conducted. F Expression of PD-1 (gMFI) 






Figure 26: CXCR5 CAR T cells mediate potent anti-tumor activity in vivo. NSG mice were injected 
with 6x105 JEKO-1 tumor cells and subsequently with CXCR5, CD19 or SP6 CAR T cells (3x106 CAR 
T cells per mouse) A Tumor growth was verified on day 5 after tumor cell injection by IVIS (exposure 
time 120s). B Progression of tumor growth was monitored by IVIS (exposure time 15s) over the course 
of 16 days after T cell injection. C Average Radiance is depicted for the different groups. Values are 




an unpaired T test comparing animals of the CXCR5 group (red) or animals of the CD19 group (blue) 
with SP6 animals. Cells were analyzed by flow cytometry on day 19 and 20. D Tumor load as fraction 
of viable JEKO-1 cells is shown for the spleen and the bone marrow. E CXCR5 gMFI on JEKO-1 tumor 
cells is depicted. An unpaired T test comparing animals of the CXCR5 and the CD19 group was con-
ducted.  F Expression of PD-1 (gMFI) is shown for CD4 and CD8 CAR T cells in the spleen and bone 
marrow. 
 
A strong anti-tumor effect of the anti-CXCR5 CAR T cells could be demonstrated in both in 
vivo JEKO-1 xenograft experiments, with an efficacy slightly stronger than the anti-CD19 CAR 
T cells in one experiment and slightly weaker in the other. Nevertheless, the antigen-specific 
CAR T cells did not completely eradicate the lymphoma cells. Progressive tumor growth in the 
anti-CXCR5 CAR group, but also the anti-CD19 CAR group, especially in the spleen was still 
observed. A reason for this could be decreased T cell functionality due to exhaustion. Ex-
hausted T cells are dysfunctional, cannot proliferate and lack effector functions. Programmed 
cell death protein 1 (PD-1) is one of the markers upregulated on exhausted T cells, as originally 
investigated in chronic infection models. These findings in infection were also applicable in 
cancer research (Sakuishi et al., 2010). PD-1 signaling was also shown to induce T cell ex-
haustion in hematologic malignancies (Mumprecht et al., 2009; Yamamoto et al., 2008). How-
ever, in both JEKO-1 xenotransplantation experiments, PD-1 upregulaton was not observed. 
Thus, T cell exhaustion appeared to be not causal for tumor progression. Progressive tumor 
growth can therefore most likely be attributed to the limitation of the NSG mouse model, in 
which human T cells lack support. NSG mice lack the cytokines IL2, IL4, IL7, IL9, IL15 and 
IL21 due to their Il2rg null mutation (Shultz et al., 2012). Another major impairment for human 
T cell function in the NSG model is the insufficient cross-reactivity of murine cytokines on hu-
man receptors (Willinger et al., 2011). In summary, these results showed that, despite limita-
tions of the NSG mouse model, the anti-CXCR5 CAR T cells achieved a significant anti-tumor 
effect in vivo, in a range comparable to the anti-CD19 CAR T cells. 
 
4.8 The CXCR5 CAR is not hampered by the soluble CXCR5 N-terminus 
In the previous xenotransplantation experiments, the CAR T cells did not completely eradicate 
the tumor cells. CAR T cell function is dependent on the interaction between the antigen-bind-
ing domain of the CAR T cell and the antigen expressed by the target cell. This interaction can  
possibly be disturbed by soluble antigen binding to the CAR. For B-cell maturation antigen 
(BCMA), shedding of the extracellular domain is described (Laurent et al., 2015). For CXCR5, 
similar mechanisms have not been reported and tumor cells with reduced antigen expression 
have not been found in the JEKO-1 xenotransplantation experiments. However, to exclude the 
possibility that antigen shedding inhibits CAR function, it was assessed whether anti-CXCR5 
CAR T cell function is compromised by the soluble CXCR5 N-terminus (Figure 27). CAR T 




JEKO-1 tumor cells at a 1:1 ratio (5x104 cells/well each). Anti-CXCR5, anti-CD19 and anti-SP6 
CAR T cells were included in the assay. 60 nM of a synthesized peptide were added, which 
included the region of the anti-CXCR5 CAR-targeted N-terminal epitope. This concentration 
was chosen as it was similar to the median soluble BCMA concentration measured in the blood 
of multiple myeloma patients. At this concentration, soluble BCMA interfered with BCMA anti-
body binding to tumor cells (Sanchez et al., 2012). Moreover, the effect of 500 nM of the 
epitope peptide was evaluated to compare if non-physiological concentrations might interfere 
with CAR binding. As a control, a synthesized peptide of the CXCR5-loop region, which is not 
recognized by the anti-CXCR5 CAR T cells, was added at the same concentrations as the 
CAR-targeted epitope peptide. As always, a minimum value with solely CAR T cells and a 
maximum value induced by PMA/ionomycin stimulation were included. IFNγ release by CAR 
T cells was measured after a 24 h incubation period. IFNγ secretion of the anti-CXCR5 CAR 
T cells was not decreased by addition of the CXCR5-CAR targeted-epitope, even at 500 nM, 
compared with addition of the control peptide or without the addition of any peptides. This 
finding showed that the presence of the CAR-targeted CXCR5 N-terminal epitope even at non-
physiological concentrations did not inhibit CAR-mediated T cell activity and potential CXCR5 
shedding is not expected to interfere with anti-tumor efficacy in the NSG xenotransplantation 
model or in the prospective anti-CXCR5 CAR T cell administration to patients. 
 
 
Figure 27: CXCR5 CAR T cells do not show decreased in vitro activity upon incubation with the 
soluble CXCR5 N-terminus. IFNγ release of CAR T cells upon 24 h incubation with JEKO-1 tumor cells 
was quantified by ELISA. The CXCR5 CAR epitope peptide or a control peptide were added to the 





4.9 CXCR5 CAR T cells are not exhausted at the time of tumor cell out-
growth 
Tumor relapse or insufficient tumor elimination by the CAR T cells in the previous experiments 
did not seem to be caused by the outgrowth of antigen-loss variants or by CAR-blocking by 
the soluble CXCR5 N-terminus. However, it was not yet fully addressed whether the CAR T 
cells experience exhaustion, which diminishes their anti-tumor efficacy. The in vivo persistence 
of anti-CXCR5 CAR T cells was studied at the time of tumor cell outgrowth to gain a better 
understanding about why NSG mice suffer from tumor relapse. To this end, CXCR5 CAR T 
cells were studied in a short-term animal experiment analogous to the previous JEKO-1 ex-
periments. NSG mice were injected with 6x105 JEKO-1 mantle cell lymphoma cells and tumor 
growth was confirmed by IVIS on day 5 (Figure 28A). Subsequently, 3x106 anti-CXCR5 or anti-
SP6 CAR T cells were administered and tumor growth was monitored by IVIS (Figure 28B). On 
day 8 and 13, four to five mice were sacrificed and femoral bone marrow and spleen tissues 
were analyzed by flow cytometry. On day 8, the tumor load was still low, but rapidly increased 
in the SP6 CAR group in the following days. On day 13, the average tumor load in the SP6 
group was 12% in the bone marrow and 0.3% in the spleen. The tumor load was strongly 
reduced in the CXCR5 CAR group. The final average tumor load in the CXCR5 CAR group 
was 0.25% in the bone marrow and 0.13% in the spleen (Figure 28C). For the JEKO-1 tumor 
cells, CXCR5 expression was assessed for the different organs and groups on day 8 and 13. 
CXCR5 was not significantly downregulated on the tumor cells in the mice treated with the 
anti-CXCR5 CAR T cells, supporting that tumor recurrence was not caused by antigen-loss 
variants (Figure 28D). Further analysis was focused on CAR T cell proliferation and exhaustion 
characteristics of anti-CXCR5 and anti-SP6 CAR T cells recovered from sites of lym-
phomagenesis. CAR T cells were quantified and total cell numbers in the spleen and femoral 
bone marrow were determined (Figure 28E). CD8+ T cell numbers were low and mostly CD4+ 
T cells were present in the tissues, with expansion of antigen-specific CD4+ anti-CXCR5 CAR 
T cells on day 8 in the bone marrow and on day 13 in the spleen. This expansion pattern for 
the anti-CXCR5 CAR T cells is in accordance with earlier and stronger tumor progression in 
the bone marrow, opposed to the spleen, as seen in the SP6 CAR group. Anti-CXCR5 CAR T 
cells could still be detected at the sites of lymphoma homing at the endpoint of the experiment 








Figure 28: CXCR5 CAR T cells are not exhausted at the time of tumor cell outgrowth. NSG mice 
were injected with JEKO-1 tumor cells and subsequently with CXCR5 or SP6 CAR T cells (3x106 CAR 
T cells per mouse). A Tumor growth was verified on day 5 after tumor cell injection by IVIS (exposure 
time 300s). B Progression of tumor growth was monitored by IVIS (exposure time 15s) over the course 
of 12 days after T cell injection. Cells were analyzed by flow cytometry on day 8 and 13. C Tumor load 
as fraction of viable JEKO-1 cells is shown for the spleen and the bone marrow. D CXCR5 gMFI on 
JEKO-1 tumor cells is depicted. E Absolute CAR T cell numbers are shown for CD8 and CD4 T cells in 
the spleen and bone marrow. F, G, H Expression of PD-1, TIM-3 and LAG-3 (gMFI) is shown for CD8 
and CD4 T cells in the spleen and bone marrow. Bars represent mean ± SEM of 4-5 mice. 
 
Expression of the exhaustion markers PD-1, T-cell immunoglobulin and mucin-domain con-
taining-3 (TIM-3) and Lymphocyte-activation gene 3 (LAG-3) was analyzed on the CAR T cells 
(Figure 28F-H). On CD4+ T cells, the markers were virtually absent. CD8+ T cells expressed 
the markers; however, they were not differently regulated in the CXCR5 CAR group compared 
with the SP6 CAR group. CD8+ T cells did upregulate PD-1 on day 8 in the bone marrow; 
nevertheless, exhaustion would be expected to induce upregulation of more than one of the 
exhaustion markers.  
In summary, anti-CXCR5 CAR T cells showed a robust anti-tumor response at day 8 and day 
13 in the bone marrow and spleen. The CAR T cells did not exhibit an exhausted phenotype 
and the tumor cells did not downregulate CXCR5. Hence, CAR T cell exhaustion or antigen 




4.10 CXCR5 CAR T cells do not show signs of exhaustion upon                      
repetitive antigenic stimulation 
In vivo, the CAR T cells did not show signs of exhaustion. Subsequently, this question was 
further addressed in an in vitro stress test, in which potential T cell dysfunction and exhaustion 
upon repetitive antigenic stimulation was studied. In this assay, the anti-CXCR5 and anti-CD19 
CAR T cells were incubated with JEKO-1 tumor cells. Every third day, the CAR T cells were 
transferred into culture dishes with fresh tumor cells in order to reconstitute a constant CAR T 
cell to tumor cell ratio. In initial experiments, T cells and tumor cells were incubated at a 1:1 
ratio (Figure 29A). Five stimulation rounds were performed and after every round, the T cells 
and the supernatant were analyzed. Before the assay, the cells were expanded with rhIL7/15 
for 14 days; thus, the cells were in culture for 29 days altogether. The specific CXCR5 and 
CD19 CAR T cells were able to kill virtually all the tumor cells repetitively over the course of 
the experiment. The non-transduced T cells did not reduce the tumor load (Figure 29B). More-
over, the specific CAR T cells produced IFNγ and proliferated to twice their original number in 
every round over 15 days (Figure 29C+D). The transduction rate was already at least 75% at 
the beginning and still increased slightly over the course of the experiment to almost 100% 






Figure 29: CXCR5 CAR T cells do not show signs of functional exhaustion upon repetitive anti-
genic stimulation. A T cells and JEKO-1 tumor cells were coincubated at a 1:1 ratio. Analyses were 
conducted every third day and the T cell to tumor cell ratio was reconstituted. B Tumor load is shown 
as percentage of viable JEKO-1 tumor cells in the culture. C Proliferation rate per transfer was calculated 
by counting the number of T cells and calculating the ratio in relation to the input T cell number. D IFNγ 
release in the supernatant was quantified by ELISA. E The fraction of CAR+ cells was quantified for 
CD4+ and CD8+ T cells. Bars and dots represent mean ± SEM of 4 independent donors (UT, CD19) or 





The exhaustion markers PD-1, LAG-3 and TIM-3 were also measured every 72 h (Figure 30). 
CD8+ T cells did not upregulate these markers during the experiment. CD4+ T cells expressed 
higher levels of PD-1, which increased during the course of the experiment in anti-CXCR5 and 
anti-CD19 CAR T cells (Figure 30A). On CD4+ T cells, the expression levels of TIM-3 and LAG-
3 were lower than on CD8+ T cells (Figure 30B+C). Only for LAG-3, anti-CXCR5 CAR T cells 
expressed higher levels compared with anti-CD19 CAR T cells (Figure 30C). Nevertheless, 
general upregulation of the exhaustion markers PD-1, LAG-3 and TIM-3 was not detected, 
indicating that the CAR T cells did not suffer from exhaustion. 
 
 
Figure 30: CXCR5 CAR T cells do not upregulate exhaustion markers upon repetitive antigen 
stimulation. The gMFI for the exhaustion markers A PD-1, B TIM-3 and C LAG-3 is shown for CD4+ 
and CD8+ CAR T cells. Cells were analyzed by flow cytometry every third day over the course of 15 
days and gated for singlets and 7-AAD negative cells. Dots represent mean ± SEM of 4 independent 
donors (UT, CD19) or 5 independent donors (CXCR5). Data was collected in collaboration with Dr. Mario 
Bunse. 
 
Additionally, the differentiation of CAR T cells into memory T cell subtypes was assessed dur-
ing the course of the experiment. In the literature, around 19% of peripheral blood CD4+ 
memory T cells (CD45RA-) were described to express CXCR5 (Morita et al., 2011). Preferred 




T cells that are arrested at an early stage of differentiation and retained some plasticity (McLel-
lan and Ali Hosseini Rad, 2019). CAR T cells for the in vitro stress test were expanded for 14 
days under rhIL7/15 supplementation to support the formation of memory cells, and then as-
sessed by flow cytometry for the distribution of the naive/memory markers CD45RA and 
CD45RO. As expected, the fraction of memory T cells (CD45RA-CD45RO+) was over 90% for 
the anti-CXCR5 CAR CD4+ T cells and slightly lower for the CD8+ T cells. The anti-CD19 CAR 
T cells harbored memory T cells in a comparable range. The large fraction of memory T cells 
within the anti-CXCR5 CAR T cells showed that depletion of CXCR5+ T cells due to fratricide 
during expansion with homeostatic cytokines did not hamper memory formation. Next, the de-
velopment of memory subsets in the in vitro stress test under inflammatory conditions was 
investigated. 
Two main subsets of memory T cells are defined: central memory T (TCM) cells 
(CD62L+CCR7+), which home to SLOs, and effector memory T (TEM) cells (CD62L-CCR7-), 
which home to tissues and are equipped with cytotoxic effector functions (Sallusto et al., 1999). 
The majority of CXCR5+CD4+ T cells in the blood coexpresses CD62L and CCR7, which clas-





Figure 31: Anti-CXCR5 CAR T cells show a memory phenotype in vitro.  CAR T cells were analyzed 
by flow cytometry every third day over the course of 15 days and gated for singlets and 7-AAD negative 
cells. Dots represent mean ± SEM of 4 independent donors (UT, CD19) or 5 independent donors 
(CXCR5). A Memory subsets defined as CD45RA-CD45RO+ are depicted. B Central memory T cells 
(CD62L+CCR7+) as fractions of memory cells are shown. C Effector memory T cells (CD62L-CCR7-) as 
fractions of memory cells are shown.  
 
Despite showing low cytotoxic potential, TCM cells perform better in adoptive T cell transfer than 
TEM cells (McLellan and Ali Hosseini Rad, 2019). The CAR T cells in the in vitro stress test 
were evaluated concerning their memory subtype at the beginning of the assay and every third 
day. In the CD8+ compartment, anti-CXCR5 and anti-CD19 CAR T cells had very similar frac-
tions of TCM and TEM cells, with a low fraction of central memory cells and a higher fraction of 
effector memory cells. The CD4+ anti-CXCR5 CAR T cells were however enriched in their 
central memory fraction and harbored a very small effector memory fraction compared with the 
anti-CD19 CAR T cells. In summary, the anti-CXCR5 CAR T cells were shown to harbor com-
parable memory subsets as the anti-CD19 CAR T cells, when expanded under rhIL7/15, with 




In the first in vitro stress tests, the T cells were cocultured at a 1:1 ratio with JEKO-1 tumor 
cells following a 14-day expansion. In this set-up, signs of T cell dysfunction or exhaustion 
could not be detected and the anti-CXCR5 CAR product showed a robust anti-tumor response 
in vitro. Nevertheless, in order to validate the protocol for the in vitro stress test, a more chal-
lenging set-up had to be applied to ultimately induce dysfunction. Therefore, CAR T cells were 
cocultured at a 1:10 ratio with JEKO-1 cells. Additionally, a first generation anti-CXCR5 CAR 
without CD28 costimulatory domain was included in the assay. First generation CARs with a 
CD3ζ intracellular domain generally lacked sufficient cytotoxicity and proliferation, resulting in 
their replacement by second generation CARs with a costimulatory domain that showed en-
hanced function and survival (Tokarew et al., 2019). As expansion of first generation anti-
CXCR5 CAR T cells proved difficult, the expansion period for all CAR T cells was shortened 
to 10 days in order to improve viability at the onset of the assay. In the in vitro stress test, the 
first generation anti-CXCR5 CAR T cells showed efficient tumor cell killing in the first two 
rounds (Figure 32A); however, they did not proliferate and could not be assessed beyond day 
6 (Figure 32B). The anti-CXCR5 and anti-CD19 CAR T cells showed a strong anti-tumor re-
sponse in the first two rounds, despite the excessive amount of tumor cells. In the following 
days, their anti-tumor capacity decreased, resulting in the complete lack of tumor removal for 
both CAR products on day 15 (Figure 32A). The anti-CD19 CAR T cells strongly proliferated 
over 4 rounds, whereas the anti-CXCR5 CAR T cells proliferated less after the first two rounds; 
in the fifth round, the anti-CXCR5 and anti-CD19 CAR T cells did not proliferate (Figure 32B).  
IFNγ release by all antigen-specific CAR T cells was robust for the first two rounds. After day 
6, the anti-CXCR5 and anti-CD19 CAR T cells produced only minor amounts of IFNγ (Figure 
32C). Further, expression of the exhaustion marker PD-1 was measured on the CAR T cells. 
CD4+ CAR T cells generally expressed higher levels and PD-1 expression increased over the 
course of the experiment. CD8+ CAR T cells showed lower expression and only anti-CXCR5 
CAR T cells upregulated PD-1 at the end of the assay (Figure 32D). Summing up, the lack of 
effective tumor killing, proliferation and IFNγ secretion upon repetitive stimulation with exces-
sive amounts of tumor cells indicated that the CAR T cells suffered from functional exhaustion. 
The CAR T cells, including the anti-CXCR5 CAR T cells, could not maintain their function in 
the 1:10 assay, as opposed to in the previous 1:1 in vitro stress test. Long-term cocultures of 
tumor cells with CAR T cells were able to induce T cell dysfunction, which validated the set-up 
chosen for the assays. Most importantly, it can be emphasized that the anti-CXCR5 CAR T 
cells remained highly functional during the 1:1 in vitro stress test and were able to maintain 







Figure 32: CAR T cells show signs of functional exhaustion upon repetitive antigen stimulation 
with excessive amounts of tumor cells. CAR T cells or non-transduced T cells and JEKO-1 tumor 
cells were coincubated at a 1:10 ratio. A Tumor load is shown as percentage of viable JEKO-1 tumor 
cells in the culture. B Proliferation rate per transfer was calculated by counting the number of T cells 
and calculating the ratio in relation to the input T cell number. C IFNγ release in the supernatant was 
quantified by ELISA. Bars represent mean ± SEM of 3 independent donors (1. Generation CXCR5 CAR 
until day 6).  
Collectively, the data show that CXCR5 has a favorable expression pattern throughout the 
body in order to be targeted by CAR T cell therapy. It provides a valuable target as it is fre-
quently strongly expressed by primary lymphoma/leukemia and especially because it allows 
dual targeting of tumor cells and tumor-supportive follicular helper T cells. The anti-CXCR5 
CAR T cells showed promising characteristics concerning their in vitro and in vivo reactivity for 




4.11 The murine splenic CXCR5+ T cell compartment undergoes changes 
upon lymphoma challenge 
As previously mentioned, physiological CXCR5 expression is not restricted to mature B cells. 
Subsets of CD4+ and CD8+ T cells express CXCR5 as well. CD4+CXCR5+ T cells, which coex-
press PD-1 and/or ICOS are commonly termed follicular helper T cells. As these T cells ex-
press CXCR5, they are most definitely targeted by the anti-CXCR5 CAR T cells. In the NSG 
xenotransplantation model, it was possible to assess the anti-tumor effect of CXCR5 CAR T 
cells by administration of human tumor cells and human CAR T cells. However, this immuno-
deficient mouse model, which lacks endogenous T cells, is not suitable to study the effect of 
anti-CXCR5 CAR T cells on the CXCR5+ T cell compartment. A syngeneic mouse model is 
needed, in which the effect of murine CAR T cells targeting murine CXCR5 on murine lym-
phoma and the endogenous CXCR5+ T cells can be studied. The generation of a murine anti-
CXCR5 CAR was beyond the scope of this thesis; however, it was possible to investigate the 
influence of lymphoma challenge on the splenic CXCR5+ T cell compartment in a syngeneic 
mouse model, which provides valuable information about how the transcriptome of CXCR5+ T 
cells changes upon tumor progression. Single cell RNA sequencing of the murine splenic T 
cell compartment was the method of choice to study the CXCR5+ T cell types in great detail, 
with a special focus on follicular helper T cells. In an effort to get an overview of the changes 
in the CXCR5+CD3+ compartment upon lymphoma challenge, C57BL/6N mice were either in-
jected with benign B cells or Eμ-Tcl1 tumor cells (3x106 cells per mouse) harvested from the 
spleen of transgenic Eμ-Tcl1 mice. The murine Eμ-Tcl1 lymphoma model recapitulates the 
progression of human chronic lymphocytic leukemia. In this mouse model, it is especially in-
teresting to analyze the impact of tumor progression on follicular helper T cells, as expansion 
of cTFH cells is described in CLL patients (Ahearne et al., 2013). After two weeks, murine 
spleens of control mice, which were injected with benign murine B cells, and diseased mice, 
which were injected with Eμ-Tcl1 cells, were harvested. The diseased mice were grouped in 
high tumor load (45%, 46%) and low tumor load (22%, 31%) in the spleen. Two animals were 
pooled per sample. The spleens were homogenized and lysis was performed to remove eryth-
rocytes. CD3+ T cells were obtained after magnetic sorting. By fluorescence-activated cell sort-
ing, doublets and dead cells were excluded, CD3+CD19- cells were selected and ultimately, 





Figure 33: CXCR5 positive T cells for single cell analysis were sorted by flow cytometry.  Before 
single cell analysis, CD3+ T cells were isolated by magnetic sort and further sorted by flow cytometry. 
Doublets and dead cells were excluded. CD3+ T cells and CXCR5+ cells were gated using an isotype 
control. CD3+CXCR5+ cells were further analyzed by single cell RNA sequencing. 
 
The sorted cells were handed over to the Genomics platform at the Berlin Institute for Medical 
Systems Biology for single cell RNA sequencing, bioinformatical preprocessing was performed 
by Tadhg Crowley. Using the 10x Genomics system, the cells were first encapsulated in a 
barcoded gel bead, one cell per bead. Inside the bead, reverse transcription took place. cDNA 
derived from each cell was labeled with a unique barcode. The resulting barcoded library was 
then sequenced, which made it possible to obtain the gene expression profile at single cell 
level. The data was analyzed using the single cell genomics toolkit Seurat. 
4.11.1 Murine splenic CD4+ and CD8+ T cells both express CXCR5 
As magnetic sorting for CD3+ T cells was performed, cells in the analysis were shown to ex-
press either the Cd8a or Cd4 gene (Figure 34A). The T cells were correspondingly grouped 
into two clusters upon visualization by Uniform Manifold Approximation and Projection for Di-
mension Reduction (UMAP) projection, which separated the Cd8a+ cytotoxic T cells (Cluster 
1) and the Cd4+ helper T cells (Cluster 2) (Figure 34B). 66% of the cells were assigned to 
cluster 1 and 34% were assigned to cluster 2. These percentages might not be representative 




might have unevenly diminished the number of more fragile T cell subsets, but rather gives an 




Figure 34: CXCR5+ Cd8a+ and Cd4+ T cells are present in the spleen. A mRNA expression of CD4 
(blue) and Cd8a (red) was depicted for murine splenic CXCR5+ T cells. B UMAP projection of CXCR5+ 
T cells grouped into two distinct clusters. Two mice were pooled for each of the three conditions. 
 
4.11.2 The fraction of effector cells is increased in the murine splenic CXCR5+CD8+ 
T cell compartment upon tumor challenge 
As expansion of circulating follicular helper T cells was described in the literature for chronic 
lymphocytic leukemia, follicular helper T cells were the main focus of analysis  (Ahearne et al., 
2013). However, it became evident that tumor challenge also impacted the CD8 compartment. 
Therefore, Cd8a+ T cells were analyzed in more detail. Cells of cluster 1, which was dominated 
by Cd8a expression, could be grouped into two distinct clusters. The smaller subset was en-
riched in mice challenged with low and high tumor load in the spleen (14%) compared with the 
control mice (7%), indicating that the enrichment was initiated early in tumor progression 
(Figure 35A). This smaller cluster differed from the bulk population by upregulation of effector 
genes (Figure 35B). In this effector subset, expression of the genes for perforin and granzyme 





Figure 35: The fraction of effector Cd8a+ T cells is expanded upon tumor challenge. A Cd8a+ T 
cell fractions are depicted in pie charts. B Expression of cluster 2 effector CD8 T cell-specific genes is 
depicted for Ccl3, Ccl4, Ccl5, S100a4, Prf1, Ifng, Gzmb and Lgals1 in violin plots. Two mice were pooled 
for each of the three conditions. 
 
4.11.3 A TFH cell-harboring cluster is expanded upon lymphoma challenge 
CXCR5 expressing Cd4+ T cells were grouped into three distinct clusters after visualization by 
UMAP projection (Figure 36A). Expression of certain TFH-specific genes, such as Pdcd1 (which 
encodes PD-1), Icos (Wing et al., 2017), Sostdc1 (Wu et al., 2020), Izumo1r (Künzli et al., 
2020), Cd200 (Chtanova et al., 2004) and Tox (Xu et al., 2019) was investigated within these 
clusters (Figure 36B). In particular, cluster 2 displayed high expression of TFH-specific genes, 
indicating that this subpopulation harbored TFH cells. Cluster 2 was further shown to be en-
riched upon tumor development. The TFH-harboring cluster 2 was increased within Cd4+ T cells 






Figure 36: A follicular helper T cell-harboring cluster is expanded upon tumor challenge. A Cd4+ 
T cells grouped in three distinct clusters as visualized by UMAP. B Expression of TFH-specific genes 
(Pdcd1, Icos, Sostdc1, Izumo1r, Cd200 and Tox) is depicted in violin plots for the three Cd4+ T cell 
clusters. C The Cd4+ T cell fractions are depicted in pie charts. Two mice were pooled for each of the 
three conditions. 
 
4.11.4 Follicular helper T cells and follicular regulatory T cells were successfully 
separated in a biased clustering   
Cells of the TFH cell-harboring cluster 2 were however shown to express Foxp3, which is a 
master regulator in the development of regulatory T cells. Foxp3 expression indicated that 
Cluster 2 did not only include follicular helper T cells, but also follicular regulatory T (TFR) cells, 
which fulfill regulatory functions in the B cell follicle (Linterman et al., 2011). It was not possible 
to separate TFH and TFR cells in an unbiased clustering, as both cell types express typical TFH 
genes and regulatory gene expression was not strong enough to dominate the clustering. 
Therefore, biased clustering was performed, using high and low expressing populations of the 
TFR-specific genes Foxp3, Ikzf2, Tnfrsf18 and Prdm1 as a basis to calculate the parameters 
for the clustering.  Using this approach, it was possible to separate the TFR cell population from 
the TFH cells (Figure 37A). Both cell populations expressed the TFH-specific genes Pdcd1 and 
Icos at high levels, with higher Icos expression for TFR cells. Bcl6, the TFH master regulator 
commonly expressed by TFH as well as TFR cells, was not expressed strongly in either cluster, 
but rather in TFH cells than in TFR cells (Figure 37B). TFR-specific genes, such as Foxp3, Ikzf2 
(which encodes Helios), Tnfrsf18, Ctla4 and Prdm1 (which encodes BLIMP-1) were strongly 
enriched in the TFR cell cluster (Figure 37C). The gene expression of Il21, which is usually 




expression pattern of TFR and TFH cell-specific genes validated the biased clustering approach. 
Upon tumor challenge, the fraction of TFR cells was increased in mice with a high tumor load 
(16%), compared with low tumor-mice (9%) and control mice (8%) (Figure 37E). 
 
 
Figure 37: Follicular regulatory T cells were separated from TFH cells in a biased clustering. A 
CD4+ T cells were grouped in two distinct clusters upon biased clustering. B Expression of Pdcd1, Icos 
and Bcl6, which are genes equally specific for TFH and TFR cells, is depicted in violin plots for the TFH and 
TFR cell clusters. C Expression of genes specific for TFR cells (Foxp3, Ikzf2, Tnfrsf18, Ctla4, Prdm1) is 
depicted in violin plots for the TFH and TFR cell clusters D Il21 expression specific for TFH cells is depicted 
in a violin plot for the TFH and TFR cell clusters. D The Cd4+ T cell fractions are depicted in pie charts. 
Two mice were pooled for each of the three conditions. 
 
4.11.5 Lymphoma challenge showed profound influence on TFH cells and TFR cells 
TFH cells and TFR cells were analyzed regarding their expression pattern of certain chemokines, 
cytokines, transcription factors, costimulatory molecules and tissue residence genes corre-
sponding to the expression analysis by Magen et al. (Magen et al., 2019). Oftentimes, gene 
expression gradually changed with increasing tumor load. It was however particularly remark-




from control samples and the samples with high tumor load. Chemokine/chemokine receptor 
expression was not changed in tumor-challenged TFH cells, apart from a decrease in Cxcr4 
and Cxcr5 expression in spleens with a high tumor load (Figure 38A).  
 
 
Figure 38: Gene expression is altered upon lymphoma challenge in TFH and TFR cells. Expression 
of A chemokine genes, B cytokine genes, C transcriptions factors, D genes encoding costimulatory 
molecules and D genes encoding tissue residence markers was analyzed for TFH and TFR cells in mice 
without lymphoma challenge (Control) and mice with low and high splenic tumor load. The color scale 
shows average gene expression; dot size depicts percentage of cells expressing the gene within the 
cluster. Two mice were pooled for each of the three conditions. 
 
TFR cells increasingly expressed chemokine genes, but Cxcr4 and Cxcr5 expression was like-
wise downregulated upon high tumor challenge. Especially Cxcr3 was strongly expressed by 
TFR cells in spleens with a high tumor load. TFH cells upregulated cytokine expression of Il4 and 
Il21 uniquely upon low tumor challenge (Figure 38B). TFR cells lost Ifng expression upon tumor 
challenge, but upregulated Il10 and Il27ra when challenged with low tumor load, and Il10ra, 




influence on the gene expression of transcription factors, especially in TFR cells (Figure 38C). 
In TFH cells, Klf3 was decreased upon tumor challenge. Pdcd11 and Tcf7 were increased in 
mice challenged with a low tumor load; Irf9 and Lef1 were induced in high tumor load. In TFR 
cells, Maf and Sub1 was strongly increased in low tumor load; Foxp3, Gata3, Stat1 are upreg-
ulated upon high tumor challenge. TFH cells upregulated expression of the costimulatory mol-
ecules CD40lg, Tnfsf8 and Tnfsf11, whereas TFR cells showed enhanced Icos expression in 
low tumor load (Figure 38D). Additionally, expression of genes involved in tissue residence 
differed upon tumor challenge (Figure 38E). In TFH cells and TFR cells, Cd69 was downregu-
lated; Klf2 and S1pr1 were upregulated with increasing tumor load in TFH cells. 
4.11.6 Lymphoma challenge profoundly influenced TFH cells and TFR cells 
For better visualization of the differences in TFH gene expression induced by tumor challenge, 
differentially expressed genes were depicted in volcano plots (Figure 39). Splenic TFH cells 
harvested from control mice were compared with cells from mice challenged with low tumor 
load or high tumor load. Genes with a p-value smaller than 0.05 and a log2 fold change smaller 
than -0.5 or bigger than +0.5 are shown in red. For TFH cells challenged with a low tumor load, 
Ly6a, Ifi27l2a, Sostdc1 and S100a11 were upregulated and fulfilled the mentioned criteria 
(Figure 39A). Upon high tumor challenge, Ly6a and Ifi27l2a were continuously upregulated 
and expression of Tnfrsf4 was increased (Figure 39B). Malat1 was downregulated in both low 
and high tumor load. 
 
 
Figure 39: Lymphoma challenge induces upregulation of specific genes in TFH cells. Non-signifi-
cantly differentially regulated genes are depicted in grey. Genes with a p-value <0.05 are depicted in 
blue; genes with a p-value <0.05 and log2FC< -0.5/ log2FC> +0.5 are depicted in red. Labels are shown 
for genes with a p-value <0.05 and log2FC< -0.3/ log2FC> +0.3. These values are additionally indicated 
by dashed lines. Mice without tumor were compared with mice challenged with a A low tumor load or a 
B high tumor load. On the y-axis, the negative log with base 10 of the p-value is plotted; on the x-axis, 




In summary, Eμ-Tcl1 lymphoma growth induced profound changes in the murine splenic 
CXCR5+ T cell compartment, both in CD8+ and CD4+ T cells. Tumor challenge influenced the 
T cell ratios within the subpopulations. In the CD8+ subset, the fraction of cells expressing 
cytotoxic effector genes was increased. In the CD4+ subset, the fractions of TFH and TFR cells 
were enlarged, with the TFH cells being increased early on upon low tumor challenge and the 
TFR cells later at a high tumor load. Single cell RNA sequencing analysis allowed to obtain gene 
expression data at single cell level. It was shown that lymphoma growth changed expression 
levels in both TFH and TFR cells for chemokines, cytokines, transcription factors, costimulatory 
molecules and tissue residence genes and induced upregulation of certain genes. Remarka-
bly, low tumor induced a unique gene expression pattern, which was different from the control 
and the high tumor sample. The collected data give a comprehensive insight in the CXCR5+ T 
cell subsets upon tumor challenge and provide information about the environment anti-CXCR5 






5.1 CXCR5 is a promising novel target for CAR T cell therapy  
Since the introduction of CAR T cell therapy, the prognosis for relapsed and refractory patients 
of aggressive B-cell lymphomas has strongly improved. The median survival has increased 
from 6 months with conventional therapy to more than two years with anti-CD19 CAR T cell 
therapy, as shown in the ZUMA-1 study (Crump et al., 2017; Locke et al., 2019). CAR T cell 
therapy has given hope to patients previously running out of treatment options. Nevertheless, 
a large fraction of patients is refractory to anti-CD19 CAR treatment or relapses. Reasons for 
treatment failure are complex and involve CAR T cell dysfunction and insufficient persistence 
in the patient, immune evasion, but also loss of CD19 expression. CD19 expression on the 
tumor population is often not homogeneous and subsets lack or express low levels of CD19 
(Abramson et al., 2019). Mechanisms of CD19 loss include genetic alteration, such as 
frameshift mutations, and loss of heterozygosity, resulting in a lack of surface antigen (Orlando 
et al., 2018). Other mutational events cause alternative splicing, which leads to CD19 variants 
that lack the epitope targeted by the CAR (Sotillo et al., 2015). CD19 loss can also result from 
alterations in the associated molecules CD21 and CD81 that form the coreceptor complex, 
which disrupts CD19 membrane transport (Braig et al., 2017; Velasquez and Gottschalk, 
2017). These lymphoma cells are not recognized and killed by the CD19 CAR T cells, which 
causes the outgrowth of loss variants. Other treatment options for patients suffering from re-
fractory or relapsed aggressive B cell neoplasms, which target novel tumor-specific or tumor-
associated antigens, are still urgently needed. The tumor-associated chemokine receptor 
CXCR5 was identified as a promising target for CAR T cell therapy.  
5.1.1 CXCR5 is highly expressed in B-NHL  
The chemokine receptor CXCR5 is crucial in directing B cells to the B cell zones of secondary 
lymphoid organs (Förster et al., 1996). Chemokine receptor expression on neoplastic B cells 
commonly mirrors the expression pattern of their healthy counterparts. CXCR5 was accord-
ingly found on B non-Hodgkin lymphomas derived from mature B cells, especially in lympho-
mas with nodular dissemination (López-Giral et al., 2004). Large-scale mRNA data accessible 
on genevestigator.com visualized Cxcr5 expression for a broad range of malignancies. A query 
of the HS_AFFY_U133PLUS_2-0 microarray database, which includes 710 cancer categories, 
showed very high Cxcr5 expression for chronic lymphocytic leukemia (n=1039), mantle cell 
lymphoma (n=37), follicular lymphoma (n=196), diffuse large B cell lymphoma (n=854), mar-
ginal zone lymphoma (n=52) and Burkitt’s lymphoma (n=16), with especially high expression 
in CLL, MCL and FL. Additionally, this dataset contained information about the Cxcr5 expres-




medium expression. In all 37 MCL samples, high Cxcr5 mRNA expression was detected. 191 
FL patients had high Cxcr5 expression and 5 FL patients had medium expression levels. In 
854 diffuse large B cell lymphoma samples, 721 biopsies highly expressed Cxcr5, 131 samples 
showed medium expression levels and 2 patients had low Cxcr5 expression. Of 52 marginal 
zone lymphoma samples, Cxcr5 was highly expressed by 39, 13 had medium expression. 12 
Burkitt’s lymphoma samples highly expressed Cxcr5 and 4 showed medium expression levels. 
In the literature, the CXCR5 expression pattern in these B-NHL entities was confirmed on pro-
tein level by flow cytometric analysis. Precursor B acute lymphoblastic leukemia, which is a 
neoplasm of immature B cells, and multiple myeloma, which originates from plasma cells, 
lacked CXCR5 expression (Dürig et al., 2001; Middle et al., 2015b). Dürig et al. published 
individual patient data and showed CXCR5 expression by flow cytometry on all 23 CLL, 4 MCL 
and 3 FL samples (Dürig et al., 2001).  
In the presented thesis, extensive CXCR5 expression analysis of B cell lines and primary B-
NHL patient material supported and expanded the expression pattern described in the litera-
ture. An important aspect in clinical application of immunotherapy is also the antigen frequency 
within the tumor cell population; antigen absence on a subset can lead to the outgrowth of 
antigen-loss variants. In the analyzed patient samples, robust and ubiquitous CXCR5 expres-
sion was detected for FL and CLL. In MCL, expression ranged from low to high; half the sam-
ples lacked CXCR5 on a fraction of cells. In MZL, one of four samples showed robust CXCR5 
expression on the main population. CXCR5 negativity was further confirmed for B cell precur-
sor neoplasms and MM. 
Abundant expression on mature B cell neoplasms makes CXCR5 a valuable target in CAR T 
cell therapy, as large amounts of patients harbor CXCR5 expressing tumors and could benefit 
from treatment with anti-CXCR5 CAR T cell therapy.      
5.1.2 CXCR5 is expressed on B cell-supportive follicular helper T cells 
Germinal center (GC) reactions ensure the production of high affinity antibodies in secondary 
lymphoid organs in response to an infection. In GCs, B cells undergo selective proliferation 
and differentiation. Most importantly, their antibody genes are mutated in a process called so-
matic hypermutation, which results in antibodies of higher affinity. Follicular helper T cells play 
a central role in the processes in the germinal centers. They are CD4+ cells characterized by 
the expression of CXCR5, which allows them to access B cell follicles and GCs. Further, they 
are described as PD-1+ and ICOS+ (Victora and Nussenzweig, 2012). B cells in the germinal 
center circulate between the light and the dark zone. In the light zone, B cells have access to 
antigen. The B cells bind the antigen and present it in an MHC complex to TFH cells, which 




way to the dark zone, in which they further proliferate and undergo somatic hypermutation. 
When they return to the light zone, the B cells with the highest antigen affinity are again se-
lected by the follicular helper T cells (Crotty, 2014). TFH cells influence many steps in germinal 
center processes, either by cytokine secretion (IL4 and IL21) or interaction of costimulatory 
molecules (PD-1, ICOS, CD40L). Cytokines produced by TFH cells, especially IL4 and IL21, 
are major inducers of GC B cell survival, proliferation and class switch (Crotty, 2011). Further, 
TFH-derived IL21 was shown to regulate germinal center size and to promote plasmablast de-
velopment from germinal centers. IL21 is strongly expressed by TFH cells and GC B cells up-
regulate expression of the IL21 receptor, favoring plasma cell differentiation (Zhang et al., 
2018). The PD-1/PD-L1/2 interaction between follicular helper T cells and B cells was de-
scribed to regulate long-lived plasma cell differentiation. In the absence of PD-1, cell death in 
the GC was increased and TFH cytokine production was reduced (Good-Jacobson et al., 2010). 
TFH cells additionally express ICOS and CD40L at high levels, which activate B cells (Breitfeld 
et al., 2000).  
The counterparts of classical TFH cells in secondary lymphoid organs are circulating TFH-like 
(cTFH) cells in the blood, which are CD4+ cells characterized by CXCR5 expression. They have 
similar functional characteristics as TFH cells in the germinal centers and support humoral im-
mune responses (Morita et al., 2011; Ueno, 2016). Peripheral blood cTFH cells are easily ac-
cessible in humans and were therefore preferentially the subject of studies.  
As described in the literature, peripheral blood cTFH cells are significantly enriched in B-NHL 
patients and the plasma concentration of the TFH key cytokine IL21 is increased, which was 
both correlated with negative prognosis (Zhou et al., 2017). In particular for chronic lymphocytic 
leukemia and follicular lymphoma, a tumor-supportive function of TFH cells was discussed. In 
CLL patients, the cTFH population is increased, especially in advanced disease stages 
(Ahearne et al., 2013; Cha et al., 2013). TFH cells are also strongly expanded in the lymph 
nodes of CLL patients (de Weerdt et al., 2019). IL4 and IL21 are the main cytokines produced 
by TFH cells. Cytokine-mediated effects on patient-derived CLL cells in vitro have been de-
scribed. IL4 increased CLL cell survival and apoptosis resistance (Dancescu et al., 1992). IL21 
stimulation induced apoptosis in leukemic cells (de Totero et al., 2008). Combined IL4/21 sig-
naling however induced proliferation in leukemic cells, without differentiation or apoptosis. IL21 
additionally promoted proliferation of side population cells, which are related to enhanced 
chemotherapy resistance (Ahearne et al., 2013). CD40 stimulation additionally induced upreg-
ulation of IL21 receptor expression on leukemic cells and enhanced the effect of IL21 stimula-
tion (de Totero et al., 2006). IL21 in combination with CD40/CD40L signaling also induced CLL 
proliferation (Pascutti et al., 2013). In vivo, IL4 supplementation in a clinical trial with CLL pa-




influence of TFH-associated factors on CLL cells, but also the reciprocal effect of CLL progres-
sion on the T cell compartment has been investigated. In a study with CLL patients, cTFH cells 
were shown to be shifted towards a TH2 and TH17-like cTFH cells, which as opposed to TH1-
like cTFH cells, secrete IL21 (Cha et al., 2013). Mouse models, such as the Eμ-Tcl1 mouse 
model, which is the most widely used and validated murine model for human CLL, were utilized 
to study how leukemia growth affects T cells. The validity of the Eμ-Tcl1 mouse model was 
further confirmed by Gorgun et al., who showed that changes in the function and CD4+/CD8+ 
gene expression profiles of T cells induced by Eμ-Tcl1 in the mouse model were similar to 
changes between CLL patients and healthy donors (Gorgun et al., 2009). Hofbauer et al. ob-
served that absolute T cell numbers increased and that the T cell subsets were skewed to-
wards an antigen-experienced memory phenotype in Eμ-Tcl1 tumor-challenged mice (Herek 
and Cutucache, 2017; Hofbauer et al., 2011).  
However, to our knowledge, an in-depth study of the tumor cell-induced changes in the T cell 
subsets with a focus on follicular helper T cells, especially on single-cell gene expression level, 
has not been conducted. In this thesis, single cell RNA sequencing of the tumor-challenged 
murine splenic CXCR5+ T cell compartment was performed and a profound impact of CLL 
pathogenesis on follicular helper T cells was described. In mice challenged with Eμ-Tcl1 lym-
phoma cells, the fraction of splenic TFH cells was enlarged. Early in tumor progression, the TFH 
cells were shown to upregulate Il4, Il21 and Cd40lg. These findings were in line with the pre-
vious findings in the literature and support the importance of TFH-mediated IL4, IL21 and 
CD40L signaling especially in the early stages of CLL. Upon Eμ-Tcl1 lymphoma challenge, 
murine splenic TFH cells upregulated Ifi27l2a, which is an interferon-stimulated gene (ISG). 
ISGs are generally involved in the inhibition of viral infections (Schoggins, 2019). Also, Ly6a 
was upregulated, which is known as an activation marker linked to proliferation, indicating an 
enhanced activation status in tumor-challenged TFH cells (Hsu et al., 2014; Malek et al., 1986). 
The TFH-specific gene Sostdc1 was upregulated early in tumor progression and Sostdc1 ex-
pressing TFH cells are described to promote follicular regulatory T cell differentiation, which is 
in line with an enriched TFR fraction in the advanced tumor stage (Wu et al., 2020). Tnfrsf4, 
which encodes CD134/OX4, is upregulated in TFH cells upon high splenic tumor load. OX40 is 
a costimulatory receptor, which promotes survival, proliferation and cytokine production in T 
cells upon OX40 ligand binding. It also serves as a T cell activation marker (Croft et al., 2009). 
Also, OX40 signaling induces CXCR5 and IL4 expression in CD4+ T cells (Flynn et al., 1998; 
Walker et al., 1999). Malat1, which encodes a long noncoding RNA, was downregulated in TFH 
cells upon lymphoma challenge. As suppression of Malat1 is a hallmark of CD4+ T cell activa-




TFH cells showed an activated phenotype when challenged with chronic lymphocytic leukemia-
like tumor cells (Hewitson et al., 2020). 
As mentioned earlier, the second B-NHL tumor entity, for which tumor support by follicular 
helper T cells is discussed, is follicular lymphoma. Pangault et al. analyzed the gene expres-
sion profile of the non-B cell compartment in lymph nodes of follicular lymphoma patients. They 
found a TFH gene signature and upregulation of genes relevant for T cell proliferation and acti-
vation, including Il4 and Tnfrsf4, which were also upregulated in Eμ-Tcl1 CLL lymphoma chal-
lenged murine splenic TFH cells as presented in this thesis. The authors were able to confirm 
TFH cells as the IL4 source and also described TFH cell enrichment in the FL lymph node micro-
environment (Pangault et al., 2010). In vitro, FL cells profited from TFH cell coculture and were 
rescued from spontaneous apoptosis. The authors also analyzed FL-derived TFH cells in detail 
and detected upregulation of Il4 and Cd40lg, which were also shown to be upregulated in the 
Eμ-Tcl1-challenged TFH cells in this thesis. FL cell culture with anti-CD40L and anti-IL-4Rα 
neutralizing mAbs confirmed that IL4 and CD40 ligand contribute to lymphoma cells survival 
(Amé-Thomas et al., 2012). It was further demonstrated that IL4 additionally contributes to FL 
tumorigenesis in an indirect manner by inducing CXCL12 in stromal cells. Induction of the 
CXCL12/CXCR4 loop promotes lymphoma cell activation and migration (Pandey et al., 2017).  
In this work, CD4+CXCR5+ cells were isolated from human peripheral blood by magnetic sep-
aration; the positive (CD4+CXCR5+) and negative (CD4+CXCR5-) sort fractions were subse-
quently cocultured with CAR T cells. It was possible to show that anti-CXCR5 CAR T cells 
specifically secreted IFNγ in response to the positive sort fraction that included the cTFH cells. 
Anti-CD19 CAR T cells did not show this reaction as CD19 was absent from T cells. This work 
could further demonstrate that cTFH cells in patient samples of FL and CLL were killed in vitro 
upon incubation with anti-CXCR5 CAR T cells. cTFH killing was exclusively performed by anti-
CXCR5 CAR T cells; anti-CD19 CAR T cell-mediated killing was restricted to CD19 expressing 
B cells. Malignant B cells are provided with strong proliferation and survival stimuli by TFH cells. 
Thus, removal of TFH cells by CAR T cell therapy could be beneficial for FL and CLL patients. 
TFH cells are also involved in the pathogenesis of autoimmune disorders. A characteristic fea-
ture of autoimmune disease is the presence of autoantibodies, which target the body’s own 
tissues (Ma et al., 2017). Interestingly, for numerous autoimmune diseases, an increase of 
cTFH cells in the blood is described (Crotty, 2014). Patients with severe systemic lupus erythe-
matosus (SLE) present with increased fractions of cTFH cells in the blood, which express the 
associated molecules ICOS and PD-1 at high levels (Simpson et al., 2010). In an SLE mouse 
model, cTFH cells were shown to expand in proportion to GC TFH cells. Autoimmunity was de-
scribed to be dependent on germinal center formation and aberrant enhanced positive selec-




improved upon loss of an allele for Bcl6, the TFH master regulator, or Sap, which encodes a 
TFH adaptor protein (Linterman et al., 2009). Enhanced IL21 production and CD40/CD40L in-
teractions were described to promote survival and plasma cell differentiation of autoreactive B 
cells in these mice (Han et al., 2015). Elevated cTFH cell percentages were found in Sjögren's 
syndrome and correlated with increased autoantibody levels (Szabo et al., 2013). TFH cell-
mediated B cell hyperactivity could be reduced by treating patients with a T cell inhibitory an-
tibody, resulting in reduced TFH cell numbers, ICOS expression and IL21 levels, and ultimately 
lower disease scores in Sjögren's patients (Verstappen et al., 2017). Another autoimmune dis-
ease, in which cTFH cells are expanded, is rheumatoid arthritis. In these patients, TFH cell ex-
pansion correlated with autoantibody levels and plasma IL21 was increased (Ma et al., 2012). 
IL21 in rheumatoid arthritis patients was further shown to induce B cell differentiation to plas-
mablasts and promote antibody production (Liu et al., 2012). In a murine arthritis model, path-
ogenesis was strikingly dependent on CXCR5 and mice lacking CXCR5 on T cells did not 
develop disease, indicating that colocalization of B cells and TFH cells is crucial for disease 
onset (Moschovakis et al., 2017). Traditional therapy of autoimmune disorders mostly depends 
on immunosuppressive agents, but long-term treatment can be tricky and can result in oppor-
tunistic infections (Rosenblum et al., 2012). CAR T cell therapy provides a new tool of targeted 
therapy. In a murine lupus model, it was demonstrated that anti-CD19 CAR T cells stopped 
autoantibody-production. Treated mice had increased survival and disease progression was 
reversed in organs typically targeted by autoantibodies in lupus (Kansal et al., 2019). Some 
clinical trials for patients with autoimmune disorders are currently in progress: Patients suffer-
ing from myasthenia gravis are treated with a CAR product targeting the B cell maturation 
antigen (BCMA) (NCT04146051). Systemic lupus erythematosus patients receive anti-CD19 
CAR T cells (NCT03030976) and pemphigus vulgaris patients are administered T cells targeting 
specific autoantibody producing B cells (NCT04422912) (clinicaltrials.gov, 2020). Reighard et 
al. proposed treatment of autoimmune patients by eliminating TFH cells with CAR natural killer 
(NK) cells. The authors developed a CAR with a PD-1 ligand domain, which binds selectively 
to TFH cells, which show high PD-1 expression. The CAR NK cells were able to kill TFH cells 
and reduce T cell-induced B cell activity. In a humanized lupus-like mouse model, it was pos-
sible to reduce symptoms upon treatment with anti-PD-1 CAR NK cells (Reighard et al., 2020). 
As anti-CXCR5 CAR T cells also target TFH cells, autoimmune patients could possibly benefit 





5.1.3 CXCR5 as a target on malignancies beyond B cell neoplasms 
CXCR5 is not only a target in the treatment of B cell neoplasms, but is also involved in the 
pathogenesis of other malignancies. Angioimmunoblastic T cell lymphoma (AITL) is a rare, 
aggressive neoplasm of follicular helper T cells. It is a mature peripheral T cell lymphoma, 
which accounts for 1-2% of non-Hodgkin lymphomas. The malignant cells commonly express 
the T cell markers CD3, CD4 and the typical TFH co-stimulatory molecules PD-1, ICOS, the 
chemokine receptor CXCR5 and the transcription factor BCL6 (Gaulard and de Leval, 2011; 
Lunning and Vose, 2017). Additionally, the cells uniformly express the ligand for CXCR5, the 
chemokine CXCL13 (Dupuis et al., 2006; Grogg et al., 2005). In AITL patients, the lymph node 
structure is destroyed and follicles are absent. Follicular dendritic cells are expanded and HEVs 
proliferate. Moreover, patients present with symptoms of B cell expansion (Ansel et al., 2000; 
Dupuis et al., 2006). The prognosis is poor, with a 5-year median survival of 32%. Oftentimes, 
induction therapy induces a strong response, but the patients relapse quickly. As of now, there 
is no gold standard in therapy; first-line treatment is usually CHOP (cyclophosphamide, doxo-
rubicin, vincristine, prednisone) combined chemotherapy. Chemotherapy can be combined 
with targeted drugs such as lenalidomide, an immunomodulatory substance used in the treat-
ment of B cell malignancies, the anti-CD52 antibody alemtuzumab, which targets both B and 
T cells, or the histone deacetylase (HDAC) inhibitor romidepsin (Lunning and Vose, 2017). As 
the prognosis is poor and treatment options are limited, patients are still in dire need of novel 
therapies against this aggressive T cell lymphoma subtype. As CXCR5 is expressed on follic-
ular helper T cells, the anti-CXCR5 CAR T cells are expected to recognize and deplete the 
tumor cells in the patient.  
Follicular dendritic cell sarcoma is another tumor entity, whose patients might benefit from 
treatment with anti-CXCR5 CAR T cells. It is an aggressive neoplasm of follicular dendritic 
cells (FDCs), which guide CXCR5+ mature B cells into the follicle by secreting CXCL13 and 
engage them in a CXCL13/lymphotoxin positive feedback loop. Most patients present with 
lymphadenopathy and receive chemotherapy, radiation and surgery, but 81% of them relapse 
(Soriano et al., 2007). In follicular dendritic cell sarcoma, neoplastic FDCs were also shown to 
secrete CXCL13 (Vermi et al., 2008). CXCL13 secreted by FDCs induces upregulation of 
membrane lymphotoxin in B cells (Ansel et al., 2000). Lymphotoxin then in turn activates FDCs 
(Myers et al., 2013). As the maintenance of FDC networks requires continues interaction with 
B cells expressing lymphotoxin, signaling inhibition quickly results in FDC disturbance (Mackay 
and Browning, 1998). Most likely, follicular dendritic cell sarcoma cells also express the lym-
photoxin receptor and disturbance of the lymphotoxin axis might reduce activation signals. This 




The CXCR5/CXCL13 axis was further suggested to play a role in some solid tumors (Kazanietz 
et al., 2019). Numerous benign solid tissues were shown to be CXCR5 negative on mRNA and 
protein level in the scope of this work. However, certain malignant cells, such as breast cancer 
cells, were described in the literature to upregulate CXCR5 expression. Panse et al. detected 
weak protein expression of CXCR5 by western blot in breast cancer lysates, but not in healthy 
tissue. Nevertheless, it has to be considered that the samples might not be free from CXCR5 
expressing immune cells. Interestingly, breast cancer cell lines, which were CXCR5 positive in 
real-time PCR and western blot, only showed intracellular CXCR5 expression in flow cytome-
try; surface expression was not detected (Panse et al., 2008). It has to be carefully analyzed if 
CXCR5 is indeed expressed on the surface of malignant cells derived from solid tumors. Ide-
ally, reactivity of anti-CXCR5 CAR T cells against potential CXCR5 expressing target cells 
should be investigated in in vitro cocultures.  
For many tumor entities, survival benefits from tertiary lymphoid structures within or near the 
tumor mass, which depend on the CXCR5/CXCL13 axis, were described. Tertiary lymphoid 
structures, which are also present in inflamed and infected tissues, resemble lymph nodes, are 
correspondingly divided in T- and B-cell zones and harbor germinal centers. They give rise to 
cells that initiate and sustain the anti-tumor immune response. The presence of these tertiary 
structures is a positive prognosis marker, especially in patients treated with immunotherapies 
(Dieu-Nosjean et al., 2014). In triple-negative breast cancer, lymphocytic infiltrates are associ-
ated with improved overall survival (Luen et al., 2019). In this type of breast cancer, patients 
with high CXCL13 levels showed longer disease-free survival (Schmidt et al., 2018). Analysis 
of the CD4 populations in breast tumors revealed that the presence of CXCL13-producing TFH 
cells is characteristic of extensive lymphocytic infiltration organized in tumor adjacent tertiary 
lymphoid structures and beneficial for patient survival and response to chemotherapy (Gu-
Trantien et al., 2013). The presence of lymphocyte infiltrates might however not necessarily 
be causal for improved survival by eliciting an adaptive immune response against the cancer-
ous tissue (Gu-Trantien et al., 2013). They might rather be an indicator of a less immunosup-
pressive tumor microenvironment, which permits the proliferation of lymphocytes. Thus, if the 
CAR T cells efficiently eradicate the tumor cells, the benefits of tumor removal might outweigh 
the destruction of possibly beneficial tertiary lymphoid structures.  
 
5.2 The CXCR5 CAR shows a satisfactory safety profile 
Toxicities in CAR T cell therapy can be caused by cytokine release syndrome (CRS), neuro-
toxicity, on-target/off-tumor autoimmune effects from attacking healthy antigen expressing tis-




2016). The cytokine release syndrome is a frequent and well-known side effect. CRS can be 
triggered by cytokine release after direct cell lysis or T cell activation, inducing a cytokine re-
lease cascade in the surrounding cells. Patients present with a broad spectrum of symptoms, 
ranging from fever to organ failure and are treated with antihistamines, antipyretics or antibod-
ies against the IL6 receptor (Shimabukuro-Vornhagen et al., 2018). Neurological toxicity, with 
symptoms like confusion and seizures, is often reversible. Pathophysiology is not well under-
stood, but possibly related to increased cytokine levels (Bonifant et al., 2016). 
The other two types of toxicities, on-target/off-tumor toxicity and general off-target toxicity have 
to be considered in the development of novel CAR T cell therapies and can be addressed in 
in vitro and in vivo experiments. 
5.2.1 CXCR5 is a safe target for CAR T cell therapy 
For the safety of a CAR T cell therapy, it is crucial to be well aware of the expression pattern 
of the target. Ideally, the targeted antigen is a tumor-specific neoantigen and restricted to the 
malignant cells. Unfortunately, this is very rarely the case. More frequently, the antigen is tu-
mor-associated and can be also found on healthy tissues. Therefore, in order to avoid on-
target/off-tumor toxicity, it has to be scrutinized whether the antigen-expressing tissues are 
vital and if not, if the tissue destruction by the CAR T cells can be clinically managed. An 
example of a tumor-associated antigen is carcinoembyronic antigen (CEA), which is not only 
expressed on many solid tumors, but also in the gastrointestinal tract. Targeting CEA with 
adoptive T cell therapy induced severe colitis (Parkhurst et al., 2011). A fatal case was de-
scribed for a patient treated with anti-ERBB2 CAR T cells targeting metastatic colon cancer, 
which recognized low level of ERBB2 on lung epithelium (Morgan et al., 2010). 
The first CAR products approved for therapy by the U.S. Food and Drug Administration tar-
geted the CD19 antigen (Boyiadzis et al., 2018). CD19 is expressed on malignant B cells, but 
also on benign B cells. Therefore, successful therapy initially eradicates the benign B cell com-
partment. The patients benefit from the treatment; reduction of the tumor mass outweighs the 
negative effects of having a compromised humoral immune answer. B cell aplasia is a positive 
indicator of CAR T cell functionality in these patients, as functional CAR T cells efficiently re-
move CD19+ benign as well as malignant B cells (Maude et al., 2014). Long-term B cell aplasia 
can also be addressed by immunoglobulin supplementation (Doan and Pulsipher, 2018). Alto-
gether, the effects of CD19 CAR therapy on the B cell compartment have been extensively 
studied and have been found to be nonhazardous. 
Immunotherapy in cancer targeting chemokine receptors has entered clinical practice. So far, 
a monoclonal antibody has been approved for the treatment of T cell malignancies and a small 




peripheral blood, was approved for autologous transplantation in non-Hodgkin Lymphoma and 
multiple myeloma (De Clercq, 2019; Subramaniam et al., 2012). Several inhibitors of chemo-
kine receptors are in pre-clinical testing or clinical trials (Mollica Poeta et al., 2019).  
Targeting chemokine receptors in CAR T cell therapy is a very novel field and, to our 
knowledge, only an anti-CCR4 CAR has been generated to date. Perera et at. suggested tar-
geting CCR4, which is not only expressed on regulatory T cells, TH2 and TH17 T cells and 
platelets, but also frequently detected on T cell lymphomas (Perera et al., 2017) 
Immunotherapeutic targeting of CXCR5 was proposed by Panjideh et at. The authors demon-
strated that a bispecific CXCR5::CD3 antibody recruits T cells to malignant B cells and effi-
ciently induces T cell activation in vitro. In a xenograft mouse model of Burkitt’s lymphoma, 
anti-tumor effects of the CXCR5::CD3 bispecific antibody and of the parental CXCR5 antibody 
were shown (Panjideh et al., 2014). One clinical trial targeting CXCR5 has been conducted to 
our knowledge (NCT02321709 by Sanofi). In a dose study conducted from 2014 to 2016 with 
systemic lupus erythematosus patients, anti-CXCR5 antibodies were injected subcutaneously. 
Severe side effects were not observed (clinicaltrials.gov, 2020; Ming, Jeffrey et al., 2018). 
However, to date, no other clinical trials targeting CXCR5 have been registered and anti-
CXCR5 therapy has never been administered systemically to patients (clinicaltrials.gov, 2020). 
In order to safely treat patients with the anti-CXCR5 CAR product, CXCR5 tissue expression 
had to be analyzed carefully. 
In this work, it was shown that CXCR5 is restrictively expressed in the hematopoietic compart-
ment. By flow cytometry, it was confirmed that CXCR5 expression is restricted to B cells and 
small subsets of CD4+ and CD8+ T cells in peripheral blood of healthy donors. This corresponds 
to the expression pattern described in the literature (Förster et al., 1994). Additionally, experi-
ments presented in this thesis showed that the anti-CXCR5 CAR T cells reacted against 
CXCR5 expressing benign B cells in vitro. Thus, treating patients with anti-CXCR5 CAR T cells 
will presumably remove their benign mature B cells. However, as mentioned earlier, B cell 
aplasia is well described in patients treated with anti-CD19 CAR T cell therapy and was shown 
to be tolerable. B cell depletion has been widely used in therapy for about twenty years. Long-
term B cell depletion has been especially studied upon treatment with the anti-CD20 monoclo-
nal antibody Rituximab in autoimmune patients. It became evident that B cell depletion did not 
increase the risk for malignancy or infection, except for hepatitis B reactivation, and was overall 
well tolerated, even for a long period of time. However, it has to be considered that the vaccine 
response and immune responses to novel antigens are impaired in these patients (Chen and 
Cohen, 2012). In contrast to CD19 or CD20, CXCR5 is restrictively expressed on mature B 




suggesting that they also spare benign B cell precursors and the B cell aplasia is less pro-
nounced than for the anti-CD19 CAR T cells.  
Apart from B cells, CAR T cell reactivity against CXCR5 expressing CD4+ cells was shown in 
this work. Upon CAR T cell infusion, CXCR5+CD4+ and CXCR5+CD8+ T cells will likely be 
depleted in the patient. T cell aplasia is much more severe than B cell aplasia and puts the 
patients at risk for potentially fatal infections (Scherer et al., 2019). However, only small T cell 
fractions are targeted by the anti-CXCR5 CAR T cells. The group could show in a syngeneic 
mouse model that mice were still able to produce an antigen-specific T cell response upon 
administration of murine CAR T cells targeting murine CXCR5, indicating that cellular immunity 
in the patients will most likely not be compromised. In this experiment, CAR T cells were in-
fused in irradiated C57BL/6N mice and after over two weeks, their efficacy was confirmed by 
detection of continuous CAR T cell presence and B cell depletion. Subsequently, the mice 
were immunized with immunogenic SV40 large T antigen expressing tumor cells. After 8 days, 
antigen-specific CD8+ T cells could be detected (Bunse*, Pfeilschifter* et al., 2021). 
As mentioned, the elimination of tumor-supportive CXCR5+CD4+ TFH cells is a desirable con-
sequence. CXCR5+CD8+ T cells were recently described as a subset with anti-tumor function 
in follicular lymphoma (Chu et al., 2019). CD4+CXCR5+FOXP3+ follicular regulatory (TFR) cells 
act as opponents to TFH cells and suppress the GC reaction, activation of B cells and TFH cell 
cytokine secretion. In diffuse large B cell lymphoma, they are most likely beneficial for the 
patients (Cha et al., 2018). Nevertheless, the benefit of tumor cell removal by the anti-CXCR5 
CAR T cells should be of higher therapeutic significance. 
A great risk factor in adoptive T cell therapy is the expression of the targeted antigen in unre-
lated tissue, leading to inflammation and organ damage. In order to exclude CXCR5 expres-
sion on non-hematopoietic tissue, CXCR5 expression was carefully analyzed. PCR on a cDNA 
library of 48 human tissues showed very restricted Cxcr5 expression on mRNA level. A broad 
panel of human primary cells and cell lines was additionally analyzed on protein level. CXCR5 
negativity could further be ensured for these endothelial cells, cells of the nervous system and 
gastro-intestinal cells. All in all, the expression pattern of CXCR5 on human tissues was re-
stricted to lymphoid tissue. Additionally, anti-CXCR5 CAR T cells were coincubated with these 
non-hematopoietic primary cells and cell lines and did not mount a reaction towards them, 
indicating that the CAR T cells did not encounter their antigen. 
In the literature, it was described that CXCR5 was upregulated on astrocytes in a murine neu-
ropathic pain model (Jiang et al., 2016). The authors detected CXCL13 upregulation in neurons 
and CXCR5 activation in astrocytes upon induction of inflammation by spinal nerve ligation. 
CXCR5 expression in human nervous tissue would be disastrous for patients treated with 




experimentally by inducing an inflammatory status in human primary astrocytes as well as 
other primary cells by interferon γ incubation. CXCR5 upregulation upon inflammation could 
not be confirmed for human primary cells; additionally, coculture of anti-CXCR5 CAR T cells 
and inflamed primary cells did not result in interferon γ release by the CAR T cells.  
Also, alterations in neurogenesis of CXCR5 knockout mice have been published (Stuart et al., 
2014). Fritze et al. recently had a look at the murine subventricular zone, a region of adult 
neurogenesis, and found proliferative differences and upregulation of CXCR5/CXCL13 signal-
ing in aged CXCR5 knockout mice. The authors reanalyzed a previously published single cell 
RNA sequencing dataset of the wildtype subventricular zone, which also included neurons and 
astrocytes. They were able to confirm the absence of CXCR5 and CXCL13 in these cell types, 
indicating that the alterations in the CXCR5 knockout mice were caused by an indirect effect 
(Fritze et al., 2020). This throughout investigation emphasizes that it has to be considered that 
alterations in neuronal tissues do not necessarily have to be accredited to CXCR5 expression 
by neuronal cells. 
As human and murine tissues express CXCR5 in a similar pattern, more information about 
potential CAR-mediated on-target/off-tumor toxicity can be collected in a syngeneic mouse 
model. In this group, the safety of anti-CXCR5 CAR T cell treatment was further analyzed in 
immunocompetent sublethally irradiated mice injected with murine CAR T cells targeting mu-
rine CXCR5. In these mice, the numbers of CXCR5+ B cells and CXCR5+CD4+ T cells were 
strongly reduced, indicating potent anti-CXCR5 activity. In the treated mice, liver, lung and 
colon tissues were free from inflammatory infiltrates and serum markers did not indicate any 
organ damage (Bunse*, Pfeilschifter* et al., 2021). As the CAR T cells did not seem to have 
caused damage in tissues for which CXCR5 expression is not expected, this experiment fur-
ther contributed to the validation of CXCR5 as a safe target.  
In summary, the CXCR5 expression under homeostatic and inflammatory conditions as char-
acterized in this thesis is limited to lymphoid tissues. Due to this restricted expression pattern, 
CXCR5 appears to be a safe target for CAR T cell therapy. 
5.2.2 Anti-CXCR5 CAR T cells do not show off-target reactivity 
Adoptive T cell transfer-mediated toxicity can be caused by off-target effects. In clinical testing 
of an affinity-enhanced T cell receptor product directed towards melanoma-associated antigen 
3 (MAGE-A3) for treatment of myeloma and melanoma, patients died from cardiogenic shock. 
T cell infiltrates in the myocardium and severe tissue damage were detected; however, the 
heart tissue lacked MAGE-A3 expression. Exhaustive research ultimately revealed that the 
TCR-engineered T cells recognized a peptide derived from the protein titin, which is specific 




product caused fatal neurotoxicity in a number of patients. It was eventually found out that the 
TCR-engineered T cells recognized homologous peptides of other MAGE-A proteins; previ-
ously unknown MAGE-A12 expression was detected in brain tissue (Morgan et al., 2013; Zajac 
et al., 2017). The experiences from the MAGE-A3 trials make it clear that off-target effects can 
have serious consequences for the treated patients. Off-target toxicity upon recognition of 
cross-reactive peptides has not been detected in CAR T cell trials (Bonifant et al., 2016). Nev-
ertheless, potential off-target effects must be considered in pre-clinical testing and addressed 
as extensively as possible in preparation for a clinical trial (Krackhardt et al., 2018). Off-target 
toxicity cannot be excluded by expression analysis on protein or mRNA level. Thus, flow cy-
tometry applying the CXCR5 antibody or performing PCR for Cxcr5 expression on a tissue 
cDNA library is insufficient; this only helps to prevent on-target/off-tumor toxicity caused by 
anti-CXCR5 CAR T cells targeting CXCR5 on tissues with unexpected CXCR5 expression. 
Several assays were therefore performed to exclude potential off-target effects of anti-CXCR5 
CAR T cells. Numerous cocultures of anti-CXCR5 CAR T cells incubated with antigen-negative 
target cells showed that the CAR T cells did not release IFNγ in the absence of CXCR5; IFNγ 
was secreted exclusively in response to CXCR5. This indicates that CXCR5-targeted T cells 
do not recognize other unrelated structures on the target cells in vitro. Additionally, off-target 
reactivity was assessed in vivo. Immunodeficient NSG mice were injected with different 
amounts of anti-CXCR5 CAR T cells. Immunodeficient animals had to be used to prevent that 
the recipients mount an immune reaction towards the human T cells and deplete them. Also, 
the anti-CXCR5 CAR T cells target human CXCR5 and do not recognize murine CXCR5. Signs 
of organ damage or inflammation were not detected in the mice. In this immunodeficient mouse 
model, the anti-CXCR5 CAR T cells did not cause off-target effects.  
The data collected in in vivo and in vitro experiments suggest that the anti-CXCR5 CAR T cells 
exclusively recognize CXCR5. The anti-CXCR5 CAR seems therefore suitable for clinical test-
ing, as off-target reactivity could not be detected.  
 
5.3 Anti-lymphoma activity of anti-CXCR5 CAR T cells 
In this work, the anti-CXCR5 CAR T cells were shown to mount a robust anti-lymphoma effect 
in vitro and in vivo. CAR T cells generally either kill directly or secrete cytokines to induce cell 
lysis upon binding to the target cell (Benmebarek et al., 2019). Direct killing is supported by 
the release of inflammatory cytokines, such as interferon γ and tumor necrosis factor (TNF), 
which act on malignant cells and immune cells. They inhibit pathways required for the tumor 
cell to mediate immune evasion. Deletion of key signaling genes of IFNγ signaling, TNF sig-




mediated direct killing. TNF was further shown to induce cytokine-mediated cell death and 
bystander killing (Kearney et al., 2018). IFNγ, mainly produced by TH1 and cytotoxic CD8+ T 
cells, induces MHC upregulation on target cells, which makes them more visible to the immune 
system; it also acts anti-proliferative and pro-apoptotic (Castro et al., 2018; Kotredes and Gam-
ero, 2013). IFNγ was a suitable read-out for the coculture assays performed in this thesis, as 
cytokine production, opposed to direct cytotoxicity, is only achieved at a high activation thresh-
old (Lanzavecchia et al., 1999). A fast-acting killing mechanism is the release of granzyme/per-
forin cytotoxic granules by the CAR T cells. The Fas/Fas ligand pathway, initiated upon mem-
brane bound expression of tumor necrosis factor (TNF) family ligands by the T cell, is involved 
in a slow-acting killing mechanism. Both direct lysis mechanisms induce apoptosis in the tar-
geted cell upon activation of a caspase cascade, resulting in the cleavage of cellular substrates 
(Benmebarek et al., 2019). Research of human cytotoxic T cells showed that the main mode 
of cytotoxicity is granule exocytosis (Yasukawa et al., 2000). For CAR T cells, the preferred 
cytotoxic killing pathway appears to be dependent on the target cell type. CAR T cells against 
CD5 were developed, which is expressed on most T cell leukemias/lymphomas, but also on 
benign T cells. The CAR T cell culture suffered to a certain extent from fratricide during expan-
sion in vitro, meaning that anti-CD5 CAR T cells killed CD5 expressing CAR T cells. Inhibition 
experiments with pathway blockers revealed that fratricide is dependent on granzyme/perforin-
mediated killing, whereas tumor cell killing was mediated to a higher degree also by Fas/Fas 
ligand interaction (Mamonkin et al., 2015). As CXCR5 is not only expressed on B lymphoma 
cells and on follicular helper T cells, but is also upregulated in T cell subsets upon activation, 
fratricide was also a concern during the generation of the anti-CXCR5 CAR T cells. Förster et 
al. first showed that a fraction of peripheral blood T cells upregulated CXCR5 on day three 
after onset of activation with an anti-CD3 monoclonal antibody (Förster et al., 1994) and it was 
later demonstrated that in vivo activated CD4+ T cells upregulated CXCR5 (Ansel et al., 2000). 
Further research confirmed that CXCR5 marks activated memory CD4+ T cells. CXCR5 is in-
duced upon contact with antigen-presenting dendritic cells and downregulated upon terminal 
effector cell differentiation (Schaerli et al., 2001). During the generation of anti-CXCR5 CAR T 
cells, T cells were activated by anti-CD3/28 stimulation prior to γ-retroviral transduction in order 
to improve efficiency. CXCR5 upregulation on activated T cells resulting in fratricide of anti-
CXCR5 CAR T cells could be the reason why total anti-CXCR5 CAR T cell numbers at the end 
the expansion period were reduced by around 30% compared with CAR T cell numbers of the 
anti-CD19 CAR product. Another reason for reduced CXCR5 CAR T cell expansion could be 
tonic signaling due to differences in the scFvs of the CXCR5, CD19, and SP6 constructs (Cal-
deron et al., 2020). Tonic signaling is also dependent on the CAR surface expression levels, 




by modifying the vector or using a different one (Ajina and Maher, 2018). Nevertheless, it was 
easily possible to generate sufficient numbers for in vitro and in vivo experiments. In this thesis, 
anti-CXCR5 CAR T cells achieved an expansion rate of around 15 over the course of 10 days, 
which was comparable to the expansion rate described for anti-CD19 CAR T cells in clinical 
protocols using the CliniMACS Prodigy (Jackson et al., 2020; Mock et al., 2016). In the group, 
first experiments using the CliniMACS Prodigy showed that high cell counts are achievable. 
The manufacturing process can be further optimized to obtain even higher cell numbers for 
clinical application. 
5.3.1 Comparison between the anti-CXCR5 CAR and the anti-CD19 CAR 
The aim of this thesis was to present anti-CXCR5 CAR T cell therapy as an alternative to anti-
CD19 CAR T cell therapy. Relapsed and refractory patients suffering from diffuse large B-cell 
lymphoma treated with anti-CD19 CAR T cells (Kymriah) in the JULIET study showed overall 
response rates of 52%. Thus, many patients could benefit from alternative CAR T cell therapies 
instead of or upon failure of anti-CD19 CAR T cell therapy (Schuster et al., 2019). Anti-CXCR5 
CAR T cells, but not anti-CD19 CAR T cells, could also be administered to many patients 
suffering from B-NHLs that lost CD19 expression. In this thesis, CAR T cells equipped with the 
anti-CD19 CAR were included in many experiments as a reference for anti-CXCR5 CAR T cell 
functionality. Anti-CD19 CAR T cells were suitable for a comparison with the anti-CXCR5 CAR 
T cells due to the large overlap in the expression profiles of their antigens. Many B-NHLs ex-
press both CD19 and CXCR5. The dissociation constant of the non-humanized rat anti-human 
CXCR5 mAb RF8B2 was 0.7 nM, whereas the value for the CD19 mAB FMC63 was 1.1 nM 
(Cheng et al., 2007; Emrich, 1995). Both CAR constructs were second generation CARs with 
a CD28 costimulatory domain and a CD3ζ activation domain (Bluhm, 2018). Most definitely, 
differences in the activity between the anti-CXCR5 CAR T cells and anti-CD19 CAR T cells 
can rather be attributed to their distinct antigens than to the affinity or structure of the CAR 
constructs. Due to the different functions of these tumor-associated antigens, their densities 
naturally differ. CD19 is a transmembrane glycoprotein of the immunoglobulin superfamily and 
regulates B cell signaling thresholds (Wang et al., 2012). CD19 is expressed throughout most 
B cell development stages, whereas CXCR5 expression on B cells is restricted to mature cells. 
CXCR5, as a chemokine receptor, is a G protein-coupled receptor with seven transmembrane 
domains. It acts in guiding B cells, but also CXCR5+ T cells, such as TFH cells, to the B cell 
zones of secondary lymphoid organs following the CXCL13 gradient. Expression levels similar 
to CD19 would not be physiological for a chemokine receptor. In this work, Quantibrite analysis 
of CXCR5 and CD19 on lymphoma cell lines revealed that CD19 expression is up to 10 times 




quantified by IFNγ ELISA, was comparable to the reactivity of the anti-CD19 CAR T cells. The 
mantle cell lymphoma cell line, which was used in the NSG xenotransplantation experiments, 
expressed on average 10940 CD19 molecules/cell, but only 1667 CXCR5 molecules/cell. 
However, the anti-tumor effect of the anti-CXCR5 CAR T cells was in a similar range as of the 
anti-CD19 CAR T cells and was not diminished due to a lower CXCR5 antigen density on the 
tumor cells. As antigen levels contribute to CAR T cell activation, but other factors, such as 
CAR expression density on the T cell, antigen localization and accessibility, play an important 
role as well, the observed CXCR5 expression levels are sufficient to mount functional activity 
in in vitro assays and in the xenotransplantation experiments (Arcangeli et al., 2017; Walker et 
al., 2017). In fact, in the assays involving the primary patient material, a stronger response of 
the anti-CXCR5 CAR T cells was observed for some tumor samples. 
According to the different nature of the antigens, lymphoma cells benefit from expressing 
CXCR5, as it regulates homing to B cell follicles in secondary lymphoid organs. In a mouse 
model of chronic lymphocytic leukemia, it was demonstrated that leukemic cells depend on 
CXCR5 expression to access survival niches and lack of CXCR5 resulted in slower tumor 
growth kinetics (Heinig et al., 2014). Therefore, CXCR5 antigen escape upon anti-CXCR5 CAR 
T cell therapy would be disadvantageous for the tumor, as lymphoma cells that lack antigen 
expression could not enter these survival niches, whereas CD19 antigen loss does not seem 
to have a negative effect on tumor progression. 
5.3.2 Intrinsic characteristics of CXCR5 CAR T cells  
The success of CAR T cell therapy can be impaired for various reasons. Reduced CAR T cell 
persistence can be caused by (i) inadequate expansion of the CAR T cell product, (ii) elimina-
tion due to immunogenic CAR sequences by the host immune system, (iii) immunosuppression 
by the tumor, (iv) benign B cells inducing tolerance by expressing tumor-associated antigens, 
(v) activation-induced cell death (AICD), (vi) exhaustion upon chronic/tonic CAR/TCR trigger-
ing and (vii) T cell contraction upon lack of antigen (McLellan and Ali Hosseini Rad, 2019).  
T cell exhaustion occurs upon persistent antigenic/inflammatory stimulation in cancer or 
chronic inflammation. Upon exhaustion, T cells experience loss of effector functions and ex-
press inhibitory receptors (Wherry and Kurachi, 2015).  
The functional characteristics measured in the stress test are influenced by the effector and 
memory T cell subset diversification, which largely contributes to the quality and durability of 
the anti-tumor response (Busch et al., 2016). Effector memory T (TEM) cells are able to exert 
immediate effector functions and home to tissues, whereas central memory T (TCM) cells mi-
grate to lymphoid organs (Sallusto et al., 1999). Despite their poor cytotoxicity, TCM cells are 




memory cell pool and give rise to TCM cells, but also TEM cells, and differentiate into effector T 
cells to mount an immune response (Graef et al., 2014; McLellan and Ali Hosseini Rad, 2019). 
A minor memory subset, stem cell memory T (TSCM) cells are very similar to central memory T 
cells with even more pronounced self-renewal capacities (Busch et al., 2016; Gattinoni et al., 
2011). TSCM cells were shown to engraft and proliferate drastically better in NSG mice and 
showed better anti-tumor activity compared with TCM and TEM cells. Especially TEM cells both 
proliferated and functioned poorly (Gattinoni et al., 2011). Culture conditions during the T cell 
expansion period influence the T cell subset composition. T cells required IL7/15 to maintain 
their proliferative capacities in vitro and showed enhanced proliferation and activation in hu-
manized mice expressing IL7/15 (Drake et al., 2016). In a lymphoma xenotransplantation 
model, CAR T cells expanded with IL7/15 showed superior engraftment, anti-tumor activity and 
improved long-term survival compared to cells expanded with IL2. IL7/15 culture drove, upon 
infusion in the immunodeficient mice, CD8+ central memory differentiation, whereas IL2 culture 
generated more CD8+ effector memory cells (Zhou et al., 2019). IL7/15 were shown to promote 
TSCM cell accumulation (Cieri et al., 2013). Altogether, many publications favor IL7/15 supple-
mentation for T cell expansion for adoptive transfer. The in vivo expansion of CAR T cells in 
the patient also benefits from these cytokines; preconditioning lymphodepletion removes cel-
lular cytokine “sinks” and increases the levels of IL7 and IL15 in the patients, which enhances 
the function of adoptively transferred T cells (Klebanoff et al., 2005). 
CAR T cells for the stress test and in vivo experiments were expanded using IL7 and IL15. At 
the end of the expansion period for CAR T cells used in the stress test, T cell memory subpop-
ulations were determined by flow cytometry. The vast majority of anti-CXCR5 CAR T cells were 
memory T cells, with on average around 10% CD4+ TCM cells, 10% CD8+ TCM cells, 20% CD4+ 
TEM cells and 40% CD8+ TEM cells. IL7/15 expansion drives TCM cell formation; however a major 
factor that influences the phenotype, persistence and expansion capacity of CAR T cells, is 
the choice of the costimulatory domain (Jafarzadeh et al., 2020). The anti-CXCR5 CAR har-
bors a CD28-based costimulatory domain, which drives TEM cell formation. Possibly, switching 
to a 4-1BB-based CAR could have improved longevity and anti-tumor efficacy in the xeno-
transplantation experiments using NSG mice, as the 4-1BB costimulatory domain promotes 
TCM cell formation, which perform better in the mice.  
CD28- and 4-1BB-based costimulatory domains influence the metabolic characteristics of CAR 
T cells. CAR T cells with CD28 domains show enhanced glycolysis and increased effector 
memory T cell differentiation. CAR T cells with 4-1BB domains have increased respiratory 
capacity, fatty acid oxidation and mitochondrial biogenesis. Enhanced survival of 4-1BB-based 
CAR T cells was found to be associated with an enriched population of central memory T cells 




whereas CD28-based CAR T cells could be detected for around 30 days, but both have similar 
long-term response rates (Kawalekar et al., 2016; Weinkove et al., 2019). In aggressive B-
NHL, CD28-based CARs achieve a higher response rate and in B-ALL, 4-1BB-CARs induce 
longer progression free survival. Thus, the ideal costimulatory domain might be disease-de-
pendent and clinical trials, which compare the two domains, are underway (Weinkove et al., 
2019). As of now, there is not a clear preference for any of the signaling domains in clinical 
application, with the first two FDA approved anti-CD19 CAR products Kymriah harboring a 4-
1BB domain and Yescarta haboring a CD28 domain and the equal usage of both these do-
mains in clinical trials (Mchayleh et al., 2019; Weinkove et al., 2019). Therefore, for the treat-
ment of patients, a CD28-based anti-CXCR5 CAR construct as presented in this thesis is suit-
able. 
5.3.3 CXCR5 CAR T cell-mediated anti-tumor activity in animal models 
An immunodeficient xenotransplantation model allowed growth of human-derived tumor cells 
in vivo. NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice harbor mutations that render them defi-
cient in B, T and NK cells and enable the engraftment of human cells. In vivo imaging using 
bioluminescence made it possible to track and quantify the growth of luciferase-transduced 
lymphoma cells in the mouse over time. In this model, a striking anti-tumor effect of anti-
CXCR5 CAR T cells against JEKO-1 mantle cell lymphoma cells was demonstrated. The cell 
line was injected intravenously; tumor growth was mostly localized in the bone marrow. Anti-
CXCR5 CAR T cells were shown to reduce tumor load and control tumor growth over the 
course of over two weeks. A comparison between the anti-CXCR5 and the anti-CD19 CAR T 
cells was performed twice. One time, the anti-CD19 CAR T cells showed superior performance, 
and one time, the anti-CXCR5 CAR T cells performed better, indicating that they have very 
comparable anti-tumor efficacy.  
However, the anti-CXCR5 CAR T cells did not induce complete tumor elimination and durable 
remission in the mice. Several mechanisms could account for this. First, tumor escape could 
be explained by outgrowth of CXCR5 negative loss variants; however, CXCR5 was not down-
regulated on tumor cells harvested from mice in the anti-CXCR5 CAR group. Secondly, CAR 
T cell function could potentially be hampered by CXCR5 shedding of the anti-CXCR5 CAR-
targeted epitope. Shedding was described for B-cell maturation antigen (BCMA). The enzyme 
γ-secretase cleaves BCMA’s extracellular domain, generating soluble BCMA (sBCMA) frac-
tions (Laurent et al., 2015). Soluble BCMA is increased in the serum of multiple myeloma pa-
tients, who experience expansion of BCMA+ plasma cells (Sanchez et al., 2012). CXCR5 shed-
ding has never been reported; however, shedding of other G-protein-coupled receptors is 




CXCR5 shedding could result in reduced surface expression of anti-CXCR5 CAR targeted 
molecules on lymphoma/leukemic cells. As previously mentioned, downregulation of CXCR5 
expression was not observed on tumor cells analyzed at the end point of experiments. Addi-
tionally, soluble CXCR5 could possibly block anti-CXCR5 CAR activity, as hypothesized for 
sBCMA, which was found to decrease binding of an anti-BCMA antibody in vitro at concentra-
tions measured in MM patients (Chen et al., 2019). Activity reduction of CXCR5 CAR T cells 
upon incubation with the CXCR5 N-terminal epitope was not observed at concentrations simi-
lar to the sBCMA serum concentrations described for MM patients or higher concentrations, 
indicating that soluble CXCR5 is most likely not the cause for incomplete tumor removal in the 
NSG mice and would most likely not interfere with anti-CXCR5 CAR T cell treatment in pa-
tients. In the in vivo experiments, the anti-CXCR5 CAR T cells were analyzed at the time point 
of tumor outgrowth, but signs of exhaustion, as classified by upregulation of the exhaustion 
markers PD-1, LAG-3 and TIM-3, were not observed in comparison to SP6 CAR T cells. These 
findings excluded T cell exhaustion as a potential cause for incomplete tumor removal in the 
mice. 
Most likely, the lack of a durable anti-tumor response of the anti-CXCR5 CAR T cells can be 
attributed to limitations of the NSG mouse model. Murine factors, such as growth factors and 
chemokines, are species-specific and do not sufficiently support the transferred human primary 
T cells. Signaling through the receptors for IL2, IL4, IL7, IL9, IL15 and IL21 is disturbed as a 
result of the mutation of the IL2 receptor γ-chain locus, which impairs T and B cell function and 
development and inhibits NK cell development (Shultz et al., 2007; Sugamura et al., 1996). 
The scid mutation further prevents T and B cell development and the NOD strain background 
harbors intrinsic deficiencies in innate immunity (Shultz et al., 2014). In these mice, lymphoid 
structures are not properly developed and differences in species-specific homing factors ham-
per trafficking of human immune cells. Another approach, in which the anti-CXCR5 CAR T 
cells might receive better support from the microenvironment, is provided with humanized 
mouse models. In humanized models, immunodeficient mice are engrafted with human pri-
mary hematopoietic cells or tissues to establish a functional human immune system (Shultz et 
al., 2012). Improved immune function can be achieved by expression of human transgenes or 
injection of human recombinant proteins (Drake et al., 2012; O’Connell et al., 2010). Also, 
genetically engineered mouse strains are available, which improve immunity in humanized 
mice by expressing human-specific factors (Shultz et al., 2012). Humanized models have been 
used to study anti-CD19 CAR T cells. Jin et al. generated a mouse model with a functional 
human immune system by administering human fetal tissues and cells and induced genet-
ically-matched autologous primary acute B-lymphoblastic leukemia. Using this model, it was 




monocytes and macrophages. The authors also registered an increase in regulatory T cells, 
which is known to happen in patients treated with anti-CD19 CAR T cells. Altogether, it was 
shown that humanized mouse models are a valuable tool to characterize the mechanisms of 
action of human CAR T cells in vivo (Jin et al., 2019). 
An alternative to study the effect of CAR T cells in vivo are syngeneic mouse models. In synge-
neic models, murine CAR T cells specific for the murine antigen are administered to immuno-
competent mice. They can help to answer questions that are left unanswered in immunodefi-
cient mouse models and, for instance, shed light on the factors influencing in vivo killing, such 
as dosage, phenotype, persistence and homing of the T cells and conditioning chemotherapy. 
In a B-ALL syngeneic tumor model, anti-CD19 CAR T cells were studied in greater detail. The 
CAR T cells were able to eliminate the tumor cells in vivo, cure the mice and induce B cell 
aplasia. The authors further showed that increased conditioning chemotherapy enhanced tu-
mor eradication and CAR T cell persistence (Davila et al., 2013). In a similar syngeneic ap-
proach, it is possible to study the reciprocal interactions of the anti-CXCR5 CAR T cells with 
the microenvironment. A suitable model is the immunocompetent Eμ-Tcl1 mouse model, which 
was also used in this thesis to investigate the influence of lymphoma growth on T cells. 
CXCR5+ Eμ-Tcl1 tumor cells are adaptively transferred into C57BL/6N mice, followed by anti-
murine CXCR5 (mCXCR5) CAR T cells, which then target the tumor cells within an intact lym-
phoid environment. Thus, it is possible to study the distribution of anti-mCXCR5 CAR T cells 
within the SLOs and their interaction with the tumor cells by immunohistology or in vivo micros-
copy. The group showed that the anti-mCXCR5 CAR T cells intermingled with Eμ-Tcl1 tumor 
cells in B cell areas, expanded and mediated strong anti-tumor efficacy (Bunse*, Pfeilschifter* 
et al., 2021). Research using the mCXCR5 CAR T cells in the Eμ-Tcl1 mouse model is still 
ongoing in the lab. The model could be used in the future to study whether elimination of 
CXCR5+ TFH cells and other T cell subpopulations by the anti-mCXCR5 CAR T cells is sup-
portive of the anti-tumor effect, for instance in comparison with the anti-mCD19 CAR T cells, 
which exclusively remove benign and malignant B cells. 
 
5.4 Targeting the TME with next generation CAR T cells 
Immunotherapy has revolutionized treatment for patients of numerous malignancies; monoclo-
nal antibody (mAb)-based therapies have largely contributed to these advances. CAR T cell 
therapy is however an autologous approach, costly in terms of time and labor. They induce 
target cell lysis and cytotoxicity is triggered by low levels of antigen. Monoclonal antibodies on 
the other hand need high levels of antigen expression in order to induce antibody-dependent 




escape easier in mAb-based therapy. Biodistribution also differs in CAR T cell and mAb-based 
therapies. They are both administered intravenously, but mAbs face greater difficulties to over-
come endothelial, epithelial and interstitial barriers. CAR T cells, however, have the ability to 
extravasate and migrate within tissues. CAR T cells additionally show considerably better du-
rability. Patients need multiple injections with mAbs, which have a short half-life in vivo, to 
induce remission. For instance, the anti-CD20 mAb Rituximab has a half-life of around three 
weeks. CAR T cells are usually only administered once and expand upon injection. They per-
sist long-term in the patients and can be found months and years after infusion, inducing a 
long lasting anti-tumor response (Caruana et al., 2014). 
Despite the introduction of anti-CD19 CAR T cell therapy to the clinic, which filled a previously 
unmet need for the treatment of patients suffering from refractory or relapsed aggressive B-
cell lymphomas, durable remission is only achieved in 33%–40% of patients. In the majority 
of refractory or relapsed B-NHL cases after anti-CD19 CAR T cell therapy, CD19 is still ex-
pressed by the tumor cells. Treatment failure in these patients is associated with poor func-
tional characteristics of the infused CAR T cells and unfavorable interactions of the CAR T 
cells with the immunosuppressive lymphoma microenvironment, resulting in immune evasion 
and T cell exhaustion (Abramson et al., 2019).  
In a study of CLL patients treated with an anti-CD19 CAR product, the authors compared the 
differences in CAR T cells of responders and non-responders. CAR T cells from completely-
responding patients showed increased expression of memory genes and an IL6/STAT3 signa-
ture, opposed to CAR T cells of non-responders, which upregulated genes involved in effector 
differentiation and glycolysis. These findings indicate that CAR T cell modifications before or 
after infusion could improve the anti-tumor response (Fraietta et al., 2018).  
Impaired trafficking to the tumor site, T cell suppression by soluble inhibitors produced by the 
tumor cells or stroma cells and checkpoint-mediated immunosuppression cause major obsta-
cles in CAR T cell treatment that can be overcome by next generation CARs, which harbor 
novel features (Höpken and Rehm, 2019). 
Armored CAR T cells or TRUCKS (T cells redirected for universal cytokine killing) have been 
proposed as 4th generation CAR T cells with the ability to secrete cytokines. The released 
cytokines can either work in an autocrine manner to support T cell survival or in a paracrine 
manner to modify the immunosuppressive microenvironment (Chmielewski and Abken, 2012, 
2020). TRUCK strategies were suggested for anti-CD19 CAR T cells. Boice et al. introduced 
CAR T cells with local and continuous HVEM (Herpes Virus Entry Mediator) production, which 
bound to BTLA (B and T lymphocyte attenuator) on follicular lymphoma cells and restored the 
inhibitory BTLA signal. HVEM is often lost in FL and loss was shown to promote lymphoma 




2016). Interestingly, the HVEM/BTLA axis acted as a negative regulator in the interaction be-
tween TFH cells, which strongly express BTLA, and FL cells. TFH cells provided more help to 
HVEM-deficient than to HVEM-expressing B cells, for which the intact HVEM/BTLA axis re-
strained TFH-mediated B cell help (Mintz et al., 2019). Thus, TFH cell-mediated support for 
HVEM-deficient FL could be disrupted by HVEM-expressing CAR T cells. 
In another approach, IL12 was secreted by anti-murine CD19 (mCD19) CAR T cells in a lym-
phoreplete mouse model with normal lymphocyte counts. Lymphodepletion is usually per-
formed before CAR T cell infusion to remove host lymphoid cells, which compete for cytokines 
and space in lymphoid tissues with the transferred CAR T cells. It is however toxic for the 
patient and also destroys immune cells with anti-tumor activity. In this model, lymphodepletion 
was not required as the CAR T cells received autocrine IL12 stimulation, which boosted cyto-
toxic activity and engraftment. It was demonstrated that the IL12 secreting CAR T cells directly 
killed mCD19+ tumor cells. IL12 secreted by the CAR T cells further seemed to lessen the 
tumor cell-mediated immune suppression and allowed host immune cells to contribute to an 
anti-tumor response in an mCD19 independent manner due to epitope spreading (Kueberuwa 
et al., 2018). 
Impaired trafficking to the tumor site is addressed by CAR T cells expressing additional chem-
okine receptors. Introduced by Di Stasi et al., chemokine receptor expressing anti-CD30 CAR 
T cells were shown to have improved homing function and anti-tumor efficacy in a murine 
Hodgkin’s lymphoma model. Hodgkin’s tumor cells preferentially attracted CCR4+ TH2 cells 
and regulatory T cells, creating an immunosuppressive microenvironment. Effector CD8+ T 
cells did not express CCR4 and were absent from the tumor site, but transgenic CCR4 induc-
tion in these cells improved migration to CD30+ lymphoma cells (Di Stasi et al., 2009). On a 
side note, expression of CXCR5 was introduced on CAR T cells in HIV research. In chronic 
HIV infection, TFH cells are a major reservoir of virus production in the B cell follicle. The authors 
developed a CAR, which targeted the viral envelope protein on cells infected with the simian 
immunodeficiency virus and expressed rhesus macaque CXCR5. CXCR5 expression allowed 
trafficking to the B cell follicle following the CXCL13 gradient ex vivo in rhesus macaque lymph 
nodes. Introduction of CXCR5 expression in CAR T cells targeting HIV infected cells could 
possibly achieve durable remission in HIV patients, as CXCR5 could aid to locate the CAR T 
cells to their target site (Haran et al., 2018).  
As of today, targeting solid tumors with CAR T cells remains especially challenging. Application 
of CAR T cell therapy in solid tumors is often constrained by limited T cell trafficking to tumor 
sites, reduced functionality in an immunosuppressive microenvironment and non-homogenous 
antigen expression on the tumor cells (Braun et al., 1999; Craddock et al., 2010; Fargion et 




therapeutic efficacy in solid tumors. Morrissey et al. first developed CAR-Ps (CARs for phago-
cytosis) and introduced them into macrophages (Morrissey et al., 2018). Klichinsky et al. es-
tablished CAR macrophages against the solid tumor antigen HER2, which are currently being 
prepared for a clinical trial. With CAR macrophages, phagocytosis in vitro in an antigen-de-
pendent manner and tumor reduction in a mouse model was shown. Apart from their direct 
anti-tumor effect, CAR macrophages succeed in modifying the tumor microenvironment. They 
induced pro-inflammatory pathways in macrophages, activated dendritic cells and T cells in 
vitro and enhanced T cell mediated anti-tumor activity in vivo (Klichinsky et al., 2020). Macro-
phages do not face the problems that T cells face in targeting solid tumors. Poor trafficking to 
tumor sites is not an issue, as tumor-associated macrophages are among the major inflamma-
tory cells that infiltrate tumors attracted by tumor-derived chemotactic factors (Biswas et al., 
2013; Green et al., 2009). Moreover, the antigenic heterogeneity of the tumor mass is over-
come by the macrophage function as an antigen-presenting cell, which engages the adaptive 
immune system after phagocytosis. Another approach to engage the innate immune answer 
against solid tumors was pursued by Chmielewski et al. with IL12 TRUCKs. Upon antigen 
encounter, cytotoxic CAR T cells release IL12, which attracts macrophages to the tumor site 
and boosts their function. Upon IL12 secretion, an innate response is triggered towards malig-
nant cells that go unrecognized by CAR T cells due to antigen loss. Additionally, immunosup-
pressive cells are reprogrammed (Chmielewski and Abken, 2012). The benefit of CAR-
mediated IL12 release was demonstrated in tumor models of hepatocellular carcinoma and 
ovarian cancer (Koneru et al., 2015; Liu et al., 2019). These novel strategies have in common 
that they elicit an innate immune response at the tumor site and exert influence on the immu-






5.5 Conclusion and further perspectives 
5.5.1 Conclusion 
In this thesis, a novel CAR directed against a chemokine receptor has been characterized that 
allows simultaneous targeting of lymphoma and the tumor-supportive microenvironment 
(Figure 40). The CAR T cells investigated in this thesis were directed against CXCR5, which 
is expressed on mature B cells and B non-Hodgkin lymphoma cells derived from mature B 
cells. CXCR5 is further expressed on subsets of T cells, most prominently the follicular helper 
T cells. In order to ensure the safety of the CAR product, extensive expression studies on 
mRNA and protein level were performed, which were able to confirm a restrictive expression 
of CXCR5 in the hematopoietic compartment. The presented results show that the anti-CXCR5 
CAR T cells specifically target CXCR5 expressing cell lines and primary patient material, in-
cluding CLL, MCL, FL and MZL, but also follicular helper T cells, which are described to support 
tumor progression in CLL and FL. In xenotransplantation models, it could be shown that anti-
CXCR5 CAR T cells efficiently reduce CXCR5+ tumor growth in vivo. The data support the anti-
CXCR5 CAR T cell product as a valuable alterative to the anti-CD19 CAR T cell product, which 
is predominantly used in clinical application. Especially in CLL and FL patients, anti-CXCR5 
CAR T cell therapy could be advantageous as tumor-supportive follicular helper T cells are 
eliminated by the CAR T cells. 
 
Figure 40: Anti-CXCR5 CAR T cells simultaneously target lymphoma and the tumor-supportive 
microenvironment. A CXCR5-expressing benign and malignant B cells as well as follicular helper T 
cells are targeted by the anti-CXCR5 CAR T cells in the B cell follicle. B Follicular dendritic cells secrete 
CXCL13, which attracts CXCR5+ cells to the B cell follicle. They engage with B cells and lymphoma cells 
in a CXCL13/lymphotoxin positive feedback loop. C TFH cells support the survival and expansion of B 




Additionally, using a mouse model of chronic lymphocytic leukemia, a strong influence of lym-
phoma growth on the CXCR5+ splenic T cell compartment was shown by single cell RNA se-
quencing. The fractions of effector CD8+ cells, follicular helper T cells and follicular regulatory 
T cells were enriched upon tumor challenge. With a special focus on follicular helper T cells, it 
was shown that profound changes were induced on transcriptional level. Il4, Il21 and Cd40lg, 
which were described to stimulate CLL cells in vitro, were shown to be upregulated early in 
CLL progression in Eμ-Tcl1 tumor-challenged TFH cells. These results support the descriptions 
of tumor-supportive functions of TFH cells in the literature and add a more detailed analysis on 
mRNA level to them.  
 
5.5.2 Future perspectives 
The treatment options for patients with refractory or relapsed aggressive B cell lymphomas 
were revolutionized by the advent of anti-CD19 CAR T cell therapy. Nevertheless, complete 
remission is still only achieved in less than 40% of patients, with a major fraction of treatment 
failures attributed to poor CAR T cell function due to disadvantageous interactions with the 
microenvironment (Abramson et al., 2019). In an immunosuppressive lymphoma microenvi-
ronment, CAR T cells can be functionally hampered by the engagement of immune-inhibitory 
checkpoints, most prominently PD-1 and CTLA-4, whose ligands are often expressed by tumor 
cells. Checkpoint-mediated immunosuppression is a huge obstacle in efficient adoptive T cell 
therapy. Checkpoint receptors engagement causes T cell exhaustion, dysfunction, suppressed 
effector activity and results in a reduced anti-tumor response (Alsaab et al., 2017; Gowrishan-
kar et al., 2018). The introduction of checkpoint blockage, one of the major milestones of im-
munotherapy, has provided a tool to diminish CAR T cell inhibition. John et al. were able to 
boost CAR T cell activity by blocking PD-1-mediated immunosuppression with an anti-PD-1 
monoclonal antibody. Mice treated with both CAR T cells and the antibody showed enhanced 
tumor regression and survival compared with the treatments administered separately (John et 
al., 2013). These preclinical experiments provided proof of principle and checkpoint blockage 
in CAR T cell therapy was further investigated in clinical trials; many trials with patients suffer-
ing from B cell malignancies treated with this combination immunotherapy are still ongoing and 
look promising (Grosser et al., 2019). Apart from administering checkpoint blockage agents, 
more sophisticated strategies were developed. CAR T cells were modified to secrete PD-1-
blocking soluble single chain variable fragments (scFv) at the tumor site. Release of PD-1-
blocking scFvs was shown to enhance the anti-tumor activity in a murine hematologic tumor 
model by two mechanisms. First, autocrine PD-1 blockage improved CAR T cell function. Sec-
ondly, paracrine blockage activated bystander tumor-specific T cells. As the secreted scFvs 




2018). In cell-intrinsic approaches, CAR T cell expression of a mock-PD-1 receptor with scav-
enger function, which reduced ligand binding to the endogenous PD-1 receptor, or PD-1 re-
ceptor knockdown by cotransduction with PD-1 shRNAs were further shown to restore CAR T 
cell effector function (Cherkassky et al., 2016). Also, in order to transform the inhibitory PD-1-
mediated signaling, anti-CD19 CAR T cells with a chimeric switch receptor were developed, 
with the extracellular domain of PD-1 and the transmembrane and cytoplasmic signaling do-
mains of CD28. These CAR T cells showed superior proliferation, cytokine production and 
killing capacities in vitro and in the patient compared to conventional anti-CD19 CAR T cells 
without the switch receptor (Liu et al., 2020b).  
Major difficulties are also related to the generation of autologous CAR T cells from patient-
derived T cells that have been influenced by cancer-mediated immune effects and chemother-
apy or other previous treatments. Also, autologous production has the disadvantages of higher 
costs, manufacturing time, which delays treatment, and the possibility of manufacturing failure. 
Allogeneic ”off-the-shelf” CAR products could overcome all these issues and provide patients 
with high-quality cells from selected donors. Risks in administering allogeneic CAR products, 
which should be kept in mind, are graft-versus-host disease (GvHD) and limited anti-tumor 
efficacy due to fast elimination by the host immune system (Depil et al., 2020). In administering 
allogeneic CAR T cells, GvHD can be reduced by T cell engineering. As GvHD can be at-
tributed to the broad repertoire of allogeneic T cell receptors, endogenous T cell receptor de-
letion is an option to address this issue, for instance by permanent deletion of T cell receptor 
chains with designer zinc finger nucleases (Kim and Cho, 2020; Torikai et al., 2012). Results 
of the first allogeneic gene-edited CAR T cell study have recently been published. The authors 
disrupted expression of the T cell receptor and CD52 in anti-CD19 CAR T cells. CD52 disrup-
tion allowed the use of an anti-CD52 antibody to induce lymphodepletion in the host. The treat-
ment was shown to have a manageable safety profile and had an overall response rate of 78% 
(Neelapu et al., 2020) (NCT03939026, clinicaltrials.gov).  
Not only T cells can be equipped with a CAR, but also natural killer (NK) cells. NK cells are 
highly cytotoxic, but show a superior safety profile for allogeneic therapy due to lower risks of 
graft-versus-host disease, cytokine release syndrome and neurotoxicity (Xie et al., 2020). Most 
clinical trials with CAR NK cells were only initiated during the last years and results are not 
published yet, but the first large-scale study was recently published (Xie et al., 2020). Liu et al. 
engineered cord blood-derived NK cells to express an anti-CD19 CAR construct and IL15. The 
CAR NK cells had strong anti-tumor efficacy and great persistence in a murine xenograft lym-
phoma model, which was especially improved upon IL15 production (Liu et al., 2018). The 
authors initiated a clinical trial with this CAR and showed treatment response in a majority of 




advantageous not only for the patients, but also considering the manufacturing process. Future 
research will show if they are suitable to ultimately replace autologous CAR T cell therapy. 
 
As presented in this thesis, CXCR5 is a promising target for CAR T cell therapy of B non-
Hodgkin lymphomas derived from mature B cells. The anti-CXCR5 CAR T cells targeted spe-
cifically CXCR5 expressing cells, spared CXCR5 negative cell and performed well in vitro and 
in vivo. Therefore, the next step is to prepare the anti-CXCR5 CAR product for clinical appli-
cation with the ultimate goal to provide an alternative to anti-CD19 CAR T cell therapy to B-
NHL patients. In clinical application, peripheral blood mononuclear cells are collected from the 
patient in leukapheresis and the apheresis product is further processed. In the next steps, for 
instance the CliniMACS Prodigy system can be used for clinical-grade manufacturing under 
good manufacturing procedure (GMP) (Wang and Rivière, 2016). It might also be interesting 
to investigate whether the enrichment of certain T cell subsets, for example memory stem cells 
might be beneficial for the final anti-CXCR5 CAR product. Upon subsequent T cell activation, 
which is often performed using CD3/CD28 beads, upregulation of CXCR5 is expected on a 
small subpopulation of activated T cells. Once the T cells are equipped with the anti-CXCR5 
CAR, this subpopulation is subject to fratricide. In this thesis, it was easily possible to generate 
sufficient anti-CXCR5 CAR T cells and potential fratricide did not seem to be detrimental to the 
final product, which was shown to be highly functional in numerous in vitro and in vivo experi-
ments. It is expected that the large-scale production for clinical application will obtain sufficient 
cell numbers in order to treat patients. Further, it could be interesting to explore the above-
mentioned ”off-the-shelf” therapies using allogeneic T cells or NK cells with the anti-CXCR5 
CAR construct. 
Using the Eμ-Tcl1 mouse model, a profound impact of lymphoma growth on CXCR5+ T cells 
in the murine spleen was shown in this thesis by single cell RNA sequencing. In order to vali-
date the data, splenic TFH cells can be isolated from Eμ-Tcl1 tumor-challenged mice and ana-
lyzed for the upregulated genes by quantitative PCR or, to obtain data on protein level, by flow 
cytometry. Further, cocultures of Eμ-Tcl1 tumor cells with TFH cells isolated from the murine 
spleen could be performed; the supernatant could be analyzed for cytokine secretion by ELISA 
and the cells could be analyzed by flow cytometry. These cocultures could also be used for 
antibody blockage experiments to validate the importance of the expressed genes for the re-
ciprocal interaction between T cells and tumor cells. It remains challenging to isolate sufficient 
numbers of viable TFH cells by fluorescence-activated cell sorting. Cells isolated by magnetic 
cell sorting can usually only be sorted for one antigen in addition to CD4 due to the set-up of 
available kits, therefore they could only be sorted for CXCR5, but not PD-1. An alternative 




induced in T cell subsets in vitro. Also, cocultures of CLL patient biopsies with human cTFH 
cells isolated from peripheral blood could be of interest. Due to the lack of a single marker 
identifying TFH cells, TFH knock-out mice are not available. Alternatively, it might be of interest 
to analyze Eμ-Tcl1 tumor progression in transgenic mice upon conditional cell ablation of cells 
expressing IL21, one of the main cytokines produced by TFH cells. Ultimately, these experi-
ments will shed light on the reciprocal interactions of lymphoma cells and CXCR5+ T cells, in 
particular TFH cells, in the B cell follicle. Insights in the mechanisms of tumor progression will 
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